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Summary
Thymidylate synthase (TS) catalyses the reductive methylation of deoxyuridine 
monophosphate by 5,10-methylenetetrahydrofolate to produce thymidylate and 
dihydrofolate. In the reaction the enzyme is present initially as an open complex that 
closes down progressively as ligands bind. The binary complex which is formed as the 
substrate dUMP binds has an active site that is open and structurally very close to the 
unliganded state. It is upon binding of the folate cofactor that structural changes occur and 
the enzyme forms a closed ternary structure. In contrast to the movements of large 
domains seen in other proteins upon ligand binding, the changes in TS involves 
segmental accommodation in which segments of secondary structural elements all move in 
concert towards the active site. The two largest shifts involve the C-terminus and DRTG 
loop which moves 4A to close over the active site.
Sequence data from 35 organisms reveal the protein to be one of the most highly 
conserved enzymes which makes it an ideal test bed for the design of species specific 
inhibitors. This thesis is concerned with the structure-function relationships in the TS of 
the human herpesvirus VZV. The highly conserved residues in the TS family were 
thought to be present to maintain enzyme function but mutagenesis studies of several 
family members have shown that almost all the conserved residues can be substituted 
without severe disruption of enzyme activity. It is thought that only four of these residues 
are critical to maintain catalytic activity. One possible explanation for the high 
conservation could be that TS interacts with other enzymes involved in DNA synthesis. 
Affinity chromatography was performed in this thesis to detect proteins interacting with 
TS but none were identified.
To identify residues which are critical for enzyme function a region-directed 
mutagenesis protocol was established using long oligonucleotides which were targeted to 
selected regions of the protein. Using this protocol a series of temperature sensitive 
mutants were produced in different regions of the enzyme. Temperature sensitive mutants 
are a means of identifying residues which are critical for protein stability and function. 
Initial studies were carried out on buried regions of the protein as it was predicted that 
residues involved in stability would be found there. The mutant enzymes were 
characterised by in vivo and in vitro assays and examined by molecular modelling to gain 
insights into the role of the mutated residue.
Following the initial experiments, this region-directed approach was used to target 
the highly mobile C-terminus and DRTG loop region of VZV TS. The DRTG loop is a 
highly conserved region in all TS species which moves up towards the C-terminus upon 
ligand binding resulting in Arg38 forming a hydrogen bond with the C-terminal 
carboxylate of the protein. Eight mutants were constructed in the DRTG loop region,
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three of which contained base substitutions in the DRTG loop itself. The mutants all had 
reduced but significant TS activity.
Removal of the C-terminal residue from the prokaryotic enzymes results in 
complete inactivation which is believed to be due to the loss of a hydrogen bond network 
involving the C-terminal carboxylate group. By contrast removal of the C-terminal leucine 
from VZV TS results in an enzyme which retains -3% of wild type activity. These 
findings have been investigated further by targeting the region directed approach to the C- 
terminus. Four temperature sensitive mutants were produced in this region, three of 
which had major reconstructions and one contained a point mutation. All mutants 
produced reduced but significant TS activity. Kinetic analysis of one of these mutants 
revealed that dUMP K^ was reduced three fold and folate Km was greatly increased 
indicating that the mutant enzymes had difficulty forming the closed ternary complex. 
Studies with the inhibitor phenolphthalein were also consistent with this view. These 
results strengthen the previous findings that removal of the C-terminal residue did not 
result in the complete inactivation of VZV TS and confirm that there are significant 
differences between bacterial and VZV TS.
Site directed mutagenesis was used to produce an asparagine to aspartic acid 
mutation at Asn214 of VZV TS, a residue which is completely conserved in all TS 
sequences. This residue was initially thought to allow for the binding of substrate, but 
more recent studies have indicated that Asn214 is in fact conserved to discriminate 
between dUMP and dCMP binding to the enzyme. Experimental evidence has indicated 
that alteration of the corresponding residue, Asn229, of L.casei results in the enzyme 
converting from a dUMP methylase to a dCMP methylase. The N214D mutant from VZV 
was inhibited by the addition of increasing concentration of dCMP into the TS assay 
indicating that dCMP is competing with the normal dUMP substrate and confirming a role 
for Asn214 in dCMP/dUMP discrimination. This method of substrate differentiation 
could prove to be a general theme in protein-nucleic acid recognition.
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Chapter 1. Introduction
The biology and molecular biology of herpesviruses will be reviewed in the first section 
of this introduction, with special reference to varicella-zoster virus. The second section 
provides information on the structure and function of the enzyme thymidylate synthase.
1.1. Herpesviridae 
1.1.1 Introduction
Herpesviruses are widely disseminated in nature, and most animal species have 
yielded at least one herpesvirus upon examination. Of nearly 100 herpesviruses that have 
been characterised, seven herpesviruses have been isolated from humans [herpes simplex 
virus 1 (HSV-1), herpes simplex virus 2 (HSV-2), human cytomegalovirus (HCMV), 
varicella-zoster virus (VZV), Epstein-Barr virus (EBV) and human herpesvirus 6 and 7 
(HHV6 and HHV7)]. Recently Chang etal. (1994) identified an eighth herpesvirus which 
is associated with Kaposi’s sarcoma, this has been classified as a gammaherpesvirus and 
is most closely related to herpesvirus saimiri (Moore etal., 1996).
Membership of the family Herpesviridae is based on the architecture of the virion. 
A typical herpes virion consists of a core containing a linear double-stranded DNA, which 
is packaged into an icosahedral capsid approximately 100-1 lOnm in diameter. Initially the 
DNA was thought to be arranged as a toroid around a central protein "plug" (Furlong et 
al., 1972), but cryoelectron microscopy studies provided no evidence for a toroidal 
arrangement of the DNA or for the existence of a central "plug". Recent studies have 
indicated that the capsids contain little or no protein and that the volume enclosed by the 
outer capsid shell is taken up entirely by DNA (Booy et al., 1991). The capsid is 
surrounded by an amoiphous sometimes asymmetrical material, which is in known as 
tegument, and this in turn is enclosed in an envelope containing glycoprotein spikes on its 
surface.
1.1.2. Molecular and biological properties of herpesviruses
Herpesviruses initiate infection by the attachment of the viral envelope to receptors 
on the cell surface. The virus envelope fuses with the plasma membrane, the nucleocapsid 
is released into the cytoplasm and migrates to the nucleus where the DNA enters via the 
nuclear pores. Viral DNA is replicated in the nucleus forming concatemers consisting of 
head to tail repeats of the genome. The DNA is then cleaved and packaged into preformed 
capsids which acquire tegument and envelope prior to leaving the infected cell.
1
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In addition to the lytic cycle of infection, herpesviruses are able to establish a 
latent infection. In HSV the virus can persist in dorsal root ganglia in an apparently 
inactive state for varying durations, and then be reactivated by a variety of stimuli 
(reviewed by Roizman & Sears in Fields Virology 1996, Chapter 72, pp2231-2278). 
Thus after infection, viral DNA persists in the host for the entire lifetime of the individual.
1.1.3. Classification of Herpesviruses
The members of the family Herpesviridae have been classified into three 
subfamilies (i.e. the Alpha, the Beta and the Gammaherpesvirinae) on the basis of their 
biological properties such as host range in tissue culture, length of reproductive cycle, 
cytopathology and characteristics of latent infection (Roizman et al., 1992).
The members of the subfamily Alphaherpesvirinae are classified on the basis of a 
variable host range, relatively short reproductive cycle, rapid spread in culture, efficient 
destruction of infected cells, and the capacity to establish latent infections primarily but 
not exclusively in sensory ganglia. This subfamily includes HSV-1 and 2, varicella-zoster 
virus (VZV), pseudorabies virus (PRV) and equine herpesvirus 1 (EHV-1).
A nonexclusive characteristic of the Betaherpesvirinae is their restricted host 
range. Their reproductive cycle is long and infection progresses slowly in culture. The 
infected cells frequently become enlarged and carrier cultures are readily established. The 
virus can be maintained in latent form in secretory glands, kidneys and other tissues. This 
subfamily includes human cytomegalovirus (HCMV) and murine cytomegalovirus.
The Gammaherpesvirinae only infect their natural host and cannot infect 
experimental animals outside the family or order. Viruses in this group are specific for 
either T- or B-lymphocytes, and infection is frequently arrested at a prelytic stage, with 
persistence and minimal expression of the viral genome (latent infection), or at a lytic 
stage, causing cell death without the production of infectious virus progeny. Members of 
the gammaherpesvirinae include Epstein-Barr virus (EBV), herpesvirus saimiri (HVS) 
and herpesvirus ateles (HVA).
1.1.4. Herpesvirus DNAs
Herpesviral genomes are highly diverse, they range in size from 125 to 230kbp 
with around 70 to 200 genes and they exhibit widely differing base compositions and 
patterns of repeated sequences. The variation in the size of the genome of any one 
herpesvirus appears to be minimal, but not insignificant. Thus, many viral DNAs contain 
terminal and internal reiterated sequences. Because of variability in the number of these 
reiterations, the size of individual genomes may vary by more than lOkbp. Spontaneous 
deletions also occur and have been noted in both HSV, EBV and HCMV strains passaged
2
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outside the human host (reviewed by Roizman in Fields Virology 1996 Chapter 71,
p2221-22260).
The base composition of herpesvirus DNAs varies from 31 to 75% G+C. 
Furthermore, herpesvirus DNAs vary with respect to the extent of homogeneity of base 
sequence distribution across the length of the genome (Roizman et al., 1992).
Probably the most interesting feature of herpesvirus DNAs is their sequence 
arrangement. There are six main types of genome structures, differing in the size and 
relative arrangement of repeated and unique sequences. According to this scheme the 
herpesviruses can be divided into six groups.
Complete sequencing of seven mammalian herpesviral genomes has shown that 
viruses from all three subfamilies contain a subset of 40 genes common to all the viruses, 
suggesting that these viruses share a common evolutionary origin. Detailed phylogenetic 
analysis has estimated that the three subfamilies arose approximately 180 to 220 million 
years ago (McGeoch et al., 1995). Channel catfish virus, however, does not show such 
similarities to the mammalian and avian viruses (Davison, 1992), suggesting that fish 
herpesviruses form a distinct and diverse subfamily.
1.2. Varicella-Zoster Virus
1.2.1. Introduction
Varicella-zoster virus is the causative agent of two common well defined diseases: 
chickenpox (varicella) upon primary infection, and shingles (herpes zoster) after 
reactivation of the latent virus from dorsal root ganglia. Chickenpox is a highly 
contagious but commonly mild disease, usually of children, and shingles is a local 
vesicular condition caused by the reactivation of VZV within a dermatome. Normally, 
neither chickenpox nor shingles is life-threatening, although the latter is often extremely 
painful. Both diseases, however, may have serious consequences in immune- 
compromised patients (reviewed in Davison, 1991).
Primary VZV infection is presumed to be initiated by the inoculation of the 
respiratory mucosa with infectious virus transferred in respiratory droplets or by contact 
with infectious vesicular fluid from an infected individual (Nelson & St. Geme, 1966). 
During the incubation period, which lasts from 10-21 days, the virus probably spreads to 
regional lymph nodes and then causes primary viraemia with associated viral replication in 
the liver and spleen. A secondary cell-associated viraemic phase begins at 24 to 96 hours 
which results in the transport of the virus to skin and respiratory mucosal sites and it is 
the replication of the virus in the epidermal cells that causes the characteristic rash of 
varicella. The termination of viral replication requires the induction of VZV specific 
immunity. During this period of primary infection the virus gains access to the cells of the
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trigeminal and dorsal root ganglia and establishes latency. The virus can remain in this 
latent state for up to several decades before being reactivated to produce shingles 
(reviewed by Arvin in Fields Virology 1996, Chapter 79 pp2547-2576).
1.2.2. Classification of VZV
Based on its morphology, VZV is classified as a member of the family 
Herpesviridae (Roizman et al., 1992) and is further classified along with the herpes 
simplex viruses in the subfamily Alphaherpesvirinae, by virtue of its ability to replicate 
and spread quickly and efficiently. In common with other alphaherpesviruses, VZV 
establishes a life-long latent infection of sensory nerve ganglia, from which it can later 
reactivate.
The VZV particle, like that of all herpesviruses, is now appreciated as one 
comprising of four major elements; the core containing a linear double-stranded DNA, an 
icosahedral capsid, a tegument, and an envelope containing viral glycoprotein spikes on 
the surface. The enveloped particle is pleomorphic to spherical and 180 to 200nm in 
diameter.
1.2.3. Genome structure of VZV
The molecular biology of VZV has lagged behind that of the other human 
alphaherpesviruses, HSV-1 and HSV-2, due to the inability to obtain large quantities of 
cell-free infectious virus in tissue culture. VZV is extremely cell-associated and is usually 
passaged in vitro by seeding infected fibroblasts, rather than cell free virus, onto fresh cell 
monolayers. Therefore, most VZV research has followed routes that tend to avoid the 
need to work with cell-free virus and work has focused more on the genetic material of 
VZV.
The complete nucleotide sequence of the Dumas strain of the VZV genome was 
determined in 1986 by Davision and Scott. The genome is a linear double-stranded DNA 
molecule about 125,000bp in length and is thus one of the smallest herpesvirus genomes. 
It has a G+C content of 46%, rather lower than that of most herpesviruses (Ludwig et al., 
1972). The genome is usually present as a linear duplex in virions: however, Straus etal., 
(1981) and Kinchington et al., (1985) reported the presence of rare circular forms of 
DNA released from virions.
Restriction endonuclease mapping (Dumas et al., 1981; Davison & Scott, 1986) 
revealed that the genome is composed of two unique regions, a unique long region (UL, 
approx 100,000bp) and a unique short region [Us, 5,232bp, Figure 1.1]. The unique 
long region is flanked by inverted repeat regions [terminal repeat long (TRL) and internal
4
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repeat long (IRL), each 88.5bp| and the unique short region is flanked by inverted repeat 
regions [terminal repeat short (TRS) and internal repeat short (IRS), each 7,319.5bp],
The VZV genome exists predominantly in two isomeric forms (Dumas et al., 
1981; E ckeretal.,  1982) as the Us region can be directed in either orientation in 50% of 
genomes. In contrast, the U, region is directed in one orientation in 95% of genomes and 
in the opposite direction in 5% of genomes (Davison, 1984; Hayakawa & Hyman, 1987; 
Kinchington etal. ,  1985).
140 16020 40 60 80 100
VZV
TRL IRLIRS TRS
US
UL
HSV-1
IRL IRS TRS
US
ULTRL
UL
95%
5%
Figure 1.1. Comparison of VZV and HSV-1 genom es
The top panel shows schematics of the VZV (125kbp) and HSV-1 (152kbp) genomes 
and a scale in kbp is shown above. Inverted repeats (TRL/IRL and TRS/IRS) are 
shown as coloured boxes. The bottom panel shows the different isomers of the VZV 
genome; the two predominant forms contain the long segment in a single orientation, 
while the short segment is detected in an equimolar ratio in either of the two possible 
orientations, as indicated by the arrows. A small percentage of the VZV DNA molecules 
exist either in a circular form or with the long segment inverted (Davison, 1984; 
Hayakawa & Hyman, 1987; Kinchington et al., 1985).
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The DNA sequence of the Dumas strain of VZV was originally thought to contain 
at least 68 unique genes, three of which are present in two copies in the IRS and TRS 
regions and two (42 and 45) are probably expressed as spliced mRNA. Two additional 
genes have been proposed since the original sequence assignments were made (Davison 
& Scott, 1986; McGeoch et al., 1993); ORF 9A (Barnett et al., 1992) and ORF 33.5 
which encodes an N-terminal tmncated form of ORF 33 (Telford et al., 1992). The 
arrangement of the open reading frames in the genome is shown in Figure 1.2. Although 
some of the genes have putative polyadenylation signals shortly after the ends of their 
ORF's, many of the genes are arranged in unidirectional families of up to four genes with 
a single putative polyadenylation signal at the 3' end of the family. This type of gene 
arrangement has been documented extensively for HSV (Wagner, 1985).
The DNA sequence of the Dumas strain of VZV contains five regions with repeat 
elements termed R1 to R5 (Davison & Scott, 1986). R1 to R4 are G-C rich like the G-C 
rich repeats present in HSV-1 (Watson et al., 1981; Davison & Wilkie, 1981). In 
contrast, the reiterated element of R5 is longer and A+T rich. The R l, R2 and R3 regions 
are located in the UL segment of the genome, and each is within the coding sequence of 
genes. In contrast R4 and R5 appear not to code for protein, the R4 region is located in 
both IRS and TRS regions between ORFs 62 and 63 and consists of multiple 27bp 
elements (Casey et al., 1985) and the R5 region is located between ORFs 60 and 61 and 
consists of 88 and 24bp repeats (Hondo & Yogo, 1988). The Dumas strain only has a 
single copy of the R5 repeats, whereas other strains of VZV have multiple repeats. The 
variability in the number of repeats implies that the different strains of VZV have differing 
overall lengths of their genomes. The role of the reiterations in the growth of VZV is 
unknown but the relative lack of conservation of these features in position and sequence 
in different herpesvirus genomes suggests that some, perhaps all, may merely have 
accumulated in locations where they do not cause a selective disadvantage.
1.2.4. VZV and HSV-1 sequence homology
Hybridisation studies on VZV and HSV-1 DNA revealed that there was nucleotide 
homology between the two viruses. These studies indicate that large proportions of the 
VZV genome are collinear with the HSV-1 genome (Davison et al., 1983). Subsequent 
comparison of sequences of HSV-1 and VZV allowed gene homologues to be identified. 
The functions of many VZV genes could therefore be predicted from studies on HSV 
homologues.
Within the UL region of VZV, 56 of the 61 genes have homologues and 55 are 
located in similar regions of the genome. Five genes in the UL region do not have HSV-1 
counterparts. One gene in the UL region, ORF 61, has its HSV-1 homologue, Vmw 110 
located in the IRL/TRL region of HSV-1.
6
Chapter I. Introduction
“ i----------- 1-----------1----------- 1----------- 1----------- 1-----------1----------- 1----------- 1----------- 1----------- 1----------- 1----------- 1----------- 1---------- 1----------- 1-----------1----------- 1
5
4
10
4  ±_
15 20
'4  4  4  4  4
1 23 4 5 6 7 8 9A9 10 11 12 13 14
- i  1----------- 1-----------1 i i----------- 1----------- 1-----------r -
20 25 30 35 40
□ c
4  4  4
15 16 17 18 19 20 21 22
i 1----------- 1----------- r -
40
4
I i 1 r -
45 50 55
4 _
60
4
4  4  4  4
23 24 25 26 27 28 29 30 31 32
- I ----------- 1 1 —  1----------- 1 I----------- 1---------- 1“
60
4
65 70 75
4  4
80
4
4  4
33.5 33 34 35 36 37 38 39 40 41 42 43
44 45 46 47 48 49 50 51 52 53 54 55 56 57
I----------- 1----------1------------ 1----------- 1----------- 1--------- 1------------ 1----------- 1----------- 1----------- 1-------
100 105 110
“ I----------- 1
120
u  <zi|c
4 4
115
4  .4.
Dl l i a
+ 4
585960 61
i--- 1--- 1--- 1--- 1--- 1
120 125
4
62
4  4  4
63 64 65 66 67 68 69 70
71
Figure 1.2. The arrangement of the open reading frames in the genom e of VZV
Polyadenylation sites are indicated by the vertical arrows. The colour scheme is as 
follows: red indicates enzymes, blue proteins in the capsid, tegument or those involved 
in capsid maturation/DNA packaging, yellow shows proteins involved in transcription or 
translational control, green membrane proteins, and finally white indicates unknown 
function. (Data taken from Davison 1991, 1993: Ostrove 1990; McGeoch etal., 1993).
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In the Us region of VZV, all four of the VZV genes have homologues within the 
Us region of HSV-1, although the positions of the genes are rearranged relative to HSV-1 
(Davison et al., 1986). The three genes in the IRS/TRS regions of VZV (ORFs 62, 63 
and 64) each have HSV-1 homologues; ORF 62 has its HSV homologue Vmw 175 
located in the IRS/TRS repeat region of HSV-1, whereas ORFs 63 and 64 have their 
HSV-1 homologues located in the Us region of HSV-1.
Five genes in VZV (ORFs 1,2, 13, 32 and 57) do not have homologues in HSV- 
1. However, four of them (ORFs 1, 2, 32 and 57) have homologues in equine 
herpesvirus type 1, another member of the alphaherpesvirus family (Telford et al., 1992). 
The fifth gene ORF 13, encodes the viral thymidylate synthase. Although no other 
alphaherpesvirus is known to encode this enzyme, it is encoded by four 
gammaherpesviruses [HHV8 (Moore et al., 1996), EHV2 (Telford et al., 1995), HVS 
(Horness et al., 1986) and HVA (Richter et al., 1988)].
1.2.5. Gene products of VZV involved in nucleotide metabolism
Comparison of the VZV ORFs with those of the more fully characterised HSV-1 
proteins permitted many gene functions to be assigned. Additional information as to the 
likely function of the predicted VZV genes has also been gained from either sequence 
comparison with non-herpesvirus proteins or from experimental work (reviewed by 
Davison, 1991). The genetic relationship between VZV and HSV-1 forms the major basis 
for the properties or functions assigned to the VZV genes in Table 1.1.
VZV specifies a large number of enzymes involved in DNA synthesis. Pyrimidine 
deoxyribonucleoside kinase (dPyK), the product of ORF 36, was identified on the basis 
of its homology to HSV-1 thymidine kinase (Sawyer et al., 1986). The VZV enzyme is a 
70Kd dimer composed of two identical 35Kd subunits. The enzymological properties of 
VZV dPyK differ from those of HSV-1 TK (Ogino et al., 1977; Cheng et al., 1979; 
Sawyer et al., 1986), particularly in that VZV phosphorylates deoxycytidine in preference 
to thymidine. The VZV enzyme, like TK, phosphorylates and therefore activates 
acyclovir. Acyclovir resistant strains of VZV have point mutations in the TK gene near the 
adenosine triphosphate (ATP) or thymidine binding site or mutations that result in a 
truncated protein (Sawyer et al., 1988). In addition to specifying dPyK, which is 
involved in the salvage pathway for thymidine metabolism, VZV also encoded the enzyme 
thymidylate synthase which is involved in the pathway for the de novo synthesis of 
thymidylate. This enzyme bears strong homology to TS proteins from other organisms 
and several approaches have demonstrated that it is a functional enzyme (Thompson et al., 
1987).
VZV ORFs 18 and 19 are homologous to the small and large subunits of HSV-1 
ribonucleotide reductase (RR) (Davison, 1986). This enzyme catalyses the conversion of
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ribonucleoside diphosphates to their corresponding deoxyribonucleosides. Chemical 
inhibition of VZV RR by the inhibitor 2-acetylpyridine 5-[(dimethylamino) thio carbonyl] 
thiocarbonohydrazone (A1110U) potentiates the antiviral activity of acyclovir, 
presumably by decreasing intracellular pools of deoxyribonucleoside triphosphates and 
increasing the level of acyclovir triphosphate (Spector, 1989). This resultant 100-fold 
increase in the ratio of the concentrations of acyclovir triphosphate to dGTP facilitates the 
binding of the inhibitor to the target enzyme, DNA polymerase, resulting in increased 
inhibition of virus replication.
VZV also specifies deoxyuridine triphosphatase (dUTPase) an enzyme that 
catalyses the conversion of deoxyuridine triphosphate (dUTP) to its corresponding 
monophosphate (dUMP), providing both a mechanism to prevent incorporation of dUTP 
into DNA and a pool of dUMP for conversion to dTMP by thymidylate synthase. Uracil 
DNA glycosylase is encoded by ORF 59, this functions in DNA repair and acts to correct 
insertion of dUTP and excise deamination of cytosine residues in DNA (reviewed in 
Davison, 1991).
1.2.6. Regulation of VZV genes
Gene expression of many herpesviruses is co-ordinately regulated and 
sequentially ordered in a cascade fashion. The most extensive analysis has been done for 
HSV-1 genes which are classified as a , (3 and y (Honess & Roizman, 1974, 1975) or 
immediate early (IE), early (E) and late (L) (Clements et al., 1977). The inability to obtain 
high-titre cell free VZV has made it difficult to achieve synchronous infection of cells in 
culture to determine the temporal classes of VZV genes. It is still unclear whether VZV 
follows a distinct cascade pattern during which the three classes of genes (immediate 
early, early and late) are sequentially expressed as found in other herpesviruses such as 
HSV-1 (Honess e ta l,  1974).]
Gene regulation during HSV-1 infection in tissue culture has been extensively 
studied. The IE genes are transcribed by the unmodified host RNA polymerase II at the 
onset of infection. The promoter regions of each of the IE genes contain one or more 
copies of the conserved sequence TAATGARAT, which mediates stimulation of IE 
transcription by the virion tegument protein Vmw 65 (Ace et a l, 1989). Vmw 65 does not 
bind directly to DNA (Marsden et al., 1987) but is incorporated into a multiprotein 
complex at TAATGARAT. In addition to Vmw 65 the complex contains the cellular 
factors Oct-1, which binds to TAATGARAT, and HCF, a large protein which is cleaved 
to a number of smaller products (Gerster & Roeder, 1988). Three of the immediate early 
proteins produced are important transactivators required for maximal expression of early 
and late genes (Everett, 1984a; O'Hare & Hayward, 1985; Sacks et al., 1985). Two of 
these proteins Vmw 175 (IE 175 gene product) and Vmw 63 (UL54 gene product) are
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Table 1. Functions assigned to VZV genes
(Taken from Davison 1991,1993; Ostrove 1990; McGeoch eta!., 1993.)
_________ Counterpart____________________________________________________________
2 —  Function Unknown
3 UL55 Function Unknown
4 UL54 IE protein; Post-translational regulator of g en e  expression
5 UL53 Possible membrane protein
6 UL52 Component of DNA-helicase-primase
7 UL51 Function Unknown
8 UL50 Deoxyuridine triphosphatase
9 UL49 Tegum ent protein
9A UL49A Possible membrane protein
10 UL48 Tegum ent protein; transactivates IE g e n e s
11 UL47 Tegum ent protein
12 UL46 M odulates IE gen e  transactivaton by UL48
protein
13 —  Thymidylate Synthase
14 UL44 Membrane glycoprotein (gpV )-role in cell entry
15 UL43 Function Unknown, probable integral m em brane protein
16 UL42 Subunit of DNA polym erase
17 UL41 Virion host shutoff protein
18 UL40 Ribonucleotide reductase small subunit (R2)
19 UL39 Ribonucleotide reductase large subunit (R1)
20 UL38 Capsid protein
21 UL37 P ossib le DNA binding function
22 UL36 Tegum ent protein
23 UL35 Capsid protein
24  UL34 M em brane-associated phosphoprotein
25 UL33 Role in capsid maturation/DNA packaging
26 UL32 Function Unknown
27 UL31 Function Unknown
28 UL30 Catalytic subunit of DNA polym erase
29 UL29 Single-stranded DNA binding protein
30 UL28 Role in capsid maturation/DNA packaging
33 UL26 P rotease involved in virion maturation
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VZV Gene HSV-1 Gene function
_____________ Counterpart__________________________
3 3 .5  UL26.5 Internal protein of immature capsids (p rocessed  by UL26
34 UL25 Virion protein
35 UL24 Function Unknown
36 UL23 Thymidine kinase
37 UL22 Membrane glycoprotein (gplll) -role in cell entry
38 UL21 Role in virion m orphogenesis
39 UL20 Integral mem brane protein; role in virion eg ress
40 UL19 Major capsid protein
41 UL18 Capsid protein
42+45 UL15 P ossib le term inase
43 UL17 Function Unknown
44 UL16 Function Unknown
46 UL14 Function Unknown
47 UL13 T egum ent protein; probable protein kinase
48 UL12 DNase-role in maturation and packaging of DNA
49 UL11 Myristylated tegum ent protein- role in
envelopm ent and virion transport
50 UL10 Probable integral membrane protein
51 UL9 Or/-binding protein; DNA helicase
52 UL8 Component of DNA helicase-prim ase com plex
53 UL7 Function Unknown
54 UL6 Role in virion m orphogenesis
55 UL5 Component of DNA helicase-prim ase com plex
56 UL4 Function Unknown
57 —  Function Unknown
58 UL3 Function Unknown
59 UL2 Uracil-DNA glycosy lase
60 UL1 Function Unknown
61/71 RL2 IE protein; transcriptional regulator
62 RS1 IE protein; transcriptional regulator
63 /70  US1 IE protein; transcriptional regulator
64 /69  US2 Virion protein
65 US9 Tegum ent protein
66 US3 Protein kinase
67 US7 Membrane glycoprotein (gpIV)
68 US8 Membrane glycoprotein (gpl)
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essential for normal viral growth. The third transcriptional activator, Vmw 110 is not 
essential for viral replication in tissue culture (Stow & Stow, 1986; Sacks & Schaffer,
1987). Genetic and biochemical evidence has shown that the HSV-1 IE polypeptide Vmw 
175 is essential for the expression of early and late gene products and transactivates a 
number of early gene promoters in synergy with Vmw 110 protein but the role of the 
other EE proteins is still unknown (Courtney et al., 1976; Marsden et al., 1976; Watson & 
Clements, 1978, 1980; Preston, 1979a; Dixon & Schaffer, 1980; Preston, 1981; DeLuca 
et al., 1985).
Four VZV IE proteins have been identified, three of which are phosphoproteins 
(reviewed by Cohen in Fields Virology 1996, Chapter 78 pp2525-2542.). The largest 
phosphoprotein has been assigned to ORF 62, whereas identification of the other proteins 
is uncertain at present. The product of VZV gene 62 is believed to be the VZV equivalent 
of HSV-1 Vmw 175 as the genes are located in equivalent positions and there is extensive 
predicted amino acid sequence conservation between them (McGeoch et al., 1986). Also 
VZV ORF 62 has been shown to be a potent activator of gene expression in transient 
transfection assays (Everett & Dunlop, 1984; Everett, 1984; Inchauspe et al., 1989) and 
the regions of the Vmw 175 polypeptide that have been shown to be the most important 
for its transactivation and repression phenotypes are the most highly conserved (Paterson 
& Everett, 1988a; DeLuca & Schaffer, 1988). The same regions are also highly 
conserved in the other alphaherpesvirus homologues of Vmw 175 (Grundy et al., 1989; 
Cheung, 1989; Vleck et al., 1989). The most compelling evidence that VZV IE 62 and 
HSV-1 Vmw 175 are functionally homologous is that HSV-1 mutants with lesions in 
Vmw 175 can be complemented by either transfected plasmid or transformed cell lines 
which express VZV IE 62 (Fesler et al., 1988).
VZV ORF 10 is the homologue of HSV-1 Vmw 65. The two genes have similar 
locations within their respective viral genomes. The predicted amino acid sequences of 
VZV ORF 10 and Vmw 65 are highly homologous except that ORF 10 lacks the acidic 
carboxyl terminus of Vmw 65 which is required for transactivation (Davison & Scott, 
1986; McGeoch et al., 1988; Moriuchi et al., 1993). VZV, like its HSV-1 homologue 
transactivates VZV ORF 62 and HSV-1 genes in transient expression assays (Moriuchi et 
al., 1993), however, ORF 10 protein does not transactivate the putative VZV IE ORF 4 
and ORF 61 genes (Kinchington et al., 1994; Moriuchi et al., 1994). Mutagenesis studies 
on the VZV ORF 62 promoter indicated that TAATGARAT-like elements contribute to 
transactivation of the VZV IE62 by the ORF 10 protein (Moriuchi et al., 1995).
ORF 61 is an IE gene of VZV and is thought to be the HSV-1 Vmw 110 
homologue, because both genes are located in similar parts of the genome, and the 
predicted gene products share a cysteine rich putative zinc-binding finger in the amino- 
terminal region and additional limited amino acid homology elsewhere (Perry et al., 
1986). However, the two proteins exhibit different properties in transient expression
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assay systems in vitro, HSV-1 Vmw 110 transactivates HSV-1 genes, while VZV ORF 
61 has been shown to be a transrepressor (Everett, 1984; O'Hare et al., 1986). 
Experimental evidence has shown that cell lines expressing VZV ORF 61 complement the 
growth of an HSV-1 Vmw 110 deletion mutant and thereby verify that VZV ORF 61 is 
the functional homologue of HSV-1 Vmw 110 (Moriuchi et al., 1992). The ability of 
VZV ORF 61 to complement a Vmw 110 deletion mutant of HSV-1 implies that despite 
marked differences in amino acid sequences and in activities in transient expression 
assays, the two proteins have similar functions during virus infection.
The VZV gene exhibiting the highest degree of similarity to the HSV-1 gene 
encoding Vmw 68 is VZV ORF 63 (Davison & Scott, 1986). Although the sizes of the 
two proteins are rather different, i.e. the VZV gene 63 product has a theoretical molecular 
mass of 30.5kDa, whereas its HSV-1 homologue has a molecular mass of 68kDa, and the 
total degree of amino acid conservation is low, they have one conserved domain with a 
degree of similarity ranging from 25-49% (Davison & McGeoch, 1986). The literature is 
unclear as to whether VZV ORF 63 by itself directly transregulates other VZV promoters 
since results from cotransfection experiments demonstrate that the VZV 63 protein 
strongly represses the expression of VZV gene 62. In addition, transient expression 
assays have shown that VZV gene 63 protein can activate the thymidine kinase gene 
which encodes a typical early protein, but it cannot affect the expression of late genes 
encoding glycoproteins I and II. The results from these transient expression experiments 
strongly suggest that the VZV gene 63 protein could play a pivotal role in the repression 
of IE gene expression as well as in the activation of early gene expression (Jackers et al., 
1992). Recent experimental evidence, however, has demonstrated that ORF 63 exerts 
only minimal effects on diverse VZV putative IE and E promoters and it was noted that it 
did not directly inhibit the ORF 62 promoter as had previously been reported (Kost et al., 
1995).
VZV ORF 4 protein shares considerable amino acid sequence homology with 
HSV-1 IE protein IE63, especially in the carboxy terminus. The carboxyl terminal region 
of IE63 is rich in cysteine and histidine residues and has been shown to bind zinc. While 
the carboxyl region of ORF 4 also contains cysteine and histidine residues, it is not 
known whether this region also binds zinc. The amino terminal regions of these two 
proteins have limited amino acid homology, however both are highly acidic. Despite 
structural similarities, VZV ORF 4 and HSV-1 DE63 behave differently in transient 
expression assays. ORF 4 protein transactivates a wide variety of target constructs. In 
contrast, EE63 acts as a transrepressor or a transactivator depending on the presence of 
different mRNA processing signals. Although IE63 is required for HSV-1 replication the 
role of ORF 4 in viral infection is not well understood. Cell lines expressing ORF 4 are 
unable to efficiently complement HSV-1 IE63 mutants (Moriuchi et al., 1994).
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1.2.7. VZV DNA replication
VZV DNA replication is thought to occur in four stages based on evidence from 
replication of the HSV-1 genome (Davison, 1984). Firstly linear DNA in the virion 
circularises. Since the VZV genome is not terminally redundant the simplest method for 
circularisation involves direct ligation of the termini to produce a novel L-S joint identical 
in sequence to the normal L-S joint. The circular molecule then begins to replicate, and 
isomerisation may occur by homologous recombination between the inverted repeats. 
More extensive replication of the circular molecule occurs to generate head-to-tail 
concatemers probably by a rolling circle mechanism (Ben-Porat & Rixon, 1979; Jacob et 
al., 1979). Finally concatemers are cleaved to generate linear DNA for packaging into 
virions.
Origins of HSV-1 replication have been located in two distinct regions, namely 
close to the centre of UL (oriL) and within the inverted repeats IRS and TRS (oris). The 
HSV-1 origins lie betweeen the 5' ends of divergently transcribed genes. Two early genes 
which encode the viral DNA polymerase and major DNA binding protein flank oriL 
(Quinn & McGeoch, 1985; Gibbs et al., 1985), whereas the genes flanking oris belong to 
the IE class of genes. These specify the polypeptides Vmw 175 and either Vmw 68 or 
Vmw 12 (Wagner, 1985). Studies have revealed that VZV contains an origin of 
replication in IRS/TRS regions - termed oris located between ORFs 62 and 63 and ORFs 
70 and 71 (Davison, 1986; Stow & Davison, 1986). In contrast to HSV-1, VZV does not 
appear to contain an origin of replication between its DNA polymerase and major DNA 
binding protein genes.
VZV oris contains a45bp, almost perfect palindrome with the sequence (TA)]7 at 
its centre. Mutation of the palindrome results in the loss of replicative activity. HSV-1 has 
the sequence (AT)5 and (AT)6 in its oriL and oris respectively. Adjacent to the VZV oris 
palindrome is the sequence CGTTCGCACTT, which is present in both the HSV-1 oris 
and oriL (Stow & Davison, 1986). Further upstream from the oris palindrome is the 
sequence CATTCGCACTT. Transfection experiments using the VZV replication assay 
indicate that the 45bp palindrome and the sequence CGTTCGCACTT are essential for 
replication activity, whereas the sequence CATTCGCACT contributes additional activity 
but is not essential. A second sequence farther upstream from the other 2 sequence does 
not contribute to the replication activity (Stow et al., 1990). Experiments have 
demonstrated that VZV is not able to support the replication of a plasmid containing HSV- 
1 oris; however HSV-1 is able to partially support the replication of a plasmid containing 
VZV oris (Stow & Davison, 1986).
Sequence analysis has revealed that the genome of VZV has homologues to all 
seven of the essential HSV DNA replication genes (McGeoch et al., 1988; Wu et al.,
1988). VZV gene 51 is homologous to HSV UL9 which encodes a protein that binds to 
the viral DNA origins of replication and is thought to play an important role in the
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initiation of viral DNA synthesis. The VZV origin binding protein, binds to the three sites 
adjacent to the palindrome at the sequences CGTTCGCACTT (located at two sites) and 
CATTCGCACTT (Chen & Olivo, 1994). The former sequence conforms to and the latter 
sequence contains a single base mismatch from the consensus sequence YGYTCGCACT 
used by the HSV-1 ori binding protein (Koff & Tegtmeyer, 1988).
1.2.8. Assembly and release of VZV from infected cells
Controversy exists as to how herpesviruses mature within and egress from cells. 
Added uncertainties exist for VZV replication, because the model needs to account for the 
inefficient formation and release of infectious progeny.
Two major and competing models for VZV egress have been proffered. Jones and 
Grose (1988) showed that naked particles traverse the nuclear membrane and become 
incorporated into and enveloped by large cytoplasmic vesicles. Virus-specific 
glycoproteins are released from the trans-Golgi network (TGN) and fuse with large 
cytoplasmic vesicles so their glycoprotein content is available to decorate the envelopes of 
newly arriving particles. The mature enveloped virions are then transported to the cellular 
membrane via the cytoplasmic vacuole. Exit of the virions at the cellular membrane takes 
place when cytoplasmic vacuoles harbouring VZV particles fuse and become incorporated 
into the cellular membrane. This model does not specify how nonenveloped 
nucleocapsids move from nucleoplasm to cytosol, how viral tegument gains access to the 
space between nucleocapsid and viral envelope or why enveloped viral particles are 
observed in perinuclear cisternae.
The competing model from Gershon and colleagues (Gershon et al., 1973; 
Gershon et al., 1994) proposed that nucleocapsids assemble in the nuclei of infected cells 
and bud through the nuclear membrane to reach the perinuclear cisterna-rough 
endoplasmic reticulum (RER). A temporary envelope is acquired from the inner nuclear 
membrane, this envelope fuses with the RER, delivering unenveloped nucleocapsids to 
the cytosol, where they travel until they reach the rrans-golgi network. Glycoproteins of 
the viral envelope are synthesised in the RER independent of the nucleocapsids and 
tegument proteins are probably synthesised by free ribosomes. The tegument proteins 
probably bind to the tails of the glycoproteins and are transported through an intermediate 
compartment to reach the golgi stack, where high mannose proteins are modified to 
become complex oligosaccharides. The glycoproteins are finally transported to the trans- 
golgi network where they accumulate on the surface of a trans-golgi derived sac. The 
concave surface of the trans-golgi derived sac becomes the viral envelope, while the 
convex surface becomes a transport vesicle, which diverts virions from the secretory to 
the lysosomal pathway, delivering the virions to prelysosomes where they are subjected 
to degradative enzymes. It is proposed that VZV migrates to a lysosomal pathway because
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its envelope glycoproteins are glycosylated with mannose residues which become 
phosphorylated at the six position (Gabel et al., 1989). Mannose-6-phosphate chains 
render the evolving particles susceptible to binding and uptake by lysosomes bearing 
mannose-6-phosphate receptors. This model requires that an alternative pathway must be 
operative in some cell types in vivo to allow virus egress without lysosomal degradation. 
Therefore, this process explains the cell-associated nature of VZV in vitro but the 
mechanism by which the virus escapes diversion from the secretory to the lysosomal 
pathway in vivo remains to be determined.
1.2.9. VZV latency
A fundamental property of all herpesviruses is their ability to become latent, 
persist in an apparently inactive state for varying durations, and then be reactivated by 
certain stimuli. Thus, after infection, viral DNA persists in the host for the entire lifetime 
of the individual.
During HSV-1 infection, the virus accesses sensory neurons by direct spread at 
sites of mucosal or cutaneous inoculation. The viral nucleocapsids are then transported to 
the neuronal nucleus, where latency is established. During latency HSV expresses only a 
single family of latency-associated transcripts (LATs) (Croen et al., 1987; Stevens et al., 
1987) that overlap extensively with, but are opposite in polarity to, the mRNA encoding 
the immediate early protein Vmw 110. Reactivation of the virus entails de novo 
replication of virus, centrifugal migration back down the axon, and spread to local 
mucocutaneous cells (Stevens & Cook, 1971). Reactivation is a common and often 
asymptomatic event with HSV-1 (Brock et al., 1990), neither of which is true of VZV.
The nature of VZV latency has not been clarified as well as that of HSV-1. 
Whereas HSV reactivations recur numerous times, VZV infections rarely occur more than 
once. VZV latency is established during varicella, the primary viraemic infection. The 
virus may access neural tissues either haematogenously or by centripetal neural transport 
from mucocutaneous lesions. The VZV genome can be readily detected by the polymerase 
chain reaction in most human trigeminal ganglia and many dorsal root ganglia 
(Mahalingam et al., 1992), it has also been found in human geniculate ganglia and 
olfactory bulbs (Furuta et al., 1992; Liedtke et al., 1993). The cellular localisation of the 
persistent virus is less well established. Initial in situ hybridisation studies have shown 
neuronal latency (Hyman et al., 1983; Gilden et al., 1987). With more refined probes 
VZV persistence was demonstrated in non-neuronal cells (Croen et al., 1988; Meier et al., 
1993), this is in contrast to HSV which resides almost exclusively within neuronal cells 
during latency. The VZV genome possesses no obvious homologue of the HSV LAT- 
encoding sequences. Rather, in situ and Northern hybridisation studies argue for 
restricted transcription from multiple regions of the VZV genome during latency (Croen et
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al., 1988). Therefore, VZV remains latent and can reactivate in the context of a 
nonneuronal cell that can support its replication and facilitate its spread to neuronal and 
nonneuronal cells. In this process, multiple sensory nerves become infected and convey 
virus to all parts of the cutaneous dermatome. HSV, however reactivates within a 
neuronal cell that is surrounded by satellite cells which are less capable of supporting its 
productive replication and so the virus spreads readily to the skin but it does not spread 
efficiently within the ganglia. Therefore, the relative infrequency of VZV reactivation may 
reflect its nonneuronal site of latency, rendering it less subject to the neural triggers that 
provoke HSV reactivation.
1.2.10. Antiviral therapy for VZV
Over the past thirty years considerable experimental work has been carried out to 
identify agents which are effective in the treatment of VZV. One reason that it has been so 
difficult to produce non-toxic antiviral agents is that viruses replicate inside cells. 
Therefore, anything which affects the DNA of the virus can possibly affect the DNA of 
the cell.
Initial studies demonstrated that human leukocyte interferon benefited 
immunocompromised patients with varicella or zoster with a clear reduction in disease 
severity (Arvin et al., 1982). However, the precise mechanism by which the effects were 
mediated remains uncertain but it may involve non-specific augmentation of the deficient 
host responses to VZV or direct inhibition of virally driven transcription or translation. 
Experiments then moved onto nucleoside and pyrophosphate analogues which inhibit 
VZV replication. Adenosine arabinoside (vidarabine) was the first effective analogue, it 
proved to be a modestly potent but selective competitive inhibitor of VZV-encoded DNA 
polymerase (Whitley et al., 1982).
Acyclovir, which is a nucleoside analogue, is now the drug of choice for VZV 
infections because it has higher specific activity against VZV replication in vitro and better 
clinical efficacy than vidarabine, it also elicits fewer adverse effects than the 
administration of vidarabine or interferon-alpha [reviewed by Elion, 1993 (Figure 1.3)]. 
The compound itself is closely related to the natural component of DNA, guanine 
deoxyribose, except that it lacks the 2'- and 3' carbons and the 3' hydroxyl of the 
deoxyribose ring. The compound blocks the replication of VZV by shutting down virus 
DNA synthesis through an interaction with the virus-coded enzyme DNA polymerase. 
Before blockade of DNA synthesis can occur, the compound has to be phosphorylated 
into its triphosphate form indicating that ACV is a pro-drug. The compound is selectively 
monophosphorylated by the VZV-encoded thymidine kinase (TK) and further modified 
by cellular enzymes (Fyfe et al., 1978). It is clear that VZV-induced TK is very different 
from the cellular TK and this results in the high selectivity of acyclovir for the virus. The
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triphosphate form of acyclovir, which is the active antiviral agent, behaves like a 
nucleoside triphosphate and competes with dGTP for the viral DNA polymerase. As the 
DNA chain begins to elongate, it eventually incorporates a molecule of acyclovir opposite 
cytosine on the template, this results in chain termination since acyclovir does not have 
3'OH group to form a phosphodiester bond (Elion, 1983). This drug has potent activity 
against HSV, with reduced efficacy against VZV and relatively low activity against 
HCMV. The low activity against HCMV can be explained by the absence of a TK gene.
HN
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HO
Acyclovir/Deoxyguanosine
Figure 1.3. Structure of acyclovir and deoxyguanosine
Structure of acyclovir is given in solid lines. Dashed lines represent the additional 2 ’ and 
3' carbons and 3'-hydroxyl group present in deoxyguanosine. (Taken from Elion, 1993).
There are three ways in which resistance to acyclovir can occur (reviewed in 
Elion, 1993). Most commonly a reduction in activity or deletion of the virus TK can 
occur, this is not a problem in immunocompetent patients but it does occur in highly 
immunocompromised patients after prolonged treatment. A herpesvirus TK with altered 
substrate specificity can also occur which would result in acyclovir becoming inefficiently 
phosphorylated. Finally the viral DNA polymerase can become mutated which results in 
the enzyme becoming insensitive to acyclovir-triphosphate.
Although in most respects acyclovir is an excellent drug, one drawback is its 
limited oral bioavailability. This restricts the levels of drugs that can be achieved in 
individuals following oral dosing and led to the idea that an oral prodrug might be 
developed to overcome this difficulty and lead to improved dosing convenience and 
potentially greater clinical effect. Research leading to new antiherpesvirus drugs has come
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from three approaches. The first approach was directed towards improving the 
bioavailability of acyclovir by examining the potential of a variety of related prodrugs. 
Efforts were concentrated on examinination of simpler esters and 18 different amino acid 
esters were made. The L-valyl ester, L-valylacyclovir was the best prodrug [Beauchamp 
et al., 1992, (Figure 1.4)]. It has the same broad spectrum of activity as the parent 
acyclovir but delivers higher levels of acyclovir and so increases the efficacy and dose 
convenience of the drug. The second approach was to examine a large number of 5- 
substituted pyrimidines for activity against those viruses which are not potently inhibited 
by acyclovir, i.e. HCMV. This research focused on the deoxypyrimidine nucleotides and 
led to the discovery of the potent, VZV specific compound 882C [Rahim et al., 1992, 
(Figure 1.4)].
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Figure 1.4. Structures of novel VZV inhibitors
The chemical structures are shown for the L-valyl ester prodrug, L-valylacyclovir and the 
5-substituted pyrimidine 882C which is neither a guanine base or a chain terminator. 
(Taken from Darby, 1993, Purifoy e t al., 1993).
This drug demonstrates potent and highly specific VZV activity without significant 
activity against HSV or HCMV. In addition 882C is not toxic at the highest concentration 
tested. The specificity is achieved since 882C is converted to the 5'-monophosphate by 
VZV TK but not by cellular cytosolic TK. Furthermore, the monophosphate is 
specifically converted to the diphosphate by the activity of the VZV thymidylate kinase. 
The lack of activity of 882C for HSV correlates with the inability of the HSV TK to use 
882C monophosphate as a substrate. It is the triphosphate of 882C that is the potent 
inhibitor of the VZV-specific DNA polymerase and this inhibition is probably the major 
mechanism of the antiviral activity. The potency of 882C has been found to be seven
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times greater than that of acyclovir which indicates that the compound is extremely 
promising for the treatment of VZV infections. The third approach used in the search for 
new anti-herpesvirus compounds was to examine drug combinations with acyclovir 
(reviewed by Safrin et a l, 1993). This research led to the compound 348U, an inhibitor 
of herpes simplex virus ribonucleotide reductase (Spector et al., 1992). This compound 
results in decreased pools of dGTP; in combination with acyclovir, this increases the 
competitive binding of acyclovir-triphosphate to the viral DNA polymerase.
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1.3. Thymidylate  synthase
1.3.1. Thym idylate synthase in DNA synthesis
The building blocks of DNA synthesis are the deoxyribonucleoside triphosphates; 
dATP, dGTP, dCTP and dTTP (Figure 1.5). The first three of these are synthesised by 
the direct reduction of their corresponding ribonucleotides in a reaction catalysed by 
ribonucleotide reductase. In eukaryotes and certain prokaryotes reduction occurs at the 
diphosphate level and is followed by phosphorylation of the dNDPs to dNTPs by the 
enzyme nucleoside diphosphate kinase. In other prokaryotes reduction of ribonucleotides 
occurs at the triphosphate level. Ribonucleotide reductase also mediates the synthesis of a 
fourth 2'-deoxyribonucleotide, namely dUDP.
DNA
dCTP deaminase
dCTP -► dUTP dTTP
nucleoside
diphosphate
kinase
nucleoside
diphosphate
kinase ribonucleotide
reductase dUTPasedUDP dTDPdCDP
UDP
thymidylate kinase
CDP
thym idylate kinasedCMP kinase
dCMP dUMP
thymidylate synthasedCMP deaminase
Figure 1.5. De novo  pathway of pyrimidine deoxyribonucleotides synthesis. Enzymes 
are in red and thymidylate is given in blue. (Taken from Larsson, 1995).
As dTTP has no ribonucleotide counterpart, it cannot be synthesised in this way. 
Instead, it is synthesised de novo by the enzyme thymidylate synthase, which catalyses 
the formation of thymidylate via the reductive methylation of deoxyuridylate. dUM P is 
provided either by the hydrolysis of dUTP by the enzyme deoxyuridylate triphosphatase 
(dUTPase), or by the deamination of deoxycytidylate. A second means for the production 
of dTMP is via the salvage pathway where thymidine kinase catalyses the 
phosphorylation of thymidine. The phosporylation of dTMP is then catalysed by the 
enzyme thymidylate kinase and nucleoside diphosphate kinase catalyses the 
phosphorylation of dTDP to dTTP (Neuhard & Nygaard, 1987; O'Donovan & Neuhard, 
1970).
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1.3.2. The thym idylate cycle
TS is unique among those enzymes that use folate cofactors, in that for each 
molecule of dTMP formed one molecule of H4folate is consumed (Figure 1.6). This 
reaction is the only one in Nature that results in the production of dihydrofolate which is 
an oxidised form of folate that cannot be used in any biological process. Thus to continue 
dTMP synthesis the tetrahydrofolate pools must be replenished. To regenerate the reduced 
folate pools, dihydrofolate reductase (DHFR) must rapidly reduce the dihydrofolate to a 
tetrahydrofolate form and the enzyme serine trans-hydroxymethylase completes the cycle 
by catalysing the formation of N5, N l0-methylenetetrahydrofolate.
NH
NH'
deoxyribose 5'phosphate deoxyribose 5 'phosphate
+ N5, N10- 
methylenetetrahydrofolate
+ dihydrofolate
thymidylate
synthase
N5, N 10-
methylenetetrahydrof
olate
Dihydrofolate
dihydrofoiaie
reductase
senne
transhydroxymethyiase
Tetrahydrofolate Tetrahydrofolate
Figure 1.6. The thymidylate cycle
The reductive methylation of deoxyuridylate results in the production of thym idylate and 
dihydrofolate. This oxidised form of the cofactor cannot be used by the cell and is 
converted back to the reduced form via the enzymes dihydrofolate reductase(DHFR) 
and serine transhydroxymethlayse.
1.3.3. S tructure  of thym idylate synthase
The crystal structure of L.casei TS was solved by Hardy et al. in 1987. 
Subsequently, crystal structures of E.coli (Perry et a l., 1990; Matthews et a l., 1990), T4
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phage (Finer-Moore et al., 1994), Leishmania major (Knighton et al., 1994), human 
(Schiffer et al., 1991) and Pnuemocystis carinii (Perry & Stroud, unpublished data) TSs 
were solved and confirmed the striking structural homology between these enzymes 
(Figure 1.7).
Figure 1.7. A dimer of E.coli thymidylate synthase
The monomers are shown in purple and blue. The p-strands and ex-helices are labelled 
(refer to Figure 1.13). The active site cysteine is seen in yellow, dUMP is in white and 
folate is in red. (Taken from Montfort etal., 1990).
Structures of binary complexes of TS with nucleotides, folate analogues, ternary 
complexes with nucleotides and folates, as well as complexes with novel inhibitors, have 
also been reported. The folate analogue CB3717 is used in many of the complexes studied
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by crystallography as it prevents any reaction beyond that of enzyme with dUMP. Like 
C F fH 4 folate it induces covalent bond formation between enzyme and dUM P however, 
CB3717 cannot form a covalent bond to dUMP analogous to the covalent bond between 
cofactor and dUMP in intermediate II of Figure 1.10.
The native enzyme is a symmetric, obligate dimer of chemically identical units of 
about 35kDa (see Figure 1.8).
Figure 1.8. Proposed structure of thymidylate synthase dimer from varicella- 
zoster virus
The view is directly down the dimer interface between the two monomers, p-strands are 
coloured yellow, a-helices are red, connecting loops white and both substrate and 
cofactor are depicted as space filling models (Image generated by F.J. van Deursen).
The overall fold of the enzyme is common to all TSs, and is defined by a series 8 
a-helices, 10 strands of p-sheet, and several segments of coil that connect the secondary 
structural elements. The subunit interface is formed by a 5-stranded twisted p-sheet 
composed of ~ 25 residues that packs against the same sheet formed by the other subunit 
of the dimer. Each of the two subunits folds into a three-layer domain. The first layer of
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the domain is composed of the five (3-strands that form the dimer interface. The central 
layer is made up exclusively of helices, a feature not normally seen in oc/(3 domains 
(Richardson, 1981) and the third layer consists of several other helices and the carboxy- 
terminal region.
Several species of TS also contain inserts: there are six sites where these inserts 
are found around the TS core. They are all present in surface loops or in a smaller 
"variable" domain and probably do not influence the core structure. In particular, Lcasei 
contains a 50 amino acid insertion (70 percent of the variable domain) which is arranged 
as three short a-helices in the variable domain (Hardy et al., 1987). Since these insertions 
are not present in all species they cannot be relevant to fundamental aspects of structure or 
function, but may serve roles specific to the individual organism.
1.3.4. The active site and catalytic mechanism of TS
The substrate binding site of TS is a funnel-shaped cleft extending into the interior 
of each subunit (Figure 1.9). Components of each monomer contribute to each of the two 
active sites, which are separated widely on each side of the molecule. This accounts for 
the inability to dissociate the native enzyme into catalytically active monomers. Moreover 
it suggests a way for the active sites to communicate in the process of ligand binding. 
Each site contains a bound inorganic phosphate, this has been observed in all TS 
structures solved in the absence of nucleotides (Hardy et al., 1987). The left wall of the 
cavity is formed by the sharply turning part of (3-strands ii and iii and the loop between a- 
helix A and (3-strand i. The ceiling is composed of residues form the exposed NH2 
terminus of helix J and the right wall by the end of (3-strand iv. The back wall of the 
cavity is formed by four residues of the (3-sheet of the other monomer (reviewed by 
Carreras & Santi, 1995, see Figure 1.7).
The catalytic cysteine residue (Cysl98 in L.casei, Cysl83 in VZV) lies in the NH2 
terminus of (3-strand iv, close to the dimer interface, with thiol exposed on the right wall 
of the active site cavity. This thiol is the nucleophile that transiently adds to the 6-position 
of dUMP during catalysis and covalently binds to mechanism based inhibitors. In the 
Lcasei structure three arginine residues [Argl78' (Arg 163 of VZV), Argl79' (Argl64 
of VZV) and Arg218 (Arg203 of VZV), 1 denotes residues from different subunit] and 
Ser219 (Ser204 of VZV) are at the base of the cavity co-ordinated to bound phosphate. 
Arg 178' and Arg 179' are not part of the same polypeptide chain as the other active site 
residues and are donated form the other subunit of the dimer for the purpose of ligating 
the bound phosphate (Hardy et al., 1987).
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Figure 1.9. Proposed structure of a monomer of thymidylate synthase from 
varicella-zoster virus
p-strands are coloured yellow, a-helices are red, connecting loops white. The central J 
helix is green, and the active site cysteine is blue. The C-terminal residue and the DRTG 
loop are coloured cyan. Substrate and cofactor are not shown for clarity. The orientation 
is the same as in Figure 1.7 and at 90° to that in Figure 1.8. (Image generated by F.J. 
van Deursen).
The enzyme reaction occurring in the active site involves the initial formation of a 
covalent bond between the C-6 position of dUMP and the catalytic thiol (C ysl98  of 
L.casei, C ysl83 of VZV) of the enzyme to generate a nucleophilic centre at C-5, 
intermediate I (Figure 1.10). This is followed by covalent bond formation between C-5 of 
dUMP and the one carbon unit of CH0H4 folate. In general folate does not undergo direct 
reactions with nucleophiles but converts to a reactive species, which could be the 5- or 
10-iminium ions formed by opening of the 5-membered imidazolidine ring of folate. In 
kinetic studies the 5-iminium ion was proposed because the N-5 is more basic than N-10, 
and N -10 is a better leaving group (Kallen & Jenecks, 1966). The joining of dUMP and
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Figure 1.10. Chemical mechanism of TS
Formation of a covalent bond between the C-6 position of dUMP and the catalytic thiol 
of the enzyme activates C-5 of dUMP for condensation with the one carbon unit of the 
CH2H4 folate (I). A covalent bond is formed between the activated form of the cofactor 
and C-5 of dUMP (II). The C-5 proton is extracted, followed by (3-elimination of folate to 
give intermediate III. Hydride transfer from non-covalent bound folate to exocyclic 
methylene and [3-elimination of the enzyme provides the products, dihydrofolate, dTMP 
and active enzyme. (Adapted from Finer-Moore e t al., 1990).
27
Chapter 1. Introduction
folate is envisioned as a nucleophilic attack of C-5 of dUMP on the N-5 iminium ion of 
CH2H4 folate which results in the formation of intermediate II in which C-5 of dUMP is 
connected to N-5 of H4folate by a methylene bridge (Figure 1.10). The C-5 proton of 
intermediate II is abstracted, followed by (3-elimination of the folate to give the exocyclic 
intermediate III. Hydride transfer from non-covalently bound H4folate to the exocyclic 
methylene intermediate III and (3-elimination of the enzyme provide the products, H2folate 
and dTMP, and the active enzyme (reviewed in Stroud & Finer-Moore, 1995).
1.3.5. Specific features of thymidylate synthase 
The dimer interface
In addition to the active site of TS (described in section 1.3.3), a second 
distinctive feature of the enzyme is the subunit interface. This is formed by a five stranded 
twisted (3-sheet composed of -25 residues that packs against the same sheet formed by the 
other subunit of the dimer. In contrast to other proteins of known structure in which 
aligned (3-sheets stack face to face with a left-handed rotation, sheets in the TS dimer are 
related by a right-handed twist (Hardy et al., 1987; Matthews et al., 1989). The common 
left-handed twist is thought to result from the fact that the natural twist between individual 
strands in a single sheet creates a deformed rectangular surface in which diagonally 
opposite comers point either both up or both down. When two such surfaces come 
together, the left-handed rotation of one relative to the other appears to be favoured by the 
fact that down-pointing comers of the top sheet can fold down over the edge of the lower 
sheet, and up-pointing portions of the lower sheets slip up over the edge of the top sheet 
(Chothiaer al., 1977; Cohen et al., 1981). Therefore a rotation in the opposite direction 
would instead place down-pointing comers of the top sheet very close to up-pointing 
corners of the bottom sheet forcing interior portions of the sheet to separate creating an 
unfavourable cavity. However in TS it was noted that at just the point where a down 
corner of the top sheet would otherwise penetrate an up comer of the bottom sheet, the 
smaller of the two regular (3-sheets on the bottom is arched backward by the series of 
stacked (3-bulges in the lower sheet. Instead of impacting the top sheet, the bottom sheet 
slopes away in the same direction and with the same curvature as the top sheet, permitting 
a very close and favourable association between edges of the large top sheet and the 
bottom sheet while maintaining optimal side-chain packing throughout the central portion 
of the (3-sandwich. These stacked (3-bulges are locally stabilised by hydrogen bonding 
involving eight conserved residues. This stmcture anchors the phosphate of bound dUMP 
and controls the precise orientation of the catalytically essential active site cysteine.
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The central J helix
Helix J is a six-turn, unusually hydrophobic element around which other 
secondary structures of the protein fold. It is even more hydrophobic than some 
membrane spanning helices. The helix packs diagonally across the (3-sheet and is flanked 
by amphipathic helices A and H, which are on the edge of the middle layer, and helix B 
which packs on top of helix J on the opposite side from the p-sheet.
1.3.6. Ordered binding of substrate and cofactor
Intracellular pools of folate consists predominantly of polyglutamylated molecules 
with polyglutamyl groups of average length 4-7. Monoglutamated folates have relatively 
low affinity for TS while polyglutamates have much higher affinities, in some cases over 
400 times greater (Lu et al., 1984). Kinetic investigations by Darin and Aull (1978) 
suggested that when monoglutamated co-factor is used there is evidence that the ligands 
bind in an ordered fashion in which dUMP binds first followed by folate. The folate is 
proposed to bind in two steps to TS.dUMP complexes, first binding in a loose 
noncovalent adsorption complex, then forming a tight covalent complex (Santi et al., 
1987). Following catalysis, the oxidised folate is the first product to dissociate from the 
enzyme followed by the product dTMP. These results are explained by the vastly greater 
binding affinity of dUMP for TS compared to the affinity of the monoglutamated folate 
for TS.
However, the situation with respect to polyglutamated substrates is more 
complex. Galvin et al., (1976) showed that whereas monoglutamated substrates bind to 
TS only in the presence of dUMP or a pyrimidine analogue, the pentaglutamate derivative 
forms binary complexes in the absence of pyrimidine. Furthermore Lu et al., (1984) 
demonstrated that for tetraglutamate substrates the order of substrate binding and product 
release is reversed with binding of folate preceding that of dUMP and release of dTMP 
preceding that of dihydrofolate. Therefore, the polyglutamate group increases the affinity 
of tetraglutamate for TS so that the cofactor binds in the absence of dUMP.
1.3.7. Conformational changes associated with TS reaction
1.3.7.1. Binary complex formation
The active site of TS closes down progressively as ligands bind. In the binary 
complex, formed as the substrate dUMP binds, the active sites remain open and residues 
remain close to their positions in the unliganded state. Comparison of substrate bound and 
phosphate bound structures from Lcasei TS have shown no significant conformational 
differences (Finer-Moore et al., 1993). The phosphate of dUMP is co-ordinated by the
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same highly conserved arginine residues and Ser219 (Ser204 of VZV) that ligate 
phosphate in the TS.Pi structure, as well as conserved Arg23 (Arg38 of VZV, refer to 
Figure 1.13). Each of these residues forms at least one hydrogen bond with the dUMP 
phosphate moiety, while Argl78' forms an additional bond with Tyr261 (Tyr246 of 
VZV), and Arg218 (Arg203 of VZV) forms additional H-bonds with the peptidyl 
carbonyl oxygens of both Arg 178' (Arg 163 of VZV) and Pro 196 [Prol81 of VZV, 
(Fauman et al., 1994)].
The only slight difference between the TS.Pi and TS.dUMP structures shows that 
Arg23 (Arg38 of VZV) has moved to interact with the phosphate moiety of dUMP and 
has become more ordered (Finer-Moore et al., 1993). This movement may be in 
preparation for the conformational change where Arg23 forms a salt bridge with the C- 
terminal carboxylate following folate binding (see Figure 1.12).
The deoxyribose of dUMP interacts with Tyr261 (Tyr246 of VZV) and His259 
(His244 of VZV), each of which forms hydrogen bonds with the 3'-hydroxyl of dUMP 
(Finer-Moore et al., 1993, Montfort et al., 1990). The C-2' carbon of dUMP lies in the 
back of the binding pocket close to the backbone amide of Asp221 (Asp206 of VZV) and 
the Ser219 (Ser 204 of VZV) side chain (refer to Figure 1.13)
The pyrimidine moiety of the substrate is involved in an extensive hydrogen bond 
network with Asp221 (Asp206 of VZV), Asn229 (Asn 214 of VZV), Glu60 (Glu75 of 
VZV), Trp82 (Trp97 of VZV), His 199 (His 184 of VZV) and several ordered water 
molecules. Asn229 forms the only direct contact between a TS side chain and the 
pyrimidine ring and assists in the discrimination between dUMP and dCMP [see Chapter 
8, (Liu & Santi, 1992)].
The findings that dUMP binding has little effect on the conformation of TS is 
consistent with the observation that binding of dUMP has only a small effect on the UV 
light, circular dichroism and fluorescence spectra of TS (Donato et al., 1976; Leary et al., 
1975; Galivan et al., 1975). It was suggested that because of the ordered mechanism of 
substrate binding, a portion of the conformational changes that occur when the binary 
complex is formed may be associated with the process of creating a binding site for folate.
1.3.7.2. Ternary complex formation
The spectral changes accompanying binary complex formation are small compared 
with those resulting from formation of the ternary complex as the UV and CD spectra alter 
considerably upon the addition of the N5, N10-CH2FH4 to the binary complex. Formation 
of the ternary complex results in the closing down of the enzyme and the production of a 
more compact structure of the protein, corresponding to an apparent decrease of 3.5% in 
the Stokes radius (Lockshin & Danenberg, 1980). This correlates well with the 
fluorescence quenching observed upon ternary complex formation (Bellisario et al., 1976)
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and thereby provides evidence that changes in the protein conformation, as opposed to 
changes in the environment of the ligand contribute to the majority of the observed 
variations in the fluorescence spectrum.
Studies on the crystal structure of TS bound in the ternary complex with both 
dUMP and folate show significant differences in the conformation of the protein 
compared to the unbound or dUMP bound structures (Montfort et al., 1990; Matthews et 
al., 1990; Kamb et al., 1992). It is uncertain whether the cofactor and substrate together 
or the cofactor alone trigger the protein conformational change. Kamb et al., (1992) 
solved the crystal structures of E.coli TS bound to either the cofactor analogue CB3717 or 
to a tighter binding poly glutamyl derivative of CB3717. These structures suggest that 
cofactor binding alone is sufficient to induce the conformational change in TS and dUMP 
binding is not required. The crystal structures further suggest that the dUMP binding site 
is accessible in the TS-cofactor binary complex. Conformational flexibility of the binary 
complex may permit dUMP to enter the active site of TS while the cofactor is bound.
Several structures of ternary complexes between E.coli TS, nucleotides, and 
folates or folate analogues have been reported (Montfort et al., 1990; Matthews et al., 
1990; Matthews et al., 1990; Fauman et al., 1994). Interactions between TS and bound 
folates are similar in the various ternary complex structures. Initially the substrate binds at 
the bottom of the active site pocket covalently linked through C-6 to the active site Cys 
residue. The faces of the pyrimidine and ribose rings of the substrate are exposed to 
provide a complementary docking surface for the folate cofactor. The pterin ring of the 
folate binds to the surface of the exposed substrate and makes its largest contact with the 
bound pyrimidine of dUMP. The aromatic ring of the PAB A moiety of the cofactor binds 
in a hydrophobic pocket of the enzyme (Montfort et al., 1990; Matthews et al., 1990b). 
The ternary complex structure of E.coli TS complexed with dUMP and tetraglutamated 
CB3717 shows the general position of the tetraglutamate group, which adopts an 
extended conformation to interact with a positively charged binding site on the protein 
surface (Kamb et al., 1992). This same positively charged site may be responsible for 
reported interactions between TS and its mRNA [see section 1.3.9.7. (Chu et al., 1991; 
Chu etal., 1993)].
The ternary complexes formed upon ligand binding are more ordered and have 
undergone an extensive conformational change compared to the TS.dUMP structure. 
Sections of helices and sheets move as units, usually less than lA, in response to ligand 
binding in a process that has been termed segmental accommodation (Figure 1.11). Note 
that this mechanism avoids disruption of the favourable conformations and hydrogen- 
bond patterns found in these secondary structural elements.
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Figure 1.11. Segmental accomodation by TS
A single monomer of E.coli TS is illustrated in the same orientation as in Figure 1.9. 
Residues shown in yellow deviate from the original position by less than 0.5A upon 
ligand binding, whereas residues shown in blue undergo substantial movement. (Taken 
from Montfort etal., 1990).
Two of the most pronounced structural differences noted in the ternary complexes 
of TS invlove changes in the surface loop (DRTG loop) containing Arg23 (L.casei 
numbering, Arg38 of VZV) and the C-terminal tetrapeptide. The C-terminal residue 
moves more than 4A to interact with the side chain of conserved Thr24, thus forming a lid 
over the active site (Figure 1.12).
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Figure 1.12. Interactions of the C-terminal residues from L.casei thymidylate synthase, 
before and after the ligand-induced conformational change. Dashed lines represent 
hydrogen bonds. Note the water mediated hydrogen bond contact between the folate 
and the main chain of Ala315 (Taken from Carreras & Santi, 1995).
The C-terminal carboxylate forms direct hydrogen bonds with Trp85 (TyrlOO is 
corresponding residue of VZV) and Arg23 (Arg38 of VZV), while the backbone carbonyl 
oxygen of Ala315 (Ala300 of VZV) forms direct and water mediated hydrogen bonds to 
the 2-NFFand 3-NH groups of the cofactor respectively. Not only does movement of the 
tetrapeptide over the active site further anchor the folate cofactor in its binding pocket and 
sequester it from solvent, but it also provides for the exact alignment of the substrate and 
cofactor through the intricate network of coupled hydrogen bonds (see Figure 1.12).
As in the TS.dUM P structure, nucleotides in the L.casei ternary complex 
structures show the phosphate group ligated by four arginine residues and Ser219 
(Ser204 of VZV), and the 3'OH of the deoxyribose forms hydrogen bonds with Tyr261
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(Tyr246 of VZV) and His259 (His244 of VZV). The positions of Asp221 (Asp206 of 
VZV), Asn229 (Asn241 of VZV), Glu60 (Glu75 of VZV), Trp82 (Trp97 of VZV), 
His 199 (His 184 of VZV), and the two ordered water molecules that comprise the 
hydrogen bond network co-ordinating the pyrimidine in binary complexes are preserved.
1.3.8. Stoichiometry of TS reaction
TS from all sources is an obligate homodimer with residues from both subunits 
forming two active sites (Hardy et al., 1987). In the presence of cofactor, FdUMP binds 
to all TS, regardless of source, with a stoichiometry of approximately 2 mol/molecule of 
enzyme (Danenberg et al., 1974; Danenberg & Danenberg, 1979; Plese & Dunlap, 1977; 
Santi & Danenberg, 1984). Evidence from Lcasei TS indicates that the binding sites are 
not equivalent. The FdUMP.N5,N10-CH2FH4.enzyme complex with the two molecules of 
FdUMP per enzyme decayed within 24 hours to a complex with only one FdUMP 
molecule per enzyme, which was stable for a longer period of time (Aull et al., 1974; 
Santi & Danenberg, 1984). Furthermore in the presence of triglutamated forms of the N 5, 
N 10-CH2FH4, the two binding sites show a twenty fold difference in affinity for FdUMP 
(Lockshin and Danenberg, 1979).
In the absence of cofactor, only a single molecule of dUMP or FdUMP is bound 
per mol of enzyme (Galivan et al., 1976a; Beaudette et al., 1980; Langenbach, 1976), 
although Plese and Dunlap (1978) reported 1.5 nucleotides were bound per enzyme 
molecule.
These observations have been proposed to reflect a sequential action of the 
catalytic sites, where the binding of one molecule of dUMP at either site results in minor 
conformational changes, and renders the second site inaccessible. This corresponds to the 
observed changes in the fluorescence and UV spectra (Donato et a l, 1976; Galivan et al., 
1975; Leary et al., 1975). Binding of cofactor causes a much greater conformational 
change, thus providing access to the second site (Donato et al., 1976; Danenberg et al., 
1974; Santi etal., 1974; Manavlan et al., 1986). A second molecule is then bound and the 
interaction of a second cofactor molecule completes the formation of the ternary complex 
(Santi & Danenberg, 1984).
1.3.9. Thymidylate Synthase from different sources: the TS family
To date sequences are known from more than 35 different species of TS (Figure 
1.13 and 1.14). These include the human enzyme (which is a drug target for anti-cancer 
agents), thymidylate synthases from protozoa (which are generally bifunctional, with TS 
and DHFR present in a single protein), and TS from bacterial and viral species. It is 
thought that TS is encoded by many viruses to support the increased need for DNA
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Figure 1.14. The TS family
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synthesis during the viral life cycle although it is by no means widespread among large 
DNA viruses. There are only a few organisms that can adequately scavenge thymidylate 
from their environment and do not require TS, examples are the intracellular 
mycoplasmas.
A striking feature of this enzyme is the very high degree of sequence conservation 
between organisms. Approximately 10% (27 from a core of 275) of residues are 
completely conserved and a further 165 (60%) are greater than 80% conserved, thus 
placing TS amongst the most highly conserved enzymes (Perry et al., 1990). This 
contrasts with dihydrofolate reductase, the enzyme which regenerates the folate cofactor 
oxidised by TS. Although amino acid sequences of DHFR have been reported from a 
smaller range of organisms, only 6% of residues (11 from a core of 170) are completely 
conserved with a further 41 residues (24%) being greater than 80% conserved (Lagosky 
et al., 1987).
Examination of the 35 sequences shows a lack of alignment at the N-terminus and 
the bifunctional enzymes have an N-terminal DHFR domain. By contrast the C-terminal 
regions precisely align in all species, indicating the importance of this region. In all TS 
sequences there is a fully conserved proline and cytosine residue in the active site 
reflecting the requirement for orientation of the cysteine side-chain (Figure 1.13).
Generally the regions where there are extra amino acids fall outside the regions of 
secondary structure and do not upset a-helices or p-sheets. There are however three 
exceptions: a single amino acid insertion is present in p-strand i of the yeast enzymes, 
there is an insertion in helix I of Llactis and in helix K of H.influenzae. In addition long 
insertions are present in Lcasei and S.aureus as helices, termed helix E and helix F. 
Between helix G and helix H all eukaryotes have an insertion, this insertion is not present 
in the prokaryotic enzymes and may represent a eukaryotic-specific function. Inspection 
of Figure 1.13 reveals that the sequence of the insertion is relatively well conserved.
In the TS line-up H.influenzae and M.genitalium are often the sole divergent 
sequence at an otherwise highly or fully conserved position (an example is Asp of the 
DRTG loop). It is noteworthy that both sequences came from genomic sequencing 
projects using shot-gun sequence approaches rather than from sequencing of cloned and 
characterised TS genes. So it is possible that the error rate in these sequences is high.
The high degree of sequence conservation seen at the level of primary structure of 
TS is also evident at the tertiary structure level. A comparison of the 3-D structure of the 
native enzyme from E.coli and L.casei showed that they are 89% conserved in terms of 
corresponding atom types (3824 common atoms out of 4300; E.coli TS), despite sharing 
only 60% amino acid identity. While the high conservation of TS sequences is clearly 
related to the chemical reaction catalysed, it may also be linked to the interaction with 
other enzymes and to conserved conformational dynamics upon substrate binding.
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1.3.9.1. Bacteria
The first studies of TS were performed on the enzyme isolated from L.casei 
(Friedkin et al., 1962; Blakley., 1963). The isolation of a methotrexate resistant Lcasei 
strain, that over-produced TS and DHFR meant that large amounts of highly purified 
enzyme were available for study (Crusberg et al., 1970) and has resulted in the L.casei 
enzyme becoming the most intensively studied TS from all sources (Santi & Danenberg, 
1984). In this organism the TS gene appears to be closely linked to DHFR on the 
chromosome with the TS sequence preceding that of DHFR.
In B. subtilis and S. aureus the genes encoding TS and DHFR are also closely 
linked. B.subtilis has two TS loci, thyA and thyB (Piggot & Hoch, 1985). ThyB gene 
encodes a heat-sensitive form of TS (Neuhard et al., 1978) and can complement growth 
of both an E.coli thyA strain (Rubin et al., 1978) and a B.subtilis thyA thyB strain 
(Iwakura et al., 1988). The termination codon of thyB overlaps the initiation codon of 
dfrA (Iwakura et al., 1988) by one nucleotide. Both genes are transcribed from the same 
promoter located upstream of thyB indicating that the genes belong to a single operon.
The nucleotide sequence of the gene for DHFR and the partial sequence of the 
gene for TS of S.aureus (Burdeska et al., 1990) are identical to the complete nucleotide 
sequences of the genes for TS and DHFR in Tn4003, a transposon that confers resistance 
to trimethoprim (a DHFR inhibitor) in S.aureus (Rouch et al., 1989). In both cases the 
genes are separated by only 44 nucleotides on the same strand suggesting they form part 
of the same operon.
By way of contrast the genes for TS {thy A) and DHFR (frd) are widely separated 
on the E.coli chromosome (Bachmann, 1983). However the two enzymes have been 
proposed to form part of a multienzyme complex that is responsible for channelling newly 
synthesised dNTPs into replicating DNA (Matthews et al., 1978; 1988). Comparison of 
the E.coli and Lcasei TS sequences reveals consistent homology over extensive regions. 
However a dramatic difference between the two sequences is reflected by the presence of 
a 51 amino acid stretch, present midway through the L.casei sequence which is 
completely absent from the E.coli enzyme (see Figure 1.13).
The gene coding for TS in Lactococcus lactis can complement the growth of an 
E.coli thyA strain, and its predicted amino acid sequence is the most widely diverged TS 
sequence known (Ross et al., 1990a). This gene has been proposed as a safe selectable 
marker (an alternative to antibiotic resistance markers) for use in the generation of strains 
whose ultimate fate will be in food systems or for release into the environment (Ross et 
a l, 1990b).
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1.3.9.2. Bacteriophage
Within the phage T4 genome the DHFR and TS coding sequences are adjacent and 
are arranged so that the termination codon of DHFR gene (located on the 5' side of the TS 
gene) overlaps the initiation codon of the TS gene. The two enzymes form part of a multi­
enzyme aggregate, comprising both T4 and E.coli proteins and containing several more 
enzymes involved in dNTP synthesis which include dCMP hydroxymethylase, dCTPase- 
dUTPase and ribonucleotide reductase (Moen et al., 1988). This complex is termed the 
dNTP synthetase complex and produces dNTPs in a manner tightly co-ordinated with 
DNA replication (Allen et al., 1980; Chiu et al., 1982; Matthews et al., 1988; Moen et al., 
1988). Protein-protein interactions have been explored between two enzymes of the 
complex, deoxycytidylate deaminase and thymidylate synthase. These enzymes are 
functionally associated with one another since they catalyse sequential reactions. 
Experimental evidence has revealed that physical interactions occur between the enzymes 
in the presence or absence of other proteins and require one of two zinc binding sites 
which are present on the dCMP deaminase (McGaughey et al., 1996).
In addition to their catalytic roles, TS and DHFR act as structural components of 
the T4 virion base plate (Capco etal., 1973) an example of enzymes with a stable protein 
fold being recruited into a structural role. Analysis of mutants that lack both TS and 
DHFR has confirmed their role as components of the T4 virion, and also shows that these 
two genes are not essential for bacteriophage T4 viability (Wang & Matthews, 1989).
Phage 03T is a large temperate Bacillus subtilis phage which can complement 
Thy' auxotrophs upon lysogeny since it encodes TS, the product of the thyP3 gene 
(Tucker, 1969). The thyP3 gene has been cloned, is functional in E.coli (Duncan et al., 
1977; Ehrlich et al., 1976). The phage integrates into the B.subtilis chromosome by virtue 
of its homology to host thyA and flanking sequences to other regions of the B. subtilis 
genome.
1.3.9.3. Protozoa
TS and DHFR are distinct, monofunctional enzymes in most organisms. 
Generally TS is a dimer of identical subunits of about 35kDa each, and DHFR is a 
monomer of about 20kDa. In contrast, in protozoa TS and DHFR exist as a bifunctional 
protein (Bzik et al., 1987; Ferone & Roland, 1980; Garrett et el., 1984; Grumont et al., 
1986; Hughes et al., 1989; Meek et al., 1985). Both enzyme activities exist on a single 
polypeptide chain with the DHFR domain on the amino terminus and TS on the carboxy 
terminus. All bifunctional TSs have this arrangement suggesting the importance of a free 
C-terminus of TS for the enzyme reaction. The native protein is a dimer of two such 
subunits in the size range of 110-140kDa (Ivanetich & Santi, 1990).
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A model has been constructed that describes the higher-order structure and 
function of the bifunctional protein (Grumont et al., 1986). The dimeric structure of this 
enzyme probably involves important intermolecular contacts between the TS domains of 
each subunit; this is based on the high homology of the TS domain of TS-DHFR with 
other TSs, and the fact that all monofunctional TSs exist as stable dimers (Hardy et a l,  
1987). Further, there is communication between the two TS domains, since a single 
proteolytic cleavage of one also destroys activity of the other without disruption of the 
subunit structure. The substrate dUMP is capable of forming a binary complex containing 
only one mole of dUMP per TS-DHFR dimer, indicating an interaction of the subunits 
(Garvey & Santi, 1987). In addition, the DHFR domains have been found to functionally 
communicate with each other as binding of methotrexate to one domain prevents binding 
to the other. Since elements of higher-order structure are conserved in the DHFR domain 
of TS-DHFR, it was suggested that the interactions between the DHFR domains 
contribute to dimer stability (Grumont et al., 1986). Finally, a functional TS-DHFR 
interaction is implied by the substrate channelling of H2folate from the active site of TS to 
that of DHFR as seen with Leishmania tropica (Meek et al., 1985).
The TS-DHFR interaction provides the enzyme with a biological advantage as the 
H2folate produced by the TS is channelled to DHFR faster than it is released into the 
medium (Meek et al., 1985). Consequently the net rate of the sequential reactions is 
governed by the rate of TS, there is no accumulation of inhibitory H2 folate and there is 
no depletion of H4 folates, the bifunctional protein seems to be optimised for continued 
dTMP synthesis. Furthermore, the bifunctional DHFR-TS of Leishmania exhibits 
disparate binding of the usually stoichometric ligand methotrexate, with 0.5mol bound per 
mol of DHFR-TS subunit (Ferone & Roland, 1980; Meek et al., 1985). It has also been 
shown that the DHFR and TS domains may be separately inhibited by agents selective for 
one activity or the other, suggesting that the two domains retain a level of independence 
(Ferone & Roland, 1980; Meek et al., 1985).
1.3.9.4. Yeast
In the yeast S.cerevisiae, as well as in some other fungi, TS provides the only 
source of dTMP for replication. S.cerevisiae lacks the TK-mediated pathway (Grivell & 
Jackson, 1968) and the cell membrane is impermeable to phosphorylated thymine 
derivatives including dTMP. dTMP starvation in S.cerevisiae is lethal and induces DNA 
strand breakage, mitotic crossing-over, gene conversion and unequal sister chromatid 
exchange.
TS fluctuates periodically during the S. cerevisiae cell cycle (Storms et al., 1984). 
The enzyme accumulates during S-period, peaks in mid to late S-phase and then drops 
suggesting that both periodic synthesis and instability of the enzyme contribute to the
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activity profile. These observations imply that TS is precisely regulated and may represent 
one of the rare proteins in yeast whose expression is cell cycle dependent. A series of cell 
division cycle (cdc) mutants have ben produced which block S.cerevisiae at different 
stages of the cell cycle. cdc21 is the thymidylate synthase mutant (Storms et a l, 1984).
TS is thought to be part of a multienzyme complex in T4 phage (Chiu et al., 
1992), mammalian cells (Reddy & Pardee, 1980), and other cell systems. In yeast, a 
similar multiprotein complex has been described (Jazwinski & Edelman, 1984), however 
all components of this complex have not been identified. The introduction of a large 
insertion into the TS gene of S.cerevisiae has no effect on viability other than to create a 
thymidylate auxotroph phenotype which requires a second mutation to provide a dTMP 
uptake pathway, implying that if TS is part of the replication complex in yeast it is not a 
required structural component (Taylor et al., 1987).
1.3.9.5. Herpesviruses
Varicella-zoster virus (Thompson et al., 1987), herpesvirus saimiri (Honess et al.,
1986), herpesvirus ateles (Richter et al., 1988), equine herpevirus 2 (Telford et al., 1995) 
and HHV-8 are the only herpesviruses shown to date to have a TS gene (Moore et al., 
1996). The viruses belong to different subfamilies of the herpesviruses and this gene is 
apparently absent from other members of each subfamily.
A homology search of proteins predicted from completed DNA sequences of VZV 
revealed that the product of gene 13 was highly homologous to eukaryotic and 
prokaryotic TSs. Published sequences of EBV, a member of the gammaherpesvirinae, 
clearly contains no TS homologue (Baer et al., 1984) and Honess et al., (1986) were 
unable to detect novel TS activities in cells infected with HSV-1 or PRV, members of the 
alphaherpesvirinae. The origins of the VZV and HVS TS genes remain uncertain as there 
is no method to determine unambiguously whether the TS gene is an ancestral feature lost 
during divergence to herpesvirus subfamilies, or whether it has been acquired after 
divergence.
In addition to a TS, VZV and HVS specify a TK (Davison & Scott, 1984) which 
catalyses the phosphorylation of thymidine to thymidylate. Thus these viruses supplement 
cellular pathways for providing thymidylate de novo (using TS) and by thymidine salvage 
(TK). Little is known about the expression of virus TK and TS genes, but it seems 
plausible that the two enzymes are used at different stages of pathogenesis to provide 
thymidylate for DNA synthesis. The viability of TK-negative mutants of HSV-1 in tissue 
culture (Shiraki et al., 1983; Dubbs & Kitt, 1974) indicates that a virus-coded function for 
the provision of thymidylate is not required, and therefore suggests that VZV TS may also 
be dispensable. The generation of VZV mutants from cosmid DNAs has shown that VZV
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TS is not essential for replication in vitro (Cohen & Seidel, 1993) but it remains to be 
seen whether a similar situation occurs in vivo.
1.3.9.6. Plants
Dihydrofolate reductase has been purified and characterised from soybean 
seedlings (Reddy & Rao, 1976), domesticated carrot (Albani et a l,  1985) Scenedesmus 
obliquus (Backmann & Follmann., 1987) and wild carrot (Toth et al, 1987).
Analysis of TS from domesticated carrot Daucas carota revealed that TS copurified 
with DHFR and both activities migrated in non-denaturing PAGE as a band of 183kDa 
(Celia et al., 1988). In mutant cell lines overproducing DHFR, TS activity paralleled 
DHFR increase. The ratio between TS and DHFR activities was constant during enzyme 
purification except for a sharp decrease of TS activity during the last step, possibly due to 
the extreme instability of TS (Celia e ta i, 1988). Evidence of the bifunctionality of one of 
the enzymes has been strengthened by the sequencing of two oligopeptides, obtained by 
the tryptic digestion of the pure protein, which contain sequences similar to those found in 
the active sites of TS and DHFR (Celia et al., 1991a). Therefore it was concluded that in 
domesticated carrot TS and DHFR exist as a bifunctional enzyme (Cell & Parisi 1993), 
similar to, albeit larger than those found in protozoa (Ivanetich & Santi, 1987).
A different situation with regard to DHFR and TS was found by Toth and 
colleagues (1987) in wild carrot suspension and cultured cells. In these cells TS and 
DHFR activities were localised on two different polypeptides which are part of an 
enzymatic complex formed by five different subunits. Further examination of wild carrot 
suspension by Balestrazzi and colleagues (1995) has shown that in addition to the 
monofunctional DHFR a bifunctional TS-DHFR is present. A DHFR-TS gene has 
recently been cloned from Arabidopsis thaliana (Lazar et al., 1993) and immunochemical 
analysis has revealed the precence of a bifunctional DHFR-TS in Nicotiana 
plumbaginifolia and Oryza sativa (Balestrazzi et al., 1995) indicating that a bifunctional 
protein may well be ubiquitous in plant cells.
In the case of the alga Scenedesmus obliquus; Bachmann and Folman (1987) 
copurified from a 30-fold overproducing strain DHFR and TS activities as a bifunctional 
protein. This bifunctional enzyme consists of two identical subunits of molecular mass of 
about lOOkDa.
1.3.9.7. Mammals
Many studies have been carried out on the regulation of TS expression in 
mammalian cells. Initial studies focused on cell-cycle-directed events, these studies have 
shown that the maximal TS activity occurs during periods of active DNA synthesis
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(Conrad, 1971; Navalgund et al., 1980). In human, mouse and Chinese hamster, TS 
enzyme and mRNA levels are low in quiescent cells but increase approximately 20-fold 
on stimulation to re-enter the cell cycle (Ayusawa et al., 1986; Jenh et a l,  1985; Conrad 
& Ruddle, 1972). Moreover, the increase in TS enzyme levels that arises as cells enter S- 
phase appears to be regulated at both the transcriptional and post-transcriptional levels. 
Takeishi et al., (1985) suggested the possibility of translational regulation of TS 
expression given the theoretical potential of three interconvertible secondary structures, 
each containing a stem loop structure in the 5' untranslated region (5' UTR) of the human 
TS mRNA.
More recently, there has been an increased interest in the translational regulatory 
mechanisms. A study was performed by Chu et al., (1991) in which the addition of 
recombinant human TS protein to in vitro translation reactions inhibited translation of TS 
mRNA. This inhibition was specific in that recombinant TS protein had no effect on the in 
vitro translation of mRNA from other proteins. The inclusion of dUMP, F-dUMP, or 
CH2H4 folate to the in vitro translation reactions completely relieved the inhibition of TS 
mRNA translation by TS protein. These studies suggested that translation of TS mRNA is 
controlled by its own protein end product, in an autoregulatory manner.
Further studies on human TS, using an electrophoretic gel mobility shift assay, 
have indicated this translational autoregulatory process is mediated by an interaction 
between TS protein and two cis-acting elements on its corresponding TS mRNA (Chu et 
al., 1993). The first site corresponds to a 30 nucleotide sequence that includes the 
translational start site contained within a putative stem loop structure, while the second 
site corresponds to a 100 nucleotide sequence located within the protein coding region. 
RNAs with either a deletion or mutation at the translational initiation region are unable to 
compete for TS protein binding. A similar study on E.coli TS mRNA confirmed a direct 
interaction between E.coli TS protein and E.coli TS mRNA (Voeller et al., 1995). Two 
cis-acting sequences in the E.coli TS mRNA protein-coding region were identified, each 
of which binds TS with a relative affinity similar to that of full length E.coli TS mRNA. A 
third binding site was identified with an affinity for TS that was lower than that of the 
other two cis-acting elements. E.coli TS proteins with mutations in amino acids located 
within the nucleotide-binding region retained the ability to bind RNA while proteins with 
mutations at either the nucleotide active site cysteine or at amino acids located within the 
folate binding region were unable to bind TS mRNA (Voeller et al., 1995). These results 
suggested that the folate binding site and/or critical cysteine groups my represent 
important RNA binding domains.
These findings relating to autoregulation of TS appear to have biological relevance 
in that they suggest a means whereby the level of this protein is finely controlled within a 
given cell and a means for malignant cells to protect themselves in response to a cytotoxic 
stress such as F-dUMP. F-dUMP may bind to TS and produce a conformational change
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which inhibits its binding to TS mRNA. Translation of TS mRNA then proceeds 
uncontrolled, resulting in TS protein accumulation and drug resistance.
1.3.10. Crystal structure of human TS
The structure of unliganded human TS provides the first three-dimensional view 
of a mammalian TS (Schiffer et al., 1995). The structure indicates a large degree of 
similarity in the overall fold to the bacterial enzymes, which is consistent with the high 
degree of sequence identity. The major exception is the active site loop. In Lcasei TS 
structure, this region includes the end of (3-strand v, a short a-helix, the I helix and the 
beginning of (3-strand iv (refer to Figure 1.13). However, the entire active-site loop of the 
human TS structure is twisted by approximately 180° relative to the conformation in the 
L.casei enzyme structure. The structure of the human enzyme results in the active site 
cysteine residue being deeply buried in the (3-sheet dimer interface which results in the 
cysteine residue undergoing a 180°C twist upon ligand binding. In all species of TS, 
ligand binding causes conformational changes which are implicated in correctly orienting 
substrate and cofactor, and in appropriately sequestering them from the external solvent 
environment. Therefore upon ligand binding the human enzyme must reorient the active 
site residues as well as undergoing the conformational changes which lead to the closure 
of the domains around the substrate and cofactor. A possible function for the orientation 
of the active site may be to protect the catalytic cysteine from being modified in the cell.
Human TS has a unique amino terminal sequence which is 27 residues longer than 
L.casei and contains eight proline residues and seven charged residues (Schiffer et al., 
1995). This amino terminal extension is longer than any other species of TS (refer to 
Figure 1.13). Secondary structure predictions have indicated that it is present as a 
randomly coiled structure. This extension, which is not present in VZV, may have a 
function unique to the human enzyme and it has been suggested that it may be present to 
enable TS to interact with other proteins in the cell, some of which are involved in DNA 
synthesis (see section 4.1).
Two other insertions are present in human TS, one of twelve residues and one of 
eight residues at positions 117-128 (human numbering) and 146-153 (refer to Figure 
1.13). These sequences are highly conserved in all the currently sequenced eukaryotic 
TSs. As homologous insertions are not present in prokaryotes this suggests that they 
posses a eukaryote specific function (Hardy et al., 1987; Perry et al., 1990). Therefore 
the unique structures present in human TS can be used to assist in structure-based 
approaches to the development of species-specific inhibitors with antiproliferative activity 
against pathogenic TSs which do not inhibit the human enzyme.
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1.4. Mutagenesis of thymidylate synthases
1.4.1. Structural plasticity of TS
TS is extremely permissive in the amino acid substitutions that it tolerates, 
including many for residues that are highly conserved. The accommodation of such 
substitutions may be due to the structural plasticity of the protein, i.e. the ability of the 
protein to adapt to changes in its primary structure, whilst maintaining its tertiary 
structure.
Perry et al., (1990) investigated the structural plasticity of TS by comparing the 
E.coli and L.casei structures, in an attempt to generalise the effects of substitutions. A 
detailed study of the buried region of TS from both stmctures revealed three different 
mechanisms by which substitutions could be accommodated. The first is covariant 
accommodation, in which multiple sequence changes combine to minimise distortion of 
the main chain atoms and preserve the volume of the packed side chains at the same time. 
Covariant changes are seen at the centre of strand iii in the (3-sheet, which is one of the 
most structurally conserved regions of the enzyme (refer to Figure 1.13). Phe255 in 
L.casei is replaced by Gly in E.coli. The surrounding space in E.coli is filled by side 
chains of Trp253 and Thr258, versus His253 and Ala258 in Lcasei for a net change of 
only one atom in these three residues. A second covariant pair is Thr200, Leu201 of 
L.casei TS, replaced by Ala200, Phe 201 in E.coli, thus providing a similar side chain 
volume. In general, it has been found that when a substitution introduces three or more 
heavy atoms (carbon, oxygen, sulphur or nitrogen), this nearly always results in a second 
site or covariant change nearby (Perry et al., 1990). Experimental data obtained from 
mutagenesis studies of the hydrophobic core of the bacteriophage lambda repressor 
protein, demonstrate that where a mutation increases the volume of the core in excess of a 
permitted level, second site mutations that can reduce the net volume, can restore activity 
(Lim & Sauer, 1991).
The second mechanism by which mutations can be accommodated is by the 
occurrence of local changes, whereby large effects observed close to the site of mutation 
dissipate as a function of distance. This is usually achieved by a mechanism that involves 
local rearrangements, often the repacking of adjacent residues, with only minimal effects 
on the overall architecture of the protein (Perry et al., 1990).
A final mechanism by which plastic adaption can occur is by segmental 
accommodation, which is the concerted movement of individual elements of secondary 
structure. Concerted alterations are seen in the helices and external loops in TS which 
contain sites exhibiting the largest differences between E.coli and L.casei structures. The 
ensemble movement of helices B, C and G is the most prominent example of this process, 
where these structures have shifted together as a unit in Lcasei TS relative to E.coli. This 
movement has occurred to accommodate the interactions between the 3-helix unit and the
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helix D of L.casei, a helix that is absent from E.coli TS (Perry et al., 1990). The 
maintenance of hydrophobic interactions in this helical region between the two TS 
proteins represents the preservation of packing constraints during evolution.
1.4.2. Construction of mutants
Numerous mutant thymidylate synthases have been reported. Some of the mutants 
were made by conventional site-directed mutagenesis techniques, where a single residue 
was targeted for a single substitution for a specific reason. Other experiments have used 
multiple substitutions to provide replacement sets of amino acids at a chosen position in 
the enzyme (Climie et al., 1990; Michaels etal., 1990; Kim et al., 1992).
An L.casei TS gene was designed and chemically synthesised to contain 35 
unique restriction sites and codons optimised for expression in E.coli. Replacement sets 
of mutant enzymes were created by the replacement of restriction fragments of the 
synthetic gene with fragments containing oligonucleotide mixtures coding for all 20  amino 
acids at targeted positions (Climie et al., 1990). An important step in the procedure was 
the identification of catalytically active mutants by the genetic complementation of E.coli 
%2913 which is deficient in TS. Individual mutant isolates were grown under nonselective 
conditions and then patched onto minimal agar lacking thymidine. Cell growth in the 
absence of exogenous thymidine identifies mutants that express catalytically active TS. 
Using this technique, Climie and co-workers identified 125 mutants at 12 different amino 
acid positions, at which residues had previously been predicted to play roles in the direct 
binding of, or lie in close proximity to dUMP.
Michaels and co-workers (1990) used a different approach to produce multiple 
mutants of E.coli TS. They used oligonucleotide site-directed mutagenesis to introduce 
amber nonsense codons at 20 sites in the E.coli TS gene and have made 12 or 13 amino 
acid substitutions at each site by transforming the mutants into suppressor strains. The 
suppressor strains have altered tRNAs that can insert an amino acid in response to an 
amber stop codon. Suppression of the amber mutation is commonly 25-50% efficient. In 
this way they have created over 245 variants of TS. The ability of different mutants to 
complement the growth of Thy' strains in the absence of thymine was used to determine 
their catalytic activity.
More recently Kim et al., (1992) have carried out amino acid substitution analysis 
within the N-terminus of E.coli TS corresponding to residues 20-35 which contains a 
block of amino acids whose sequence have been well conserved among other known TS 
proteins. This procedure used suppression of amber mutations by tRNA suppressors and 
has yielded a bank of 124 new mutationally altered TS proteins.
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With few exceptions the data obtained with the E.coli and Lcasei enzymes by the 
two different approaches are in agreement; many of the key residues of TS can be 
substituted resulting in enzymes which still retain significant activity.
1.4.3. Thymidylate synthase assays
There are several assay systems available for the detection of TS. The in vivo 
complementation of E.coli with have a defective TS gene can be used as an initial screen. 
Individual mutant isolates are grown under nonselective conditions and then patched onto 
minimal agar lacking thymidine. Cell growth in the absence of exogenous thymidine 
identifies mutants that express catalytically active TS (Thompson et al., 1987). This 
method provides a rapid, genetic method for the assessment of whether or not TS is 
active, but it is sensitive to the level and activity of the expressed enzyme.
There are several in vitro assay systems available for the detection of TS activity. 
The most commonly used is the spectrophotometric assay, that measures the increase in 
absorbance at 340nm concomitant with dihydrofolate production. It can be adapted to 
microplate formats for kinetic studies. This assay, however may be limited by interfering 
absorbance in crude extracts. The tritium release assay is a more sensitive isotopic method 
for detectintg TS activity in vitro (Roberts, 1966). It is based on the release of tritium, as 
tritiated water, from dUMP, specifically labelled in the 5'-position, when thymidylate is 
formed. Unreacted substrates are removed by absorption onto activated charcoal, and the 
radioactivity in water is measured. The amount of dTMP generated is directly equivalent 
to the amount of [3H] released during the assay.
The cofactor independent dehalogenation of BrdUMP to form dUMP provides a 
spectrophotometric method for measuring the enzyme’s ability to bind nucleotides and 
activate C-5 for substitution (Garret et al., 1979) This reaction is slow compared to dTMP 
formation and suffers from low sensitivity.
1.4.4. Mutagenesis of residues interacting with substrates
1.4.4.1. Mutagenesis studies of residues interacting with phosphate of 
dUMP
Residues that interact with dUMP are highly conserved throughout the TS 
sequences. Nevertheless, a large variety of substitutions are permitted at such residues 
without a complete loss of enzyme activity.
X-ray structural studies on L.casei TS have shown that Arg23 (Arg38 of VZV), 
Argl78' (Argl63 of VZV), Argl79' (Argl64 of VZV), and Arg218 (Arg203 of VZV) 
form a positively charged binding site for the 5'-phosphate of dUMP (Hardy et al.,
1987). Arg 178' and Arg 179' are derived from a monomer different from the active site
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they occupy and function in. Initial studies on T4 phage TS by Frasca et al., (1988) 
reported that replacement of invariant Argl37 (corresponding to Argl79 of L.casei, 
Arg 164 of VZV) by glycine resulted in an inactive enzyme and so concluded that this 
residue must be an essential residue in the binding of dUMP. In contrast, however, most 
replacements of Arg 179' (Arg 164 of VZV) from either E.coli or L.casei TS results in 
enzymes that complement Thy' E.coli (Michaels et al., 1990; Climie et al., 1990). Purified 
R179A, E, K and T mutants of Lcasei showed relatively small differences in kinetic 
parameters compared to wild type TS. The most significant effect of all mutations is 
localised to a decrease in the net rate of association of TS with dUMP (Santi et al., 1990), 
which decreases 10 to 20 fold relative to the wild type TS. The Kcat values were similar 
for mutants and only 4 fold lower than wild type, which indicated that once substrates are 
bound within the ternary complex the catalytic steps are only moderately affected by the 
nature of the residue at 179. This might be expected since Arg 179 is positioned far from 
the reaction centre and there is no evidence that Arg 179 plays a direct role in catalysis 
(Santi et al., 1990). The high activity detected in the mutant enzymes is explained by 
"plasticity" of the enzyme and the compensatory actions of other arginine residues. In the 
crystal structure of the R179E mutant, the arginine residues Arg 178' (Arg 163 of VZV), 
and Arg218 (Arg203 of VZV) ligate the dUMP phosphate as in the wild type TS.dUMP 
complex, and Arg23 (Arg38 of VZV) has moved slightly to form a hydrogen bond with a 
phosphate oxygen different from that in the wild type TS.dUMP structure (Finer-Moore 
& Stroud, unpublished data cited in Carreras & Santi, 1995).
Substitutions for Arg 178' (Argl63 of VZV) that allow complementation of Thy' 
E.coli include basic and other hydrophilic substitutions although proline is also accepted 
in E.coli TS (Climie et al., 1990). The purified R178T mutant from L.casei is active by 
complementation and shows a 5-fold reduction in Kcat, a 1000 fold increase in dUMP , 
and a 100 fold increase in folate (Kawase & Santi, unpublished data cited in Carreras 
& Santi, 1995). The detrimental effect on the binding of dUMP can be explained by 
phosphate binding role of Arg 178', but the effect on Km of the cofactor has no known 
structural basis.
In addition to dUMP binding, Arg23 (Arg38 of VZV) forms a salt bridge with the 
C-terminal carboxylate following the structural change that occurs upon folate binding 
(Matthews et al., 1990a; Montfort et al., 1990; Matthews et al., 1990b; Fauman et al., 
1994). Few members of the Arg23 replacement set complement Thy' E.coli (Climie et al., 
1990; Michaels et al., 1990) and those members that do are structurally dissimilar. 
Studies with purified Arg23 mutants of L.casei TS show that all are weakly active in 
vitro, with 10 to 200 fold reductions in Kcat, up to 10 fold increase in dUMP values 
and 4-30 fold increases in folate values relative to those of wild type (Santi, 
unpublished data, cited in Carreras & Santi, 1995). The inability of the mutants to 
complement Thy' E.coli is best explained by their poor binding to substrates, which
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would reduce Kca/K m below the essential level needed for cell growth. The effect of 
mutations on folate binding likely results from their inability to form the salt bridge with 
the C-terminal carboxylate (Matthews et al., 1990a; Montfort et al., 1990; Matthews et 
al., 1990b; Fauman et al., 1994).
The fourth arginine residue, Arg218 (Arg203 of VZV) cannot be mutated to any 
of the other amino acids without loss of function. This residue is thought to play a role in 
the stabilisation of the active site thiolate (Cysl98 of L.casei, Cysl83 of VZV) by ion pair 
formation.
Therefore, it is apparent that although Arg 179 (Arg 164 of VZV) is bound to the 
phosphate of dUMP, it is not essential for substrate binding or catalytic activity. It can be 
replaced by neutral (Ala, Thr), positive (Lys), or negative (Glu) amino acids without 
drastic changes in kinetic constants. The three other arginine residues that were proposed 
to interact with the phosphate group of the substrate would only accept limited 
substitutions. Among these arginine residues there appears to be a hierarchy of 
substitutability. Arg 178' (Arg 163 of VZV) can be replaced by any basic amino acids as 
well as tyrosine; there are few amino acids that can be substituted for Arg23 (Arg38 of 
VZV); and Arg218 (Arg203 of VZV) cannot be mutated to any other amino acid without 
loss of function (Michaels et al., 1990).
I.4.4.2. Residues interacting with deoxyribose of dUMP
Residues interacting with the deoxyribose moiety of dUMP in Lcasei TS include 
Tyr261 (Tyr246 of VZV) and His259 (His244 of VZV), which both form hydrogen 
bonds with the 3'-OH of dUMP. The Y261M mutant of Lcasei was the only one of 14 
mutants that complement Thy' E.coli (Climie et al., 1990)
The active site cysteine residue provides an essential nucleophilic catalyst for the 
TS reaction as it forms a covalent bond with C-6 of the deoxyribose group of dUMP. 
Mutagenesis of this completely conserved residue in Lcasei (Cysl98 of L.casei, Cysl83 
of VZV)) results in complete inactivation of the enzyme (Climie et al., 1990). The 
corresponding active site nucleophile, Cysl46 in E.coli, only accepts its original amino 
acid for full activity. However, partial activity was reported with the serine substitution 
(Michaels et al., 1990). This correlates well with previous mutagenesis studies. Dev et al. 
(1988) reported that substitution of alanine, glycine or threonine at position 146 results in 
an inactive enzyme but a serine mutant retains a small amount of catalytic activity. 
Because alkoxides are capable nucleophilic catalysts in model reactions of TS, the weakly 
acidic serine might serve as a nucleophile in the TS reaction; however why this 
substitution is active in E.coli but not in Lcasei is unknown.
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I.4.4.3. Mutagenesis of residues interacting with pyrimidine of dUMP
His 199 (His 184 of VZV), Tyrl46, Trp82 (Trp97 of VZV), Asn229 (Asn214 of 
VZV), Glu60 (Glu75 of VZV) and several highly ordered water molecules form a 
hydrogen bond network around the pyrimidine ring of dUMP (refer to Figure 1.13).
Tyrl46 (Tyrl23 of VZV) is a completely conserved residue and is located near 
His 199 (His 184 of VZV) and Asn229 (Asn214 of VZV) in L.casei. This residue forms a 
hydrogen bond with an ordered water molecule that is close to C-5 of dUMP in ternary 
complexes and may assist in removal of the C-5 proton (Matthews et al., 1990; Fauman et 
al., 1994). Three mutations have been produced in this residue and all were active by 
complementation, indicating thatTyrl46 (Tyrl23 of VZV) is not essential (Climie et al.,
1990).
His 199 (His 184 of VZV) is a highly conserved residue and lies in the active-site 
cavity. From crystal structures this was suggested as a candidate general base to assist the 
removal of the C-5 proton from dUMP. Of the His 199 mutants isolated from L.casei, 
several retained catalytic activity indicating that this residue is not essential for catalysis. 
Similar findings were noted in E.coli (Dev et al., 1989).
Asn229 (Asn214 of VZV) is completely conserved and lies in the hydrophobic J- 
helix which forms the core of TS. This is the only residue which makes direct contact 
between a protein side chain and the dUMP pyrimidine ring, forming a cyclic hydrogen 
bond network with 0-4 and NH-3 of dUMP. The highly conserved nature of this residue 
was thought initially to be to stabilise dUMP in the active site. A complete replacement set 
of mutants at position 229 of Lcasei TS have been prepared, purified and characterised 
(Liu & Santi., 1993). Most of the Asn229 mutants of TS bind dUMP and catalyse dTMP 
formation as well as the wild type enzyme, thus Asn229 does not contribute to the 
binding of dUMP. Wild type TS binds to dUMP about 1000 fold tighter than dCMP. 
With the exception of N229Q, Asn229 mutants decrease the enzymes ability to 
discriminate between dUMP and dCMP [(Liu & Santi, 1992; Hardy & Nalivaika, 1992; 
Liu & Santi, 1993), refer to Chapter 8]. A similar situation was found in the 
corresponding residue (Asnl77) from E.coli, the N177D mutant gave an initial velocity 
with dCMP which was 35 fold faster than that obtained with dUMP indicating that the 
mutant enzyme is more active on dCMP than dUMP (Hardy & Nalivaika, 1992).
Crystallographic studies have shown that the completely conserved Glu60 of 
L.casei TS (Glu75 of VZV) is involved in an extensive hydrogen bond network that 
includes several conserved side chains of the enzyme, ordered water molecules, and the 
pyrimidine ring of the substrate (Montfort et al., 1990; Finer-Moore et al., 1990). 
Mutation of Glu60 leads to large losses in activity (Huang & Santi, 1994), purified 
Lcasei E60L and E60A TS mutants catalysed tritium loss from [5-3H] dUMP faster than 
dTMP formation, indicating formation of a steady-state intermediate with an acidic 5- 
hydrogen and a partitioning of the intermediate towards the reactants. A covalent complex
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consisting of E60A or E60L TS, dUMP, and the cofactor CH2H4 folate was isolated by 
SDS PAGE and shown to be chemically and kinetically competent to form dTMP. These 
results provide proof of the formation of a covalent steady-state intermediate in the 
reaction pathway of TS and demonstrate that the rate determining step in the mutants 
occurs during conversion of the covalent intermediate to dTMP (Huang & Santi, 1994).
Finally, structure-function considerations have suggested that Glu60 serves a role 
in co-ordinating a hydrogen bond network that promotes proton transfer reactions at 0-4 
of dUMP and N-10 of the cofactor orienting the pyrimidine ring of substrate and the 
pterin ring of cofactor for hydride transfer (Huang & Santi, 1994).
I.4.4.5. Mutagenesis of residues interacting with CH2H 4 folate
Although CH2H4folate is often described as a cofactor the fact that it is oxidised 
during the reaction means that it could be considered as a substrate. Folate binding to TS 
induces a conformational change in which the DRTG loop residues and the C-terminal 
residues move to cover the bound substrates. Residues involved in CH2H4folate binding 
that have been mutated include those of the C-terminus as well as Trp82 (Trp97 of VZV), 
Trp85 (TyrlOO is corresponding residue of VZV), Asp221 (Asp206 of VZV), Lys50 
(Lys65 of VZV) and Lys51 (Arg66 is corresponding residue of VZV).
Trp82 (Trp97 of VZV) and Trp85 (TyrlOO of VZV) are conserved residues that 
pack against the bound folate analogue in ternary complexes. Trp82 has been replaced 
with several amino acids and some of the mutants, including W82F, were active (Kealey 
& Santi, unpublished data cited in Carreras & Santi, 1995). The corresponding residue, 
Trp80 in E.coli could not be restored to Thy+ by any of the mutations made (Michaels et 
al., 1990). Trp85 from Lcasei has been replaced only with phenylalanine and this 
enzyme is active. However the W82F/W85F double mutant is inactive, suggesting that 
the presence of at least one of the tryptophans is essential.
The side chain of Asp221 (Asp206 of VZV) forms a hydrogen bond network with 
N-3 of the folate and may assist elimination of the cofactor from the 
TS.dUMP.CH2H4folate intermediate. Predictably substitutions at this position produce 
enzymes that do not complement Thy* E.coli, though D221C is an exception. Purified 
D221A andD221N mutants are inactive but bind nucleotides with wild type affinity and 
dehalogenate BrdUMP more efficiently than wild type TS (D.Santi, unpublished data 
cited in Carreras & Santi, 1995). This is consistent with the role of Asp221 in the 
breakdown of TS.dUMP.CH2H4folate catalytic intermediate. Substitution of this residue 
in E.coli results in an enzyme that cannot complement Thy* bacteria.
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I.4.4.6. The C-terminal residue
Carboxypeptidase cleavage of the Lcasei C-terminal valine from a single subunit 
of TS completely inactivated the enzyme and decreased the enzymes affinity for 
CH2H4folate (Aull et al., 1974). Using mutagenesis Carreras et al. (1992) demonstrated 
that a single amino acid deletion (V316Am, where Am represents an amber stop codon) 
from both subunits at the C-terminus also abolishes product formation. In contrast to the 
bacterial enzymes it has been noted that removal of the C-terminal residue from VZV TS 
(L301A) results in an enzyme which retains a significant amount (3%) of wild type 
activity, in addition this mutant has increased debromination activity which reflects the 
lower Km for dUMP (Harrison et al., 1995).
Mutagenesis studies on the C-terminal residue of Lcasei TS have shown that 
valine can be replaced with the 19 other amino acids: 14 of these mutants were active by 
genetic complementation and 18 were active by in vitro assay. In general the alterations at 
316 had little effect on the for dUMP, an increase in the Km for folate cofactor, and a 
decrease in Kcat. These observations show that Lcasei TS can tolerate the substitution of 
most amino acids for valine at the C-terminus without a complete loss of activity and that 
the position of the C-terminal carboxylate is important in both cofactor binding and 
catalysis. The apparently similar dUMP values indicated that substrate binding is not 
significantly affected by mutations in the C-terminal residue. These results are consistent 
with crystallographic studies which show that free enzyme and the binary complex have 
similar structures and that the C-terminus is not directly involved in nucleotide binding in 
the binary complex (Hardy et al., 1987; Perry et al., 1990; Montfort et al., 1990; 
Matthews et al., 1990).
Although V316Am does not catalyse dTMP fomation it does catalyse the 
dehalogenation of BrdUMP, which is a partial reaction of TS which occurs in the absence 
of folate. The Kcat and values for this reaction are not altered by mutations which affect 
folate binding and subsequent steps in the pathway (Climie et al., 1992) suggesting that 
the conformational change of the C-terminus is not involved in the dehalogenation 
reaction. All that seems to be required of the enzyme is the ability to bind nucleotide and 
form a covalent adduct between the catalytic thiol of Cysl98 and the nucleotide.
The V316Am mutant was also able to participate in the formation of the 
V316Am.dUMP.CH2H4 folate ternary complex. This complex was impaired in its ability 
to isomerise from the noncovalent to the covalent form, suggesting that the mutant is 
impaired in its ability to undergo the C-terminal conformational change. In support of this 
the crystal structure of the V316Am TS.FdUMP.CH2H4 folate complex showed that no 
covalent bonds were present between the enzyme and the ligands, and the enzyme had not 
undergone the folate-dependent conformational change (Santi, 1987; Climie etal., 1992).
The loss of TS activity in the V316Am mutant can be rationalised in several ways. 
Firstly the position of the C-terminal carboxylate in the ternary complex of V316Am
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would be moved by at least 3-4A and disrupt the hydrogen bond network that facilitates 
CH2H4 folate binding. Secondly, loss of the residue at the C-terminal position would 
abolish side-chain mediated hydrophobic interactions that contribute to the conformational 
change of the enzyme. Finally truncation of TS would disrupt hydrogen bonding of the 
penultimate residue of TS to folate.
As with the V316Am TS, deletion mutants lacking 4, 8 and 10-terminal residues 
lack TS activity but dehalogenate BrdUMP with wild type efficiency (Carreras & Santi 
unpublished, cited in Carreras & Santi, 1995). Mutants lacking eight or ten C-terminal 
residues could not form covalent complexes with FdUMP and CH2H4 folate. The addition 
of an 8-residue synthetic peptide with the same sequence as the C-terminus did not revive 
activity of an A309Am (n-8) mutant. I will show in Chapter 7 that this is not the case for 
VZV TS.
14.4.7. Mutagenesis of the dimer interface of VZV TS
p-strand i forms part of the dimer interface and is the only region of secondary 
structure to have an insertion in more than one TS sequence (refer to Figure 1.13). From 
structural studies of TS, a highly conserved glycine residue (Gly48 in VZV TS) located in 
the p-kink region of P-strand i has been predicted to be essential. Harrison et al., (1995) 
constructed a glycine to alanine mutation at position 48 in VZV TS. This mutant could 
complement TS deficient E. coli and demonstrated a two fold decrease in enzyme activity 
relative to the wild type enzyme. This highly conserved glycine residue does not appear to 
be essential for TS activity as yeast can tolerate alanine at this position and bacteriophage 
03T can permit a serine, in addition Gly31 of E.coli TS can be replaced by an alanine or 
cysteine (Kim et al., 1992).
TS from Saccharomyces cerevisiae has an insertion in p-strand i. A second mutant 
was constructed in VZV TS to determine whether the insertion seen in the yeast enzyme 
could be accommodated (Harrison et al., 1995). The amino acid substitutions G48A and 
M49P which flank the extra amino acid in the S. cerevisiae TS sequence were used to 
create the mutant G48A/48P49/M49P which mimics the central portion of S.cerevisiae TS 
p-strand i. The sequence of p-strand i of this variant of VZV TS differs from that of S. 
cerevisiae by only three out of thirteen amino acids. The mutations were found to be 
accommodated in VZV TS as the variant could complement Thy' E.coli.
TS from yeast, Plasmodium species and Lactobacillus lactis have an extra amino 
acid immediately adjacent to the carboxy-end of P-strand i. Experimental evidence has 
shown that VZV TS can accommodate an extra residue immediately adjacent to the 
carboxy-end of p-strand i , 58T59. It has been proposed that the insert in p-strand i of 
both yeast and the VZV TS mutant can be accommodated locally (within p-strand i) by the 
formation of a p-bulge. Richardson et al., (1981) have shown that bulges form
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irregularities, usually in antiparallel beta structures in which 2 consecutive hydrogen 
bonding residues on one strand are opposite a single residue on the other. The 
conformation of a p-bulge requires that a single residue on the opposite strand adopts a 
similar dihedral angle. The glycine which is situated at this position on the opposite strand 
in these species can readily adopt this conformation.
The mutant G48A/48P49/58T59 has also been studied and this produces more 
activity than the original G48A/48P49/M49P. This higher activity of the mutant suggests 
that the two changes together minimise the disruptive effects seen when the mutations are 
present singly ( Harrison et al., 1995). This is an example of covariant accommodation, 
where multiple sequence changes can combine to minimise distortion of the main chain 
atoms (Perry et al., 1990).
1.4.5. Heterodimeric thymidylate synthase mutants
The active site of TS has residues derived from both subunits. Experimental 
studies have revealed that TS dimers can be reversibly folded and dissociated with only a 
small loss in activity, this has made it possible to produce heterodimeric enzymes with a 
single functional active site.
C l98A and R178'F mutations are completely inactivate in L.casei TS. However, 
refolding C l98A in the presence of R78'F resulted in the formation of heterodimers with 
one active subunit (R178' and C198), one inactive subunit (R178'F and C198A), half the 
activity of WT TS, and similar values for substrate and cofactor (Pookanjanatavip et 
al., 1992).
A similar method of heterodimer formation has been used to create active, 
asymmetric enzymes that have a C-terminal deletion on only one subunit of the dimer. It 
had previously been discovered that removal of the C-terminal amino acid from one 
subunit of TS results in complete inactivation of the enzyme (Aull et al., 1974). Therefore 
Carreras et al., (1994) attempted to form an active V316Am-TS heterodimer by refolding 
the WT subunit in the presence of increasing concentrations of inactive V316Am. The 
results revealed that the heterodimeric mutant was active and had kinetic parameters 
similar to the R178F'-C198A heterodimer. To further establish that the activity in the 
V316Am-TS was due to heterodimeric formation and not to WT homodimers forming, a 
further heterodimer was created from two completely inactive mutants; R178'F and 
V316Am. In the heterodimer, the R178'F mutation is part of the same active site as the 
V316Am mutation and prevents dUMP from binding to this active site. The second site of 
the heterodimer has no mutations and contains the wild type residues necessary for 
catalysis of dTMP formation. Refolding of the two inactive subunits produces an 
R178'F-V316Am heterodimer that catalyses dTMP formation at a rate that is 2-fold lower 
than the wild type enzyme. Since neither of the two mutants is active on its own, the
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ability of inactive R178'F monomers to complement inactive V316Am monomers 
demonstrates that a TS heterodimer with a C-terminal deletion on one subunit can catalyse 
dTMP formation. This observation of active heterodimers with a C-terminal deletion of 
one subunit is not in accordance with previous studies of carboxypeptidase-inactivated TS 
(Aull et al., 1974; Cisneros et al., 1993).
1.5. Thymidylate synthase inhibitors
Thymidylate synthase is a target for drugs against proliferative diseases and cancer 
because it is required for the de novo synthesis of thymidylate and, hence, for DNA 
production. TS inhibition can be achieved with either fluoropyrimidines or other 
analogues, which are based on the structure of the substrate dUMP, or folate analogue 
compounds, which are based on the structure of the cofactor. Inhibition of TS by either 
antifolates or FdUMP leads to a depletion of dTTP and cessation of DNA synthesis. 
Ultimately DNA damage will occur by the misincorporation of dUTP and FdUTP. 
Increased excision of the fraudulent nucleotides might cause strand breaks.
1.5.1. Fluoropyrimidine inhibitors
The first compounds to have significant TS-inhibiting activity were the nucleoside 
analogues, predominantly 5-substituted-2'-deoxyuridine analogues. For these analogues 
to be active in vivo, they must first be enzymatically activated by being converted into the 
5'-monophosphate derivative. The necessity for the phosphate group was shown by the 
fact that deoxyuridine is not a substrate for the purified enzyme (Reyes & Heidelberger, 
1965) and exhibits a 500 fold lower binding activity than dUMP (Lockshin & Danenberg, 
1981). In addition inorganic phosphate is a competitive inhibitor of nucleotide binding 
(Lockshin & Danenberg, 1981). In in vivo studies, the necessity for the 5'- 
monophosphate group has been demonstrated by the fact that mutations in the activation 
step led to resistance.
5-monophosphate derivatives of 5-fluoro-2'-deoxyuridine, 5(triflouro-methyl)-2'- 
deoxyuridine (CF3UdR), 5-nitro-2'-deoxyuridine (N 02-UdR) and 5-ethynyl-2'- 
deoxyuridine (EYUdR) have emerged as the most potent inhibitors in both in vitro and in 
vivo experiments with nucleoside analogues (Figure 1.15).
FdUMP, the active form of FUdR, forms a covalent ternary complex with TS in 
the presence of the cofactor N5,N10CH2FH4, which is similar to the covalent catalytic 
intermediate. This complex is stable and terminates the reaction because the fluorine atom 
cannot be abstracted as occurs with C-5 hydrogen in the course of the normal TS reaction, 
presumably due to the strength of the C-5-F bond (Santi & Danenberg, 1984). The effects
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of fluoropyrimidines on leukemic cells of mouse and humans have been examined in the 
presence folinic acid, a reduced folate (Keyomarsi & Moran, 1985). Growth rate 
experiments showed that cells exposed to moderate concentrations of FUrd were initially 
inhibited but recovered, whereas with cells exposed to both FUrd and folinic acid the 
initial growth inhibitory effects were sustained. Therefore folinic acid increased the 
intracellular levels of folate, resulting in the stabilization of the ternary complex and thus a 
higher degree and duration of TS inhibition.
In contrast to FdUMP, CF^dUMP and NChdUMP can inhibit TS in the absence of 
N 5,N 1(),CFUFH4 but still interact with the active site cysteine residue forming a 5,6- 
dihydropyrimidine derivative. Their ability to interact with TS in the absence of cofactor is 
thought to be the basis of their tight binding to, and inhibition of the enzyme (Danenberg 
& Heidelberger, 1974; Wayata et ah, 1980).
EYUdR is a potent inhibitor of S-49 murine lymphoma cells and inhibits TS only 
in the presence of cofactor, by forming an inhibitory ternary complex (Barr et a\., 1981). 
This ternary complex was found to be much weaker than that formed by FdUMP 
(Danenberg et al., 1981). Furthermore, the EYdUMP complex was disrupted upon 
denaturation of the enzyme in contrast to the FdUMP based complex which remains stable 
upon denaturation (Danenberg et al., 1981).
C =  CH
HN HN
H O— HOHO—
OH OHOH
CF3UdR 
5-trifluoro-methyl- 
2' -deoxyuridine
EYUdR 
5-ethynyl-2' - 
deoxyuridine
Figure 1.15. 5-substituted deoxyuridine analogue inhibitors of TS
These compounds has been used with limited success for the treatment of 
colorectal and other carcinomas. However, the fluoropyrimidines can also inhibit cell 
growth by incorporation into DNA and RNA.
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1.5.2. Folate analogue inhibitors
Due to the limitations to the long term therapeutic uses of 5-FU, new TS drugs 
were designed which could elicit a thymineless condition, uncomplicated by other 
biochemical events, through direct inhibition of TS. The chemical approach exploited a 
quinazoline, rather than a pteridine nucleus, for the synthesis of a series of folate 
analogues. These compounds are less susceptible to metabolic degradation than 
fluoropyrimidines and are not incorporated into DNA or RNA (Harrap et al., 1989). In 
addition tetrahydrofolate is a relatively large molecule providing a variety of sites 
amenable to manipulation in the design of specific inhibitors. To reach and target enzymes 
such as DHFR or TS, antifolates enter the cell via the reduced folate carrier (RFC) protein 
transport system on the cell membrane. Efficient or poor cellular antifolate uptake is 
determined by the molecular structure and polarity of the antifolate, the presence of 
reduced folates or antifolates, the intracellular folate depletion, and RFC deficiency 
(Jansen et al., 1990). Once antifolates are inside the cell, glutamate residues are added by 
the enzyme folylpolyglutamate synthase (FPGS). These add more negative charges to the 
antifolate molecule and increase solubility, resulting in the agent’s marked reduction in 
efflux from cells and its prolonged retention in tissues having high FPGS activity, such as 
the liver (Hoffbrand et al., 1990). Moreover, polyglutamation increases the affinity of 
folate analogues for folate-dependent enzymes markedly and results in a potentiation of 
TS inhibition that may exceed by 100-fold that of the monoglutamated form (Calabresi & 
Chabner, 1990; Jackman et al., 1990). Therefore, cellular uptake of antifolates via the 
RFC and the ability of antifolates to undergo polyglutamation have major roles in TS 
inhibition.
N10-propargyl-5,8-dideazafolate (CB3717) was the first anti-folate compound to 
be developed. It is a 2-amino-4-hydroxy quinazoline carrying a propargyl on N 10 that 
greatly increases the affinity of this compound for the active site of TS (Figure 1.16). 
This folate analogue was shown to be the tightest binding, monoglutamate folate-based 
TS inhibitor at the time of its discovery. With CB3717, the formation of a covalent bond 
between TS and dUMP is still induced. However, CB3717 cannot form a covalent bond 
with dUMP, as is the case with folate and dUMP, and methylene group transfer cannot 
occur. CB3717 does not use the RFC for cellular entry but undergoes extensive 
polyglutamation by FPGS. Maximal potentiation of TS inhibition was achieved by the 
triglutamate form of CB3717 (Calvert et al., 1987). Phase I and II clinical studies 
demonstrated that CB3717 possesses clinical activity against ovarian, breast and liver 
cancers. However, severe renal toxic and profound malaise were noted even at lower 
doses and so further development of CB3717 was abandoned (Cantwell et al., 1988; 
Sessa et al., 1988; Vest et al., 1988).
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N°, N1U methylene tetrahydrofolate CB3717
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Figure 1.16. Chemical structure of N5, N10 methylenetetrahydrofolate and 10- 
propargyl-5,8-dideazafolate (CB3717).
As the renal and hepatic toxic effects of CB3717 appeared to be due to its poor 
aqueous solubility (Newell et al., 1982), further research focused on the synthesis of 
water soluble analogues. This led to the development of quinazoline compounds, in 
which the benzene ring of the amino benzoate residue has been replaced with various ring 
structures, including pyridine, thiophene, or thiazole (Jackman et al., 1991; Marsham et 
al., 1991). The N10-methylthiophene analogue, ZD 1694, was developed which 
selectively inhibits TS (Figure 1.17). Similar to CB3717, ZD1694 results in decreased 
TMP production, which leads to inhibition of DNA synthesis, resulting in cell death. In 
contrast to CB3717, ZD 1694 uses the RFC for cellular entry, and thus higher intracellular 
levels are available for polyglutamation by FPGS. ZD 1694 is an excellent substrate for 
FPGS, with an affinity 30 times higher than that of CB3717. Due to its effective use of 
the RFC and FPGS, this analogue is 500-fold more active in inhibiting cell growth than 
CB3717. This selective TS inhibitor has demonstrated antitumour effects in both 
preclinical and Phase II clinical trials and is undergoing Phase III evaluation. This drug, 
however has shown toxic effects to the bone marrow and small intestine.
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Figure 1.17. Chemical structure of N10-methylthiophene analogue, ZD1694
Antifolates that are potent TS inhibitors but do not require extensive 
polyglutamation to exert adequate cytotoxicity are presently under development; such 
agents can counteract reduced polyglutamation in tumours that express low or defective 
FPGS. Such an antifolate is ZD9331, a water-soluble quinazoline TS inhibitor that, like 
ZD 1694, uses RFC for transport and enters cells readily but is not a substrate for FPGS 
as a result of a y-tetrazole moiety that inhibits y polyglutamation (Jackman et al., 1994; 
Stephens et al., 1994). Unlike antitumour doses of ZD1694 which produced toxic effects 
to the bone marrow and small intestine, antitumour doses of ZD9331 produced only 
haematological toxicity (Stephens et al., 1994). This compound is in the preclinical stages 
of development.
1843U89 is a novel benzoquinazoline folate analogue in which the pteridine 
nucleus of the folate molecule is replaced by a lipophilic benzoquinazoline moiety. 
1843U89 is an extremely potent, non-competitive TS inhibitor in enzyme assays, with 
kinetics suggesting binding to TS at a site independent of the substrate-binding site (Duch 
et al., 1993). This analogue enters the cells via the RFC and, although an excellent 
substrate for FPGS, is metabolised only one step to the diglutamate form. In contrast to 
other antifolates, increasing the number of glutamate residues on 1843U89 enhances the 
TS binding and inhibitory actions of this compound only slightly. However, metabolism 
to the diglutamate form increases 1843U89 intracellular accumulation and retention 
markedly.
1.5.3. Bisubstrate analogues
Several bisubstrate analogues have been identified comprising a folate molecule 
covalently linked to a nucleotide analogue and designed to mimic the non-enzymic portion
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of the catalytic intermediate of the TS reaction. These analogues have been shown to 
inhibit TS (Park et al., 1979; Amamath etal., 1984).
Two such compounds, N5-dUMP-N10-propargyl-8-deazatetrahydrofolate and N5- 
dUMP-8-deazatetrahydrofolate inhibit purified TS from murine leukemic cells in a 
competitive manner with respect to dUMP. Rather than entering into the active site of the 
enzyme to produce an inhibitory ternary complex, these compounds inhibit TS by 
blocking the nucleotide and folate binding sites.
1.5.4. In vivo regulators
Pyridoxal phosphate (PLP) reversibly inhibits TS from L.casei. The inhibition is 
competitive with respect to dUMP (Chen et al., 1988, 1989). The observed changes in 
the absorption spectra of PLP resulting from the addition of TS (Chen et al., 1989) were 
consistent with the formation of a thiohemiacetal by addition of the sulphydryl group to 
the carbonyl group of PLP. This suggests an interaction between the catalytic cysteine 
residue and the carbonyl group of PLP, similar to that formed between TS and dUMP 
during catalysis (Moore etal., 1986; Chen etal., 1989).
In addition, the common metabolite glyceraldehyde-3-phosphate was shown to act 
as a competitive inhibitor with respect to dUMP, with a Kj value of 12-13|Lim (Bures et 
al., 1991). Although no evidence for the formation of a thiohemiacetal between the 
sulphydryl group of TS and the carbonyl group of G-3-P was given by Bures and co­
workers (1991), such an intermediate is known to exist in the reaction catalysed by G-3-P 
dehydrogenase (Harris & Waters, 1976). They proposed that the mechanism of 
interaction with both enzymes is similar (Bures etal., 1991).
Therefore PLP and G-3-P have a possible role in regulating DNA synthesis by 
modulating TS activity in both eukaryotic (Rode et al., 1980; Chen et al., 1989; Matherly 
et al., 1989) and prokaryotic cells (Tolleson et al., 1990). It has been observed that low 
levels of PLP are found in various rapidly proliferating cancer cells and the administration 
of pyridoxine or pyridoxal inhibits the proliferation of these cells both in vitro and in vivo 
(Thanassi etal., 1985).
1.5.5. Anti-sense oligonucleotides
As the translation of human and E.coli TS mRNA is controlled by its own end 
product in a negative autoregulatory manner, an alternative approach to the inhibition of 
enzyme function other than the use of drugs is to specifically inhibit enzyme synthesis. 
The use of anti-sense oligonucleotides to arrest translation of specific mRNA molecules 
(Helene & Toulme, 1990) has been directed at the DHFR-TS mRNA of Plasmodium 
falciparum. A 49-mer targeted at the conserved region of TS gave 50% inhibition at 6\im
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and 90% inhibition at 45jim (Sartorious & Franklin, 1991). Such an oligo is very specific 
to the DHFR-TS mRNA of P.falciparum (see section 1.3.9.3). There are delivery 
problems associated with the anti-sense oligonucleotides as they are charged and do not 
get into cells easily.
1.5.6. Oligopeptide inhibition of TS
Oligopeptides have been shown to inhibit VZV TS activity. A linear pentadecapeptide 
corresponding to the amino acid sequence of (3-strand i (LPPCHTLCQFYVANG) inhibits 
TS in vitro (ICI50=50|im). N- and C terminal deletions of this peptide have defined the 
active core as CHTLCQFY, which corresponds precisely to those amino acids at the 
interface of the two monomers. These oligos are thought to disrupt activity by preventing 
the correct formation of the dimer (H.Marsden & R.Thompson, personal 
communication).
1.5.7. Computer-assisted drug discovery
The X-ray structure of TS has been used in cycles of crystallographic analysis, 
synthesis, and inhibition assays to define high affinity heterocyclic inhibitors that 
resemble the cofactor. This led to the development of non-classical antifolates such as 
AG331 and AG337 which are lipophilic, lack a negatively charged glutamate side chain, 
and are extremely potent TS inhibitors (Figure 1.18).
HN
N— ^
AG-337
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CH
AG-331
Figure 1.18. Chemical structures of AG331 and AG337
These drugs can enter cells readily without the RFC and thus have activity in 
tumour clones deficient in the carrier protein. Drug potency is not dependent on 
polyglutamation. These drugs can exert effective TS inhibition in FPGS-deficient cells,
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however the prolonged intracellular retention of the new compounds conferred normally 
by polyglutamation is lost. Therefore, AG337 and AG331 require prolonged infusions to 
optimise antiproliferative effects.
In addition anti-TS drugs dissimilar to the substrate and cofactor remain attractive 
because they are less likely to have the side effects that are produced by the nucleotide and 
folate mimics. Shoichet et al., (1993) sought novel inhibitors of TS with a computational 
screen targeted at the structure of L.casei TS determined at 2.3A. A molecular docking 
programme (DOCK) was used to screen the Fine Chemical Directory (FCD) for 
molecules that are complementary to TS. Besides retrieving the substrate and several 
known inhibitors, DOCK proposed putative inhibitors previously unknown to bind to the 
enzyme. Three of these compounds inhibited TS at submillimolar concentrations. One of 
these inhibitors, sulisobenzone, crystallised with TS in two configurations that differ 
from DOCK favoured geometry. The structure of the complexes suggested another 
binding region in the active site that could be exploited. This region was probed with 
molecules sterically similar to sulisobenzone, which led to a family of phenolphthalein 
analogues that inhibit TS in the 1-30 micromolar range (Figure 1.19). These inhibitors do 
not resemble the substrates of the enzyme.
o
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Figure 1.19. Chemical structure of phenolphthalein
1.5.8. Resistance to TS inhibition
Three possible mechanisms of resistance to fluoropyrimidine inhibitors have been 
identified; prevention of activation, TS overproduction and structural alterations to TS. 
Characterisation of a variety of FU and FUdR resistant cell lines have shown that a 
significant decrease in any of a number of enzymes that prevent the formation of FdUMP 
or FUTP, prevent inhibition of TS.
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Jasreboff and colleagues (1983) reported distinctly different properties of TS 
purified from an FdUrd resistant Ehrlich ascites carcinoma cell line when compared to the 
parent cell line. Both a higher for FdUMP and a higher turnover number of the enzyme 
from the resistant line indicate a possible mechanism for resistance.
Another mechanism of resistance to FdUrd involving a change in the target 
enzyme was reported by Heidelberger and co-workers in 1960. In a cell free system it 
was shown that TS obtained from susceptible cells was inhibited by FdUMP, whereas the 
enzyme obtained from the resistant cells was not inhibited by FdUMP. The mechanism of 
resistance to fluoropyrimidines appears to involve the alteration of the active site in such a 
way that it can discriminate between dUMP and FdUMP. Considering the close proximity 
in size between the H atom and the F atom, it seems unlikely that the enzyme could 
distinguish between the two compounds on the substituted atom alone. However, 
substitution of fluorine in the 5-position of the pyrimidine increases considerably the 
acidity of the ring phenolic hydroxyl group, which might be sufficient for the enzyme to 
distinguish between dUMP and FdUMP (Heidelberger et a l, 1960).
The cause of resistance to FUdR in at least two murine cell lines has been shown 
to be due to 6- to 10-fold overproduction of TS (Baskin et al., 1975). This form of 
resistance has also been observed for mouse FM3A mammary adenocarcinoma cells 
resistant to the folate analogue CB3717 (Danenberg & Danenberg, 1989). These elevated 
intracellular levels of TS "soak up" the inhibitor and provides enough extra enzyme 
activity to allow the cells to survive in normally lethal levels of inhibitor (Danenberg & 
Danenberg, 1989). Normally, the translation of human TS mRNA is controlled by its 
own end product in a negative autoregulatory manner (Chu et al., 1993; Chu et al.,
1991). TS protein inhibits TS mRNA by binding of the protein to specific TS mRNA 
sequences critical for the initiation of translation. The intracellular level of TS protein is 
thus critical in the regulation of TS mRNA translation. It is possible that FdUMP, dUMP 
and selective TS inhibitors may bind to TS and produce a conformational change that 
inhibits binding to TS mRNA. Translation of TS mRNA would then proceed 
uncontrolled, resulting in TS accumulation and drug resistance (Chu et al., 1991; 
Keyomarsi et al., 1993). Observations have shown that following treatment of cells with 
the antifolate inhibitor ZD 1694, TS protein levels accumulate by up to 40-fold, whereas 
TS mRNA levels remain unchanged. In addition coadministration of a translational but 
not a transcriptional inhibitor overcame the accumulation of TS protein. Therefore TS 
accumulation was potentiated by TS expression throughout the cell cycle after ZD 1694 
treatment. These effects were attributed to a loss of inhibition of TS mRNA translation, 
whereas gene transcription remained unchanged (Keyomarsi et al., 1993).
High pre-treatment levels of TS have also been found to result in resistance to 
therapy. In 1995, Johnston et al. correlated TS protein levels and gene expression with 
the response of colorectal and gastric cancer to treatment with infusional 5-FU plus
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leucovorin (a folate analogue). Both TS protein and TS gene expression were significant 
predictors of the response to 5-FU based therapy. Patients with responsive diseases had a 
low TS protein level whereas in patients whose tumours did not respond the protein levels 
were significantly higher. A similar pattern was noted for gene expression with higher TS 
mRNA levels found in non-responsive patients. The results suggest that the ability to 
predict the response and outcome based on TS expression in the primary tumour prior to 
or early in the course of treatment, may provide the opportunity to select patients who are 
most likely to benefit from 5-FU based therapy and the possibility to offer alternatives to 
those who will not benefit.
There are multiple mechanisms of resistance to the new selective TS inhibitors, 
with most of the studies being carried out on ZD 1694. Potent inhibition of TS requires the 
active transport of the folate analogue via the RFC and subsequent polyglutamation by 
FPGS which results in increased affinity for TS and intracellular retention of the 
polyglutamate form. Therefore in drug-resistant cell lines there can be a decreased uptake 
of inhibitors via the RFC or failure to add polyglutamate (Freemantle et al., 1993).
1.5.9. Improving drug efficacy
Several strategies have been undertaken in an attempt to improve the efficacy of 
TS inhibitors. To counteract TS induction, the development of an antisense RNA that 
targets the TS mRNA sequences responsible for TS translation has been suggested 
(Keyomarsi et al., 1993). In another approach using gene therapy, cell lines resistant to 
TS inhibitors were transfected with a TS ribozyme using an EBV-based vector. This 
hammerhead ribozyme cleaves a sequence in the untranslated region of TS mRNA and the 
cells become sensitive to TS inhibition (Kobayashi et al., 1995). IFN-y has also been 
shown to enhance the sensitivity of human colon cancer cells to 5-FU (Chu et al., 1990). 
Treatment using 5-FU alone resulted in the induction of TS and a decrease of sensitivity 
to 5-FU. However, the addition of IFN-y to the treatment can reverse the development of 
resistance to 5-FU in the H630 cell line by inhibiting the overexpression of TS that results 
from 5-FU exposure. Other strategies have focused on potentiating TS inhibition or using 
agents synergistic with TS inhibitors. As folate analogues bind to TS at a site different 
from that of FdUMP, combining 5-FU with selective TS inhibitors could potentiate the 
actions of these agents. TS inhibition might be enhanced by using both a dUMP and a 
folate analogue to stabilise the ternary complex. The combination of AG331 or ZD1694 
with 5-FU led to enhanced FdUMP binding to TS and increased the growth inhibitory 
effect of these compounds on colon cancer cell lines (Van der Wilt et al., 1995).
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Aims
There were three main aims to this thesis. TS has been found to be part of a 
multienzyme complex in T4 phage and bacteria. The first aim was to establish whether 
VZV TS was found to be associated with any other proteins involved in viral DNA 
synthesis in mammalian cells.
Previous mutagenesis studies on the highly conserved residues of TS had revealed 
that many of these residues were not essential for enzyme function. Therefore the second 
aim was to generate a series of random temperature sensitive mutants which may identify 
residues that are critical for enzyme function. Initially buried regions of the protein will be 
targeted as these are the regions in which the bulk of mutations leading to protein 
instability are expected to arise. Continuing on from the initial mutagenesis experiments 
the exposed C-terminus and DRTG loop region will be targeted as these are the regions 
which show most movement upon ligand binding. There appears to be a difference 
between the bacterial TSs and the VZV TS in their response to removal of the C-terminal 
residue. As described above the removal of the C-terminal residue from prokaryotic but 
not VZV TS led to complete inactivation of the enzyme. The identification of differences 
between the VZV and other enzymes could therefore assist the development of species 
specific inhibitors.
An asparagine to aspartic acid mutation in the completely conserved residue N229 
of Lcasei led to the enzyme converting from a dUMP hydroxymethylase to a dCMP 
hydroxymethylase, and similar results were observed in E.coli. Therefore, the final aim 
of my thesis was to produce the corresponding mutation in asparagine 214 of VZV in 
order to establish whether this enzyme behaved in a similar manner to the prokaryotic 
enzymes.
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2.1. Plasmids
Plasmid 
pBS' 
pET 23 d 
pAD768
Source
Stratagene
Novagen
VZV TS-containing BamHI/Hindlll cloned into pBS' (P.T. 
Harrison, PhD thesis, Glasgow University, 1992)
2.2. Bacteria and bacteriophage strains 
Bacterial strains
Strain Genotype
BL21(DE3)* F , ompT, hsdSB, gal, dcm , (DE3)
BL21(DE3)pLysS F , ompT, hsdSB, gal, dcm, (DE3), (CmR)
BW313 relAl, spoTl, dut-1, ung-1, thi-1, Hfr KL16 (P045)
NM522* supE, thi, D(lac-/?raAB), Dhsd5(r~, m-). [F1, proAJB,]
TGI* supE44, hsd5, thil, A(Lac-proAB)/ F[traD36,proAB+, laclq,
/acZM15]
XL1* recAl, endk\, gyr A96, thi-1, hsdR 17, supE44, relA l, lac[F'pro
AB lac\\ lacZ M15 TnlO (Tef)]
Note: thy A derivatives were made of strains marked *
Bacteriophage
Bacteriophage M13 R408 and M13 K07 used in the production of single stranded DNA 
from phagemid vectors were laboratory stocks.
2.3. Bacterial growth media 
Liquid media
Luria-Bertani Medium 
Per litre:
NaCl lOg
Bactopeptone 1 Og
Yeast extract 5g
Adjusted to pH 7.0 prior to 
sterilisation
2xYT Medium t2 YD 
Per litre:
Bactotryptone 16g
Yeast extract lOg
NaCl 5g
Adjusted to pH 7.0 prior to 
sterilisation
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All LB media (both liquid and solid) was supplemented with 50pg/ml thymidine unless 
otherwise stated.
Minimal Medium (M9) M9|x4] salts
Per 400 mis: Per litre:
dH20 300ml Na2HPO4.7H20 24g
M9[x4] salts 100ml k h 2p o 4 12g
15% casamino acids 20ml n h 4ci 4g
20% glucose 4ml NaCl2 2g
1M MgCl2 0.5ml
0.8mg/ml Vitamin B 1 0 .1ml
Solid media
LB
As above except supplemented with 15g Bacto-agar 
M9
As above except 300ml db^O replaced by 300ml 2% Bacto-agar 
M9T
As above except 300ml dH20 replaced by 300ml 2% Bacto-agar with 20mls lmg/ml 
thymine.
Top agar
0 .6% bacto-agar in dK^ O
2.4. Chemicals and reagents
All chemicals were purchased from BDH chemicals Ltd, Poole, Dorset, or from Sigma 
(London) Ltd unless given below.
Ammonium persulphate (APS)
Ampicillin
Bactopeptone
Casamino acids
Deoxynucleoside triphosphates
Ecoscint A
EN3HANCE
Hydroxyapatite solid
Bio-Rad Laboratories 
Smithkline and Beecham 
Difco 
Difco
Pharmacia LKB 
National Diagnostics 
Du Pont (U.K.) Ltd. 
Bio-Rad Laboratories
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IPTG
N,N,N',N-tetramethylethylenediamine
(TEMED)
Organic solvents 
Protein assay reagent 
Replicote™
S-Sepharose
Calbiochem-Novabiochem Corporation 
Bio-Rad Laboratories
May and Baker 
Bio-Rad Laboratories 
BDH
Pharmacia LKB
2.5. Radiochemicals
All radiochemicals were purchased from Amersham International Ltd, Maidstone, UK.
Nucleotide Activity Concentration Code
[a35S]dATP 37Tbq/mmol lmCi/mmol (SJ1304)
5-[3H]dUMP 622GB q/mmol 17.8Ci/mmol (TRK287)
2.6. Enzymes and enzyme buffers
Calf intestinal phosphatase (CIP)
DNase 1
Klenow fragment of DNA polymerase 
Restriction enzymes
RNase A 
Sequenase™
T4 gene 32 protein 
T7 DNA polymerase 
T4 Ligase
T4 polynucleotide kinase 
5xligation buffer
Life Technologies, Inchinnan Business
Park, Scotland
Sigma
New England Biolabs, Bishops Stortford, 
UK.
Boehringer Mannheim, Lewes, E. Sussex, 
UK.
New England Biolabs, Bishops Stortford, 
UK.
Sigma
United States Biochemicals 
Pharmacia LKB, Uppsala, Sweden 
Pharmacia LKB, Uppsala, Sweden.
Life Technologies, Inchinnan Business 
Park, Scotland
New England Biolabs, Bishops Stortford, 
UK
Life Technologies, Inchinnan Business 
Park, Scotland.
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Buffer H
2.7. Buffers and solutions
Commonly used buffers and reagents 
Enzyme dilution buffer
0 /CHCI3
TBE
IE
TES buffer 
TM buffer
Reagents for DNA manipulations 
Loading buffer
STET lysis buffer
Lysozyme solution
TSB(transformation storage buffer)
NaOH/SDS solution
Potassium acetate/acetic acid solution
Sequencing solutions 
Labelling mix
Termination mixes (G, A, T, C):- 
G contained
A contained
Boehiinger Mannheim, Lewes, E. Sussex, 
UK
130mM Tris.HCl pH 7.5, 0.125mM DTT, 
0.15% BSA
Phenol/chloroform 1:1 (7v)
90mM Tris.HCl, 90mM boric acid, ImM 
EDTA
lOmM Tris.HCl pH 8.0, ImM EDTA 
50mM Tris.HCl pH 7.4, 5mM EDTA, 
50mM NaCl2
0.1M Tris.HCl pH 8.0, 0.1M MgCl2
15% ("7J ficoll, Bromophenol blue in 
lxTBE
8% (7 V) sucrose, 50mM Tris.HCl pH 8.0, 
40mM EDTA, 1% (7v)Triton X-100 
0.4% (w/v) egg white lysozyme, 50mM 
glucose, 25mM Tris.HCl pH 8.0, lOmM 
EDTA
7.4ml LB, 2ml 50% PEG 4000, 0.1ml 1M 
MgS04/lM  MgCl2, 0.5ml DMSO 
0.2M NaOH, 1% (W/V)SDS 
60ml 5M potassium acetate, 11,5ml glacial 
acetic acid, 28.5 ml dE^O
1.5pM dGTP, 1.5qM dTTP, 1.5^iM dCTP
8pM ddGTP, 80fiM dGTP, 80|iM dATP, 
80pM dTTP, 80jaM dCTP, 50mM NaCl 
8 |uM ddATP, 80piM dGTP, 80[iM dATP, 
80pM dTTP, 80|aM dCTP, 50mM NaCl
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T contained 
C contained
Annealing buffer (5xTM)
Stop solution
Reagents for oligonucleotide purification 
Oligo elution buffer
Oligo loading buffer
Reagents for protein purification 
Sonication buffer
Sonication buffer B
1M potassium phosphate buffer 
Potassium phosphate buffer
Reagents for protein gels 
5x Electrode buffer
Boiling mix
Coomasie blue stain 
Destain solution
8pM ddTTP, 80pM dGTP, 80|iM dATP, 
80pM dTTP, 80p,M dCTP, 50mM NaCl 
8pM ddCTP, 80pM dGTP, 80pM dATP, 
80pM dTTP, 80pM dCTP, 50mM NaCl 
0.1M Tris.HCl pH 8.0, 0.1M MgCl2 
95% (7v) deionised formamide, 20mM 
EDTA pH 7.5, 0.05% (w/v) Xylene cyanol 
FF, 0.05% (”/v) bromophenol blue
500mM ammonium acetate, 10mMMgCl2,
ImM EDTA, 0.1% (w/v) SDS
90% (7V) deionised formamide in lxTBE
50mM Tris.HCl pH7.4, lOmM DTT, 0.1% 
(v/v)Triton X-100
20mM Hepes pH7.6, 25% (7v) glycerol, 
600mM NaCl, 1.5MMgCl2, 0.2mM 
EDTA, 0.1% (7v) NP40 
1M KF^PC^ mixed with 1M K2H P04 to 
give pH 7
1M potassium phosphate pH 7, 1M DTT, 
100% (v/v) glycerol
52mM Tris base, 53mM glycine, 0.1% 
SDS
80mM Tris.HCl pH 6 .8, 2% (7 V) SDS,
0.1M DTT 20% (7v) glycerol, 
Bromophenol blue
1,25g Coomasie blue, 228ml methanol, 
45ml acetic acid, made to 500ml with dF^O 
50% (7v) dH20, 40% (7v) methanol, 10% 
(7V) acetic acid
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Tritium release assay solutions 
[2x] assay mix
Stop solution (Tritium release)
128mM NaF, 260mM Tris.HCl pH 7.5, 
64mM sucrose, 0.3% (w/v) BSA, 0.25mM 
DTT, 38mM HCHO, 1.4pM 
tetrahydrofolate
3 volumes 33% (7V) TCA, 1 volume 
5 mg/ml dUMP
Reagents for spectrophotometric assays
Spectro assay buffer 50mM TES pH7.4, 25mM MgCl2, 6.5mM
HCHO, ImM EDTA, 75mM 
mercaptoethanol
Folate dilution buffer 30mM NaHC03, 15mM HCHO, lOOmM
mercaptoethanol
Reagents for protein binding assay 
Buffer A
Coupling buffer 
Hi Trap Buffer A 
HiTrap Buffer B
20mM Hepes.NaOH pH7.5, 10% (v/v) 
glycerol, ImM DTT, ImM EDTA, NaCl at 
varying concentrations 
0.2M NaHCH03, 0.5M NaCl, pH 8.3 
0.5M ethanol amine, 0.5M NaCl, pH 8.3 
0.1M acetate, 0.5M NaCl pH7.4
Reagents for isolation and solubilization of inclusion bodies
Lysis buffer 50mM Tris.HCl pH 8.0, 25% (w/v) sucrose,
ImM EDTA
Detergent buffer 0.2M NaCl, 1% (7V) deoxycholic acid, 1%
(v/v) NP40
Triton X-100/EDTA solution 1% CO  Triton X-100, ImM EDTA
Urea-containing buffer 50mM phosphate buffer with varying
concentrations of urea
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Chapter 3. Methods
3.1. Growth and maintenance of bacteria and bacteriophage
3.1.1. Overnight cultures
A well isolated single colony or 50pl of a glycerol stock was used to inoculate 
5mls of L-broth in a 20ml universal, supplemented with the appropriate antibiotics and 
thymidine. The culture was incubated with vigorous shaking at 37°C overnight.
3.1.2. Bacterial glycerol stocks
A 10ml overnight culture of the appropriate clone was set up in a 20ml universal. 
Cells were harvested by centrifugation at 7000rpm for 5 minutes in a Beckman 
centrifuge. The cell pellet was resuspended in 5ml of 2% bactopeptone. 5mls 80% 
glycerol and 20jll1 25mg/ml thymidine were added to this, mixed and stored at -70°C.
3.1.3. Antibiotics
Antibiotics were used at the following final concentrations, unless otherwise 
stated: Ampicillin (Amp) 100(ig/ml, Kanamycin 75jig/ml, Chloramphenicol 25pg/ml.
3.1.4. Titration of helper phage
A 10ml overnight culture of the appropriate bacterial cells was set up. 3ml 
aliquots of molten top agar were equilibrated to 45°C in a waterbath. A series of 1 in 10 
dilutions of the M l3 R408 or M13 K07 helper phage were made in T2 buffer. lOOpl 
cells and IOOjllI of the diluted helper phage (in the range 10'6 to 10'12) were added to the 
equilibrated top agar, mixed together and immediately poured on to LB plates. Once the 
top agar layer had solidified the plates were incubated overnight at 37°C. Helper phage 
plaques were counted the next day and the titre calculated.
3.1.5. Growth of helper phage
An individual phage plaque was transferred into 0.5 ml LB. This was vortexed 
and incubated at 37°C to liberate phage. 0.25mls was used to infect 150mls of 
exponentially growing E.coli NM522 Thy' cells which were incubated with vigorous 
shaking at 37°C overnight. The overnight culture was cleared of bacteria by 
centrifugation at 9K for 10 minutes at 4°C. The supernatant was decanted to a fresh
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tube and recleared by a further centrifugation step prior to heat-inactivation at 65°C for 
20 minutes. The phage stock was allowed to cool to room temperature and stored at 
4°C. The titre of the helper phage was determined as described above.
3.2. Bacterial manipulation
3.2.1. DMSO-PEG 4000 transformation (Chung and Miller, 1988)
This method is the one routinely used for the transformation of bacterial cells. 
20ml of LB was inoculated with 1ml of NM522 Thy‘ bacterial cells and incubated at 
37°C with vigorous shaking until A600 was ~ 0.3. Cells were pelleted by centrifugation 
at 9K for 5 minutes at 4°C and resuspended in 2ml transformation storage buffer (TSB). 
The resuspended cells were made competent by incubation on ice for 15 minutes.
10 to lOOng of DNA was added to lOOpl of the competent cells and incubated on 
ice for 30 minutes. 900pl of LB (supplemented with thymidine) was added to the cells 
and incubated at 37°C for 1 to 1-5 hours. IOOjllI was spread on to LB plates 
supplemented with ampicillin and thymidine and incubated at 37°C overnight. A 
positive (~10ng plasmid DNA) and a negative (no DNA) control were also included in 
this experiment.
3.2.2. Calcium chloride transformation (Maniatis et a l, 1985)
In order to overcome some of the solubility problems that occurred during protein 
purification from BL21(DE3) cells, the vector containing the variant of interest was 
transformed into BL21 pLysS using the CaCl2 technique. The strain transforms poorly 
using the DMSO PEG4000 technique. IOjliI from an overnight culture of BL21 pLysS 
cells was inoculated into lOmls 2YT containing 25|ig/ml chloramphenicol and grown 
for ~3 hours at 37°C. The cells were pelleted at 3K for 3 minutes in a Sorvall SS34 
rotor (4°C) and the pellet was resuspended in 0.5ml ice-cold 0.1M MgCl2. The cells 
were re-pelleted as before and resuspended in ice-cold 0.1M CaCl2 and incubated on ice 
for 30 minutes. 5jll1 of DNA was added to 100(il of the competent cells and incubated 
on ice for 20 minutes prior to heat shock at 42°C for 90 seconds. Cells were added to 
0-5ml 2YT broth and incubated at 37°C, with vigorous shaking for 30 minutes. IOOjllI 
was spread onto LB plates containing ampicillin and chloramphenicol.
3.2.3. Electroporation
Bacterial electroporation was carried out as described in the Invitrogen 
Electroporator II manual, version 3.0.
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Preparation of electrocompetent cells (Dower et a l, 1988)
500ml of LB was inoculated with a 10ml overnight culture of NM522 Thy' and 
incubated at 37°C with vigorous shaking until A600 was 0.5-0.6. Cells were split into 
two centrifuge bottles and incubated on ice for 30 minutes and then pelleted by 
centrifugation at 3.5K for 15minutes in a Sorvall GS3 rotor. Supernatant was removed 
and the pellet was then thoroughly washed: the cells were resuspended (by shaking) in 
50mls ice-cold water, 50ml volumes of water were continually added to the cells until a 
final volume of 500mls was reached. The suspended cells were centrifuged at 3.5K for 
15 minutes and the pellets were resuspended in lOmls of ice-cooled 10% glycerol and 
combined. The cell suspension was then added to pre-cooled 30ml tubes and spun in a 
pre-cooled Sorvall SS34 rotor at 5800K for 15 minutes, the supernatant was decanted 
and pellet was resuspended in 1 % glycerol by vortexing. The final cell suspension was 
aliquoted in 40pl amounts into microfuge tubes in a dry ice bath and stored at -70°C.
3.2.4. Generation of thyA strains of E.coli (Stacey & Simpson, 1965)
2mls minimal media supplemented with thymidine (TdR) and trimethoprim 
(20|Ug/ml) was inoculated with 40(il of an appropriate overnight culture and incubated, 
with vigorous shaking, at 37°C overnight. 40|xl of this culture was used to inoculate 
2mls of fresh media and incubated as before. A single loop of this culture was used to 
streak for single colonies on minimal media plates supplemented with TdR and 
incubated at 37°C overnight. Individual single colonies were patched onto minimal 
media plates and minimal media plates supplemented with TdR and incubated at 37°C 
overnight. Colonies growing only on minimal media plates supplemented with TdR 
were classified as Thy' strains.
3.3. DNA isolation
3.3.1. STET lysis plasmid DNA preparation
1.5ml from a 5ml overnight culture was centrifuged for 40 seconds in the 
microfuge (12K) to pellet the cells. The cell pellet was resuspended in 200jnl STET 
buffer and 20p,l lysozyme (lOmg/ml) was added. The solution was boiled for 40 
seconds and centrifuged for 10 minutes at 12K. The debris and chromosomal DNA was 
present as a fluffy pellet and removed from the supernatant using a toothpick. 0-1 
volumes 3M sodium acetate and 2 volumes isopropanol were added to the supernatant 
and placed in a dry ice/ethanol bath for 5 minutes. The DNA was precipitated by 
centrifugation at 12K for 10 minutes and the pellet was dried under vacuum. The 
lyophilised pellet was resuspended in 20|il dH20.
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3.3.2. Qiagen™ midi plasmid preparation
lOOmls of LB supplemented with ampicillin was inoculated with lOmls of an 
overnight culture of the appropriate plasmid containing E.coli strain and incubated in a 
100ml conical flask overnight at 37°C with vigorous shaking.
The plasmid was isolated from the bacteria as described in the MIDI protocol of 
the Qiagen™ handbook.
3.3.3. DNA template preparation for double stranded sequencing (Maniatis et a l,
1985)
A single colony was inoculated into 5mls LB and grown at 37 °C overnight. 1.5ml 
of the culture was spun down in microfuge for 1 minute and the cell pellet was 
resuspended in ice-cold 50mM glucose, lOmM EDTA and 20mM Tris.HCl pH 8.0. 
50jll1 of lysozyme solution was added prior to incubation at room temperature for 5 
minutes. 200pl of NaOH/SDS solution was added, the solution was mixed and 
incubated at room temperature for a further 5 minutes. 150|il of potassium 
acetate/acetic acid solution was added, the contents were mixed and incubated on ice 
for 15 minutes. The solution was centrifuged for 5 minutes in microfuge (12K) and the 
supernatant was removed to a fresh tube. 1ml of ethanol was added and the solution was 
incubated at room temperature for 1 minute. The DNA was pelleted by centrifugation at 
12K for 5 minutes, the supernatant was discarded, 200pl ethanol was added and the 
solution incubated at room temperature for 1 minute. The DNA was repelleted by a 
further 5 minute centrifugation at 12K, the pellet was dried under vacuum and 
resuspended in 50jj,1 water.
To denature the DNA, 4 |i l  2M NaOH and 4 fil 2mM EDTA were added to the 
5 0 p l  sample, mixed and incubated at 90°C for 5 minutes. 8p,l 2M sodium acetate pH 
5 .0 , 1 4 p l of water and 160pl ethanol were then added prior to incubation at room 
temperature for 10 minutes. The denatured DNA was pelleted by centrifugation at 12K 
for 20 minutes and washed in 70% ethanol. The pellet was dried under vacuum and 
resuspended in 10|Lil dH20.
3.3.4. ssDNA sequencing preparation (Katayama, 1990)
A single colony was inoculated into 5ml 2YT broth containing ampicillin 
(100p,g/ml), thymidine (50pg/ml) and M l3 K07 helper phage (2xl08 pfu/ml) and 
incubated at 37°C with vigorous shaking for 2 hours. Kanamycin was added to a final 
concentration of 70pg/ml and the culture incubated at 37°C with vigorous shaking 
overnight.
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3x 1.5ml samples from the 5ml overnight were centrifuged at 12K for 10 minutes 
in a microfuge to pellet the cells. 1ml of the supernatant was transferred to a fresh 
eppendorf tube and 300p,l of a 2.5M NaCl/20% PEG 4000 solution was added, vortexed 
and incubated on ice for 20 minutes. The phage was pelleted by centrifugation in a 
microfuge at 12K for 5 minutes and the supernatant discarded. The phage pellets were 
resuspended and pooled together in 400jll1 0.3M sodium acetate. An equal volume of 
0 /CHCI3 was added, the solution was vortexed vigorously and microfuged for 5 
minutes. The top aqueous layer was transferred to a fresh eppendorf tube and 1ml 
ethanol added prior to incubation at room temperature for 30 minutes. The ssDNA was 
pelleted by centrifugation at 12K for 5 minutes and the supernatant carefully discarded. 
The ssDNA pellet was dried in the speedivac for 5 minutes, resuspended in 10|il TE 
buffer and stored at -20°C.
3.3.5. Uracil-ssDNA preparation (Kiinkel, 1985; Kiinkel et al, 1987)
Uracil-enriched ssDNA for use in mutagenesis experiments was prepared as 
follows. lOmls of 2YT (lOOpg/ml ampicillin and 100pg/ml uridine) was inoculated 
with 50jil glycerol stock of E.coli BW313 dut' ung' containing plasmid pAD768 and 
incubated at 37°C with vigorous shaking overnight. The 10ml culture was added to 
200ml of 2YT supplemented with ampicillin and uridine (lOOpg/ml) in a 2 litre baffled 
flask and incubated at 37°C with vigorous shaking until A600was 0.5. M13 R408 helper 
phage was added to a final pfu/ml of 5xl09 and the culture incubated at 37°C with 
vigorous shaking for a further 8 hours. The cells were pelleted by centrifugation at 7K 
for 20 minutes using a Sorvall GS3 rotor and the supernatant kept and spun again. To 
the final supernatant 0.25 volumes of 3.75M ammonium acetate/20% PEG 6000 
solution was added, mixed, split in two and incubated on ice for 30 minutes. The phage 
precipitate was collected by centrifugation at 9K for 30 minutes using a Sorvall GS3 
rotor. The phage pellet was allowed to air dry for 10 minutes and then resuspended in 
TE buffer (400pl per pellet). The protein was removed by chloroform extracting twice 
and 0 /CHCI3 extracting 3 to 6 times or until the interface became clear. The aqueous 
phase was chloroform extracted one final time and removed to a fresh tube. 0.36 
volumes 7.5M ammonium acetate and 2.5 volumes ethanol were added and the solution 
was incubated on ice for 20 minutes. The ssDNA was pelleted by centrifugation at 12K 
for 20 minutes, washed with 70% ethanol and dried under vacuum. The pellet was 
resuspended in 50fxl dH20. This ssDNA template was checked to ensure it was uracil 
enriched by transforming ljul sample into a dut+ung+ host (NM522) and a dut' ung" host 
(BW313). The concentration of ssDNA produced was estimated spectrophotometrically 
( 1 A260 unit = 40pg/ml ssDNA).
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3.4. DNA manipulations
3.4.1. Restriction enzyme digests
Restriction enzyme digests were usually carried out in 10 to 50pl reaction 
volumes. Restriction enzyme buffers are available commercially at lOx concentration 
and were diluted accordingly. Enzymes were added at 1 to 10 units (U) per jig DNA 
and incubations performed at 37°C for 3 hours or overnight.
When mini or STET prep DNA was digested, RNase was added to a final 
concentration of 20pg/ml for the last hour of the incubation. Digested DNA to be used 
in cloning experiments was always 0/CHCl3 extracted (to remove the restriction 
enzymes) and ethanol precipitated prior to use.
3.4.2. Removal of 5’-phosphate groups
1 unit of calf intestinal phosphatase (CIP) was added to the restriction digest 
reactions and incubated as normal. The DNA was extracted with 0/CHCl3 and ethanol 
precipitated prior to cloning.
3.4.3. DNA ligations
Ligations were usually performed in a total volume of 20jil. lOOng of vector and 
17ng insert DNA were mixed with 4pl 5x ligation buffer, 1.5 units T4 DNA ligase and 
the volume made up to 20|il with dH20. The ligation mix was incubated at 15°C 
overnight. 1 OjllI of the ligated DNA was used for transformation of E.coli.
3.4.4. Isolation of DNA from agarose gels
DNA was isolated from agarose gels using a Pharmacia Sephaglass™ kit as per 
the manufacturer’s instructions.
3.5. Oligonucleotides
3.5.1. Synthesis and purification
Oligonucleotides for sequencing primers and site-directed mutagenesis were 
synthesised on a Cruachem PS250 DNA synthesiser. Oligonucleotides were provided 
still attached to the column upon which they were synthesised. Removal of the 
oligonucleotide involved flushing the column with one column volume (~0.25ml) of 
concentrated ammonia solution, and incubating at room temperature for 20  minutes. 
This process was repeated until 1.5ml of concentrated ammonia had been flushed 
through the column. The oligonucleotides were incubated at 55°C for 5 hours to remove
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the protecting group and subsequently dried overnight under vacuum. The pellet was 
resuspended in 50|l i 1 dH20 and stored at -20°C until required.
1 5jll1 of the oligonucleotide was mixed with an 25jll1 of loading buffer (lxTBE, 
90% deionised formamide) and boiled for 2 minutes. The sample was loaded on to a 
15% polyacrylamide gel along with 5 to 10pl formamide dyes (in a separate well) as a 
marker track. Electrophoresis was performed at 400V in lxTBE buffer. For 
oligonucleotides of length 15 to 30 bases the Bromophenol blue band was allowed to 
migrate approximately 7cm down the gel (-1 hour). For oligonucleotides 30 to 60 bases 
in length the Bromophenol blue band was allowed to migrate to approximately the end 
of the gel (-2-3 hours).
To isolate the oligonucleotide the gel was removed from the glass plates and laid 
on cling film. The DNA was visualised using the shadow casting technique, which 
involved illumination of the gel whilst on a thin layer chromatography (TLC) plate 
using a short-wave UV lamp. The DNA appears as a dark band against a uniform green 
fluorescent background. The slowest moving band towards the top of the gel was 
excised, cut into several smaller pieces and eluted in 0.5 ml oligonucleotide elution 
buffer overnight at 37°C. The eluted oligonucleotide was centrifuged at full speed in a 
microfuge for 5 minutes to remove any polyacrylamide. The supernatant was carefully 
removed to a fresh eppendorf tube and phenol/chloroform extracted once followed by a 
chloroform extraction. The DNA was precipitated with two volumes of ethanol, placed 
in a dry ice/ethanol bath for 10 minutes and centrifuged at full speed in the microfuge 
for 10 minutes. The DNA pellet was resuspended in 50pl of dH20 and stored at -20°C 
prior to use. The concentration of DNA was determined spectrophotometrically (1 A260 
unit = 33(ig/ml oligonucleotide).
3.5.2. Spiked oligonucleotides
Spiked oligonucleotides for use in region directed mutagenesis were synthesised 
on the Biosearch 8600 DNA synthesiser using phosphoramidite mixes containing 96% 
of the normal nucleotide and 1.33% of each of the other three nucleotides (Ner et al., 
1988; McNeil & Smith, 1985).
3.5.3. Oligonucleotide sequences
A complete list and sequences of all the oligonucleotides used in this project are 
shown below.
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Oligonucleotide for site-directed mutagenesis 
Sequence
TCC-AGC-AAT-GTC-GAA-CGG-TAC
Mutation
N214D
Spiked oligonucleotides for region directed mutagenesis
Number Sequence targeted (see Figure 6 .0  Size
RO1 C A A- ATT-GT A-TCG- AGC-TTG-C AT-TCC-A A A-T AA 57mer
AGA-T A A-CGT-T CC-G AT-TCC-TGT-TCG-ATC 
R09 GGT-AAG-AAG-TGC-AT A-TCC-AGC-A AT-GTT-GAA 54mer
CGG-TAC-CCC-AAG-GCC-CAT-ATC-CCC 
ROl 1 ATC-TAT-ATG-ATT-CAA-GTA-AAT-ATG-TGC-ATC 54mer
CCC-C AT-TGT - ATG-A AT-T AA-ATC-TCC 
RO 13 TCG- ATC-GCG-TTT-CCG- A AC-TCC- AT A-CCT-T AA 57mer
A AT - ATC-ATC-C AC-TTG-TTT-T AA-GT A-CTG 
RO 15 CGC-TCC-AA A-ATG-TCT-CC A-CTG-G A A-GCC-GT A 57mer
AAT-GGG-GCC-AAG-GTC-CCC-CGT-GTG-TCT 
RO 19 TT A-A AG-AGC-C AT-TTC-C AT-TTT-T AG-GGG-GGG 57mer
GTG-TGG-ATT -AT A-TCC-ATC-A AG-CTG-AAA 
RO20 AGC-C AT-TTC-C AT-TTT-T AG-GGG-GGG-GTG-TGG 5 lmer
ATT AT A-TCC-ATC-AAG-CTG-AAA
Sequencing primer oligonucleotides
Number Primer sequence fsee Figure 6.1s)
59 GTCTGTGTATATCAT
58 GTCCC ATTT AA AGTC
60 CCATTGTATGAATTA
57 TGG AGGT AGT ACC AT
61 TTT AATTGTATCT AT
62 CCACGACGGCCCTCC
3.6. Mutagenesis
3.6.1. Oligonucleotide site-directed mutagenesis
Oligonucleotide site directed mutagenesis was used to introduce a specific 
mutation at a defined site within the TS gene. The strand selection scheme of Kiinkel 
was employed using a uracil-enriched template strand which is degraded in a dut+ ung+ 
host strain (Kiinkel, 1985). 500pmole oligonucleotide was phosphorylated in 4|il 5x 
ligation buffer containing 10 units of T4 polynucleotide kinase at 37°C for 30 minutes.
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The T4 kinase was inactivated by incubation at 65°C for 15 minutes. The 
phosphorylated oligonucleotide was diluted with dH20 to a final concentration of 
5pmole/pl. 1 jlxI phosphorylated oligonucleotide was annealed to O.lpmole U-ss DNA 
(estimated spectrophotometrically) in 1 OjllI TM buffer at 37°C for 30 minutes. The 
annealed oligonucleotide was filled in by the addition of 1 jLil 5mM dNTPs (a 5mM 
solution of all four dNTPs), 5 units Klenow fragment of DNA polymerase I, 1 unit of 
T4 ligase and 2.0pg gene 32 protein in 20jll1 ligation buffer. After a 2 hour incubation a 
further 5U Klenow and 1U of ligase were added and incubated at room temperature for 
another 2 hours. The DNA was stored at -20°C.
3.6.2. Region directed mutagenesis
Spiked oligonucleotides were designed to have on average two base changes per 
oligonucleotide. They were used to introduce random mutations to a targeted region of 
the TS gene (see Figure 6.1). Mutagenesis was performed as outlined for site-directed 
mutagenesis (see section 3.6.1), again using the strand selection system of Kiinkel.
3.7. Mutant screening
3.7.1. Growth complementation assays
1 to 5|LLl mutagenised DNA from both the site-directed mutagenesis and region directed 
mutagenesis was used to transform NM522 Thy' bacteria. Transformants were picked, 
using sterile toothpicks, patched onto M9 and M9T plates and incubated overnight in 
order to determine whether the colonies were Thy+ or Thy'.
3.7.2. Temperature sensitive clones
Clones obtained from region directed mutagenesis using spiked oligonucleotides 
were screened for temperature sensitivity. AmpR colonies (grown at 37°C on LB agar 
plates) were picked, using the blunt end of a toothpick and patched onto three M9 and 
three M9T plates which had been divided into 50 patches by a template. The same 
toothpick was used to patch all six plates. The plates were incubated at three 
temperatures, 30°C, 37°C and 42°C for 24 hrs and the growth was scored. The plates 
were patched in the order 42°C, 37°C and 30°C to ensure that failure to grow at the high 
temperature was not due to an inadequate inoculum. Temperature sensitive mutants 
gave a Thy+ phenotype at 30°C but a Thy' phenotype at 37°C and 42°C.
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3.7.3. Restriction digests
Candidate mutant clones were screened by restriction digest analysis of the 
plasmid DNA prior to sequencing to remove those clones that did not give the correct 
restriction pattern and contained “monster” plasmids arising from aberrant filling-in 
reactions. Restriction analysis was performed as described in section 3.4.1.
3.7.4. DNA sequencing
All DNA sequencing was performed in a 96 well micro-titre plate using a 
Sequenase™ kit. 3 j l l 1 (~10-30ng) sequencing primer, was annealed to 0.1-1.0|ig of 
DNA (ssDNA or dsDNA) in 10|il lx reaction buffer by incubating at 37°C for 30 
minutes in an eppendorf tube. The annealed reaction mix was transferred to a micro- 
titre plate and 1 jul DTT, 2p,l label mix (previously diluted 1 in 3), l-2jil [a-35S]dATP, 
and 2 j l l 1 Sequenase enzyme (previously diluted 1 in 8) added. The plate was spun in a 
centrifuge at IK for 30 seconds to mix the reagents and incubated at room temperature 
for 5 minutes. 3.5p,l of this mix was transferred to a separate well containing 2.5|il of 
ddGTP. This was repeated for the other three dideoxy termination mixes (ddATP, 
ddTTP, ddCTP) and the plate sealed with a plate sealer (Flow Laboratories Ltd or 
Corning) and incubated at 37°C for 15 minutes. 4 j l x 1 of stop solution was added to the 
sequencing reaction and the plate boiled for 2 minutes prior to loading.
Sequencing reactions were resolved on a 4% polyacrylamide (7.7M urea, 0.5x 
TBE gel). Prior to use both sequencing plates were coated with Repelcote™ and 
washed once with 100% ethanol before the gel was poured. Electrophoresis was 
performed at 60W in 0.5xTBE. For normal runs the bromophenol blue was used as a 
marker to terminate electrophoresis. For longer runs the gel was run for a further 1-2 
hours. The sequencing gel was washed in 10% acetic acid for 30 minutes, transferred to 
3MM paper and dried on a vacuum gel drier for 90 minutes. The gel was exposed to 
Kodak S 100 film overnight at room temperature.
3.8. Mutant characterisation
3.8.1. Crude TS extracts (Thompson et al., 1987)
350ml LB supplemented with ampicillin (100p,g/ml) and thymidine was 
inoculated with 10ml of an overnight culture of a suitable clone and incubated at 37°C 
(30°C for the temperature sensitive mutants) with vigorous shaking until A600 ~ 0-5. A 
small volume of culture was removed and kept on ice for a phenotype check (see later). 
The cells were pelleted by centrifugation at 7K for 10 minutes (Sorvall GS3 rotor) at 
4°C. The supernatant was discarded and the pellet resuspended in 10ml TES buffer and
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vortexed to disrupt any lumps. The suspension was transferred to a 15ml falcon tube 
and the cells were pelleted once more (MSE bench top centrifuge) by centrifugation at 
3K for 10 minutes at 4°C. The supernatant was removed using a pipette and the pellet 
was frozen/thawed once, resuspended in 2 volumes of sonication buffer. Sonication was 
performed (using a Branson sonifier) with the microprobe on setting 5 and entailed 
3x30 second bursts with 30 seconds cooling (on ice) between each burst. The crude 
sonicate was transferred to eppendorf tubes and spun at 12K for 10 minutes in a pre­
cooled microfuge at 4°C. The supernatant was removed to fresh tubes and the protein 
concentration determined prior to being snap frozen in a dry ice/ethanol bath and stored 
at -70°C.
To check the phenotype of the extract a drained loop full of the culture was 
streaked to single colonies on a LB agar plate (supplemented with 50|Hg/ml thymidine 
only) and incubated at 30°C, 37°C or 42°C overnight. Single colonies were then 
patched on to M9, M9 plus thymidine and LB (supplemented with 100|ig/ml ampicillin 
and 50|ig/ml thymidine) agar plates and incubated at 30°C, 37°C or 42°C for 
temperature sensitive clones.
3.8.2. Protein concentration determination
A modified version of the Bradford assay was used to determine the protein 
concentration of crude and purified protein extracts. Assays were performed in micro- 
titre plates using an Anthos HTII plate reader at a wavelength of 620nm.
400|il of Bradford reagent was aliquoted into a series of wells and lOpl BSA 
protein standards were added with concentrations ranging from 0 .2-1.6mg/ml. l - 10|il of 
the sample protein was added to a well and mixed prior to reading the plate. The plate 
reader plots a standard curve from which the amount of protein present in the sample 
can be calculated.
3.8.3. Tritium release experiments
3.8.3.I. Tritium release assay
This assay is based on the release of tritium as tritiated water from 5-[3H] dUMP 
to the solvent (Roberts, 1966). 5|il of TS extract was mixed with lOjil [2x] assay mix, 
0.4|iCi 5-[3H] dUMP and dH20 to give a total volume of 40jil. The reaction mix was 
incubated at 30°C for 15 minutes and terminated by addition of stop solution and 940|nl 
2% charcoal suspension, which was used to absorb any unreacted [3H] dUMP. The 
sample was vortexed and centrifuged for 5 minutes following which 500jnl supernatant 
was removed into a scintillation vial. 5ml Ecoscint A was added prior to liquid 
scintillation counting in a Beckman LS5000CE scintillation counter. A total counts
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control was included using 5(il dH20  instead of extract and 940jll1 dH20 instead of 
charcoal suspension. A background control was also included by replacing extract with 
5jll1 dH20  and adding 940pl charcoal, this value was subtracted from all experimental 
values. Assays were performed in duplicate on two or more independent extracts for 
each clone. The amount of extract used was adjusted so that less than 30-60% of the 
total counts are released. This ensures that assays are in the linear region of the reaction 
curve.
The amount of dTMP generated is directly equivalent to the amount of [3H] 
released during the assay. The amount of [5-3H] dUMP added to the reaction in pmol 
can be calculated from its specific activity. The total counts represents the equivalent 
amount of product (dTMP)
pmol dTMP produced = sample CPM x pmol 5 -[3H] dUMP added
Total CPM
From protein concentration, the specific activity of TS in the crude extracts can be 
expressed in terms of pmol dTMP produced per jug protein per minute.
3.8.3.2. Temperature profiles
The tritium release assay was also used to examine the temperature profiles of the 
temperature sensitive mutants. 70jil of the crude extracts were held at 42°C and at 5 
minute intervals over a 30 minute period, 5jll1 samples were removed, added to the 
tritium release reaction mix at 30°C and assayed (section 3.8.3). A wild type sample 
was also assayed at the same time to give a control sample.
3.8.3.3. Phenolphthalein inhibition
Phenolphthalein was first identified as an inhibitor of TS using the DOCK 
computer programme (Shoichet et al., 1993). This programme identifies molecules that 
will fit into the active site of enzymes and thus act as competitive inhibitors.
The tritium release assay was carried out as normal but with the addition of 50- 
500pM concentrations of phenolphthalein into the reaction mix. A stock solution of 
phenolphthalein was made at ImM in 70% ethanol and a corresponding amount of 
ethanol was added to the control reactions.
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3.8.3.4. Inhibition by folate analogues
Several inhibitors have been produced by ICI which resemble the structure of the 
folate cofactor, these folate analogues have all been derived from one parent compound. 
CB3717 (see Figure 1.16). These inhibitors were used at varying concentrations in the 
tritium release assay.
3.9. Construction of high level expression clones
To enable large quantities of protein to be purified from a bacterial culture system 
mutant TS genes were cloned into the vector pET23d under the control of the strong 
bacteriophage T7 promoter. This vector when transformed into the host E.coli strain 
BL21 (DE3) is inducible by IPTG allowing high levels of protein to be expressed.
An NcoI-EcoRI fragment from pAD768 which contained the TS coding region 
was ligated into an appropriately cleaved pET23d backbone. The ligation mix was 
transformed into NM522 Thy'cells and the construct was validated by restriction 
digestion of mini-prep DNA. This step was required because of the poor transformation 
efficiency of BL21 (DE3) cells. DNA from the NM522 clones was used to transform 
the constructs into BL21 (DE3) or BL21 (DE3) pLysS cells.
3.10. Purification of mutant enzymes
3.10.1. Preparation and extraction
Both NM522 Thy' bacteria and BL21 (DE3) Thy' cells were used for preparation 
of extracts. A fresh single colony was picked into 20ml LB supplemented with 
lOOjiig/ml ampicillin and 50|Hg/ml thymidine and incubated at 37°C (or 30°C for 
temperature sensitive mutants) with vigorous shaking overnight. 2.5ml of this overnight 
was used to inoculate 750ml LB supplemented with lOOpg/ml ampicillin and 50pg/ml 
thymidine in a 2 litre baffled flask. A total of 6 litres (8 flasks) was inoculated and 
incubated at 37°C or SOPC with vigorous shaking until the A600 ~ 0.5. At this point 1ml 
was transferred to a universal and incubated at 37°C or 30°C as before. To the flasks 
IPTG was added to a final concentration of 0.2mM and incubation at 37°C or 30°C 
continued for a further 2-3 hours to allow induction of the protein to take place. 1ml of 
the induced culture was removed to a universal and along with the previous 1ml sample 
processed (as described in section 3.10.3) to check for protein induction.
The induced culture was centrifuged at 9K for 15 minutes (Sorvall GS3, 4°C) and 
the resulting pellets were resuspended in a total of 10ml TES buffer. A further 10ml of 
TES buffer was added and the suspension vortexed to disrupt any lumps. The cells were 
once again pelleted by centrifugation at 9K for 15 minutes (Sorvall GS3, 4°C) and the 
supernatant discarded. The bacterial pellet was resuspended in 15ml 50mM potassium
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phosphate buffer pH 7.0 and vortexed vigorously prior to sonication. Sonication was 
performed (using a Branson sonifier) with the microprobe on setting 5 and entailed 3 x 
30 second bursts with 30 seconds cooling (on ice) between each burst. The crude 
sonicate was centrifuged at 18K for 30 minutes (Sorvall SS34, 4°C) and the supernatant 
removed and kept at 4°C. The remaining cells were resuspended in a further 10ml 
50mM potassium phosphate buffer pH 7.0, re-sonicated and spun as before. The two 
supernatants were combined and stored at -70°C prior to purification.
3.10.2. Preparation of extracts from BL21 pLys S cells
The cells were grown up and pelleted as in section 3.10.1. The combined pellet 
was frozen then thawed at room temperature and resuspended in 10ml sonication buffer 
B, ImM DTT and 0.5mM PMSF were added to the buffer prior to sonication. The cell 
suspension was sonicated using the Branson sonifier on setting 5 for 10 seconds and the 
sonicate was transferred to a 5ml tube and pelleted at 35,000K for 20 minutes 
(ultracentrifuge, Sorvall T865 rotor). The supernatant was recovered and stored at 
-70°C.
3.10.3. Protein mini-gel electrophoresis
SDS polyacrylamide gel electrophoresis was performed using a Bio-Rad MINI- 
PROTEAN™ II kit. Gels were cast according to the manufacturers instructions and 
consisted of a separating gel (12% polyacrylamide, 0.37M Tris.HCl pH 8 .8 ) and a 
stacking gel (4% polyacrylamide, 0.125M Tris.HCl pH 6 .8).
Bacterial cultures to be tested were initially pelleted by centrifugation of 1ml of 
the appropriate culture in a microfuge (12K) for 1 minute. The supernatant was 
removed and the pellet resuspended in 50pl dH20 and then 5 0 jll1 of boiling mix added. 
The sample was boiled for 2 minutes prior to loading on the gel. Electrophoresis was 
performed at 220V in lx electrode buffer for 45 minutes or until the Bromophenol blue 
dye front had reached the bottom of the gel. The gel was removed from the casting 
plates and the top stacking layer carefully discarded. The gel was stained using a 
Coomassie blue stain for 20 minutes and then destained for 20 minutes. The destain was 
discarded and the process repeated. Destained gels were air dried overnight between a 
sheet of porous cellophane (Bio-Rad).
3.10.4. Hydroxylapatite chromatography
Protein to be purified was initially loaded onto a hydroxylapatite (HTP) column 
and then an S-Sepharose column. All chromatographic procedures were performed at
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4°C. A 30ml column was poured by resuspending ~12g hydroxylapatite in 3 volumes of 
50mM potassium phosphate buffer pH 7.0 and mixing by gentle swirling. The 
hydroxylapatite was allowed to settle and the buffer decanted, fresh buffer was added 
and the process repeated. The washed hydroxylapatite was finally resuspended in an 
equal volume of 50mM potassium phosphate buffer pH 7.0 and poured in to the column 
and allowed to settle. To wash and equilibrate the column, two column volumes of 
50mM potassium phosphate buffer pH 7.0 were pumped through the column at 
1 ml/minute.
Samples were kept from all stages of the chromatography (loading, washing and 
eluting) for analysis on a protein mini-gel (see section 3.10.3). The supernatant usually 
appeared viscous after sonication and was thus diluted to a final volume of 50ml with 
50mM potassium phosphate buffer pH 7.0. The sample was added onto the column at 
0-5ml/minute, and the flow through collected. The unbound protein was removed by 
washing (1 ml/minute) the column with 60mls (2 volumes) of 50mM followed by 
lOOmM potassium phosphate buffer pH 7.0. The TS protein was eluted from the 
hydroxylapatite by washing the column in 2 volumes 300mM potassium phosphate 
buffer pH 7.0 at 1 ml/minute.
Samples were collected from every stage of the HTP column and 10pl aliquots 
were mixed with 5jll1 boiling mix and run on a protein gel as before (section 3.10.3) in 
order to determine whether TS was eluted in the 300mM wash.
3.10.5. Ammonium sulphate precipitation and dialysis
The partially purified TS protein from the hydroxylapatite column was 
precipitated with 70% (w/v) ammonium sulphate. Solid ammonium sulphate was added 
slowly to the protein solution while stirring on ice and the solution was left stirring for a 
further 60 minutes. The precipitate was pelleted by centrifugation (Sorvall SS34, 4°C) 
at 10K for 40 minutes and the pellets were resuspended carefully without frothing in 
4ml of 50mM potassium phosphate buffer pH 7.0. The protein solution was dialysed 
overnight against 1 litre of 50mM potassium phosphate buffer pH 7.0 using Spectra/Por 
(Mol Wt. cut off 10,000) dialysis tubing. The dialysed protein solution was centrifuged 
(12K, microfuge) to remove any sediment and the supernatant stored at 4°C prior to 
loading on to an S-sepharose column.
3.10.6. S-sepharose chromatography
All chromatographic procedures were performed at 4°C. A 10ml S-sepharose 
column was poured using fast flow S-sepharose suspension (Pharmacia). As before 
samples were kept from all stages of the chromatography (loading, washing and
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eluting) for analysis on a protein mini-gel. The column was washed and equilibrated 
with 4 column volumes of 50mM potassium phosphate buffer pH 7.0 at 1 ml/minute. 
The dialysed protein sample was loaded directly on to the top of the column and 
pumped on at 0.5ml/minute. The unbound protein was washed from the column with 2 
volumes 50mM potassium phosphate buffer pH 7.0 at lml/min. The TS protein was 
eluted from the column using a salt gradient. The gradient was achieved using mixing 
chambers which contained 20ml 50mM potassium phosphate buffer pH 7.0 in one 
chamber and 50mM potassium phosphate buffer pH 7.0 plus 400mM KC1 in the other. 
The gradient was applied to the column at 0-5ml per minute, and fractions collected 
every 2 minutes.
The Bradford assay was used to visualise which fractions contained the TS 
protein. These fractions were tested for activity (tritium release assay) and stored at 
-70°C until required.
3.11. Purification of protein from inclusion bodies
3.11.1. Isolation of inclusion bodies from total cell extracts
Bacterial cells expressing the protein were harvested by centrifugation at 7K for 
10 minutes (Sorvall GS3) and resuspended in lOmls lysis buffer. Lysozyme was 
dissolved in a small volume of lysis buffer and added to a final concentration of 
0-1 mg/ml. The cell suspension was incubated on ice for 30 minutes and then freeze/ 
thawed, as the solution was thawed it became viscous. MgCl2, MnCl2 and DNase I were 
added to the suspension to final concentrations of lOmM, ImM and 10|Lig/ml 
respectively and the viscosity of the solution decreased as the DNA was digested by 
DNase I. An equal volume of detergent buffer was added to the lysate and centrifuged 
at 5,900K for 10 minutes (Sorvall SS34). The supernatant was transferred to a fresh 
tube without disturbing the white tight pellet (inclusion bodies) and upper "jelly-like 
layer" (membrane proteins). The pellet was resuspended in Triton X-100 solution, to 
remove most of the membrane proteins, and the inclusion bodies were spun down. This 
procedure was repeated until the jelly-like was no longer seen.
3.11.2. Solubilisation of inclusion bodies
The inclusion bodies were solubilised in 10 volumes of 8M urea buffer using a 
pipette and the sample was centrifuged at 20K for 1 hour (Sorvall SS34). A large jelly- 
like pellet was obtained and the supernatant was collected. The pellet was resuspended 
in urea-containing buffer, centrifuged again at 20K and the supernatant collected. The 
supernatants were analysed by SDS-PAGE.
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3.11.3. Re-folding of proteins
To remove the urea and allow the protein to refold, the supernatant containing 
solubilised inclusion bodies was dialysed against decreasing concentrations of urea in 
50mM phosphate buffer. The supernatant was dialysed against 50mM phosphate buffer 
containing 8M urea, 4M urea and 2M urea for 1 hour in each case. Finally the 
supernatant was dialysed overnight against 50mM phosphate buffer containing no urea. 
Insoluble material was removed by centrifugation and a sample of the supernatant was 
collected in each case and run on a mini protein gel (section 3.10.3).
3.12. Kinetic characterisation of mutants
Steady-state kinetic constants were determined using the spectrophotometric 
assay as described (Pogolotti et al., 1986). Reactions were set up in microplate wells 
and the change in absorption at 340nm was monitored on an Anthos Labtec HTII 
microplate reader. 1 OOjllI of spectro assay buffer was added to the plate, the 
concentrations of dUMP and folate were varied and dH20  was added to give a final 
volume of 200|il. When dUMP concentration was varied the folate was constant at 
880 |llM ; when folate was varied, the dUMP concentration was constant at 1.25 mM.
3.13. Protein binding assays 
3.13.1.35S-Methionine labelled cells
A small flask of MeWo cells were grown in Dulbecco’s medium at 37°C until 
sub-confluent and 1ml of stock VZV was added. 3-4 days post infection the infected 
cells were transferred to a sub-confluent medium flask and incubated at 37°C until 
plaques had developed. The cells were then transferred to a large flask. Having allowed 
plaques to form in the large flask, the medium was decanted and Eagles methionine free 
medium was added and the cells were incubated at 37°C for 1.5 hours. Following 
incubation the medium was decanted, fresh medium containing 50(iCi/ml 35S- 
methionine was added and the cells were incubated overnight at 37°C to enable 
labelling to take place. Cells were removed from the incubator after -16 hours, the 
medium was decanted and the cells were washed twice with phosphate buffer saline 
(PBS). 3mls of Buffer A was added to the flask and the cells were scraped off and 
pipetted into a 15ml falcon tube, this was repeated using 2ml of buffer. The cells were 
incubated at 4°C for 1 hour and centrifuged at 3K for 20 minutes (Sorvall SS34, 4°C). 
The supernatant was removed and the pellet stored at -20°C.
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3.13.2. Preparation of labelled cell extracts (Boehmer and Lehman, 1993)
The labelled cells were resuspended in Buffer A (1.2M NaCl), transferred to a 
Dounce homogeniser and lysed with 10 strokes of the tight fitting pestle. The lysed 
cells were cleared by centrifugation at 55,000rpm for 60 minutes (ultracentrifuge, 
Sorvall T865 rotor). Nucleic acid was precipitated from supernatant by the drop-wise 
addition of 0.05vol of 0.3M spermidineHCl/lMNaCl/0.31 vol of 5% streptomycin 
sulphate both in buffer A. After a 30 minute incubation on ice the nucleic acid 
precipitate was removed by centrifugation at 25,000rpm for 30 minutes (ultracentrifuge, 
Sorvall T865 rotor). The supernatant was dialysed against 500ml buffer A (0.1M NaCl) 
overnight. After dialysis, the precipitate was removed by centrifugation at 55,000rpm 
for 30 minutes (ultracentrifuge, Sorvall T865 rotor), and the supernatant was stored at 
-70°C (~500|il). A sample was removed from the supernatant and retained for gel 
analysis.
3.13.3. SDS-PAGE analysis of radiolabelled samples
A 50ml SDS-PAGE gel was cast consisting of a separating gel (12% 
polyacrylamide, 0.37M Tris.HCl pH 8 .8) and a stacking gel (4% polyacrylamide, 
0.125M Tris.HCl pH 6 .8). 10(il of the labelled extracts were added to boiling mix and 
water to give a final volume of 50|il, and boiled for 2 minutes prior to loading. 
Electrophoresis was performed at 150V in 1 x electrode buffer until the bromophenol 
blue dye front had reached the bottom of the gel (4-5hours). The gel was removed from 
the casting plates and the top stacking layer carefully discarded. The gel was stained 
using a Coomassie blue stain for 20 minutes. The gel was then destained for 20 
minutes, the destain discarded and the process repeated. Following destaining the gel 
was rinsed in dH20  and placed in EN3HANCE to improve the detection of the 
radiolabelled extracts. After 30 minutes the gel was removed and washed for 20 
minutes in dH20 , this process was repeated three times. The gel was dried under 
vacuum for 1 hour and placed against X-ray film in a cassette case at -70°C, initially 
overnight and then longer if required.
3.13.4. HiTrap affinity column
Purified protein was bound to a 1ml NHS activated HiTrap column as in the 
instruction booklet for Pharmacia HiTrap™ affinity columns. The viral infected or 
mock infected cells were applied and the column was incubated at 37°C for 30 minutes. 
The column was washed with 2 volumes of buffer F (0.1M NaCl) and developed with 
10ml linear gradients of NaCl (0.1-1M) followed by elution with 1ml at 1.0M and 4mls
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at 0.1M NaCl. Samples were removed at each stage of the process and retained for gel 
analysis (section 3.10.3).
3.13.5. Precipitation of samples from HiTrap column.
lOjLig/ml of BSA and 1 volume of 40% TCA were added to the 2ml samples 
collected from the column. The fractions were precipitated on ice, centrifuged at 12K 
for 15 minutes in a microfuge and the supernatant was removed. The remaining pellet 
was rinsed in ethanol followed by ethanol/ether and dried under vacuum for 5 minutes. 
The pellets were resuspended in boiling mix, boiled for 2 minutes and analysed by 
SDS-PAGE (section 3.10.3).
3.14. Molecular modelling
Two models of VZV thymidylate synthase, one of the ternary complex and the 
other of the native enzyme with bound phosphate, have been constructed by Celia 
Schiffer and Robert Stroud (personal communication). The models are based upon the 
co-ordinates of the ternary complexes of E.coli TS with CB3717 and dUMP ( Montfort 
et al., 1990) and the co-ordinates of the E.coli TS structure with bound phosphate 
respectively (Perry et al., 1990). All residues from the E.coli sequence that differed 
from the equivalent residue of the VZV sequence was substituted by the latter using the 
graphics programme INSIGHT (Dayringer et al., 1986). The substituted residues were 
positioned in a conformation which overlapped as much as possible with that of the 
residue existing in the E.coli structure. Where a VZV residue was larger than one it 
replaced, it was placed in a conformation which corresponds to the most frequent found 
for that amino acid in protein structures. The model lacks the first 19 amino acids from 
the VZV sequence, and the two short insertion sequences common to all eukaryotic 
thymidylate synthases (residues 105-116 and 134-141; VZV numbering), that are not 
found in the E.coli enzyme. At the time the model was generated, these regions of the 
human TS being studied by this group (Schiffer et al., 1991) were unresolved. The 
model of the VZV native TS was refined by 200 cycles of conjugate gradient 
minimisation with the refinement package of XPLOR. Due to difficulties in the initial 
stage of the energy minimisation, the a-carbon atoms were constrained to stay fixed, 
thus allowing only movement of side chains to remove any energetically unfavourable 
contacts.
Computer analysis of DNA and protein sequences were performed on the Micro 
Vax computer using the software package from the University of Wisconsin Genetics 
Computer Group (GCG Inc., Wis.). The models of the VZV TS native enzyme and the 
ternary complex (generated as above) were visualised and manipulated using INSIGHT
89
Chapter3: Methods
II (Biosym technologies) run on a Silicon Graphics and Indigo workstation and an Iris 
Workstation.
In collaboration with Adrian Lapthorne (Chemistry), Setor was used to introduce 
and evaluate point mutations in the VZV ternary model (Evans, 1993). In the absence of 
the crystal structure detailed modelling of the mutations was deemed inappropriate.
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Chapter 4. Protein-protein interactions of VZV TS
The results and discussion are divided into five chapters. The first chapter deals 
with the examination of protein-protein interactions of TS by affinity chromatography. 
The second chapter then carries on to develop an improved protocol for obtaining purified 
TS in a soluble form. Chapters 6 and 7 investigate the effect of mutations, initially on 
buried regions of the TS protein and then on the more solvent exposed C-terminus and 
DRTG loop region. The final chapter examines an arginine residue which has been found 
to discriminate between dCMP and dUMP binding in bacterial TS and other enzymes.
Protein-Protein interactions of VZV TS
TS is one of the most highly conserved enzymes known and its high degree of 
sequence conservation was initially thought to be due to constraints on enzyme structure 
and function. The enzyme, however, is extremely permissive in the amino acid 
substitutions that it tolerates, and many residues that are highly conserved and/or 
important for structure or function can be mutated without loss of enzyme activity. The 
observation that so many residues of the protein are not essential for enzyme function 
raises the question of why these residues are conserved. There are several possible 
explanations for this conservation paradox. Because no mutant has been reported that 
catalyses dTMP formation more efficiently than the wild type TS, conservation may 
simply result from optimisation of TS activity (Carreras & Santi, 1995). Alternatively, 
some residues may be conserved for reasons other than catalysis, such as mRNA binding 
(Chu et al., 1991,1993). The most likely explanation, however, for the high conservation 
is that TS interacts with other enzymes involved in DNA precursor biosynthesis and 
forms part of a multienzyme complex (Reddy et al., 1980). A similar situation exists for 
the histone proteins as they also show high sequence conservation. These proteins are 
assembled into an octamer around which DNA is wrapped to form a nucleosome core. It 
is thought that the high conservation of these proteins is to allow the proteins to interact 
with the DNA in the nucleosome and with each other (Luger et al., 1997).
Using protein affinity chromatography, Wheeler and colleagues (1992) have 
identified a multienzyme complex in bacteriophage T4. Purified deoxycytidylate 
hydroxymethylase from T4 was immobilised onto an affinity column and whole cell 
extracts were applied to the column. The column retained several proteins that were 
identified by SDS-PAGE as the products of specific T4 genes (Wheeler et al., 1992). 
These include several enzymes involved in DNA precursor biosynthesis, thymidylate 
synthase, dCMP deaminase, dihydrofolate reductase, dCTPase-dUTPase and 
ribonucleotide reductase. Two of the enzymes in the complex are functionally associated
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with one another as they catalyse sequential reactions; the dUMP that is produced by the 
enzymatic deamination of dCMP serves as the substrate for thymine nucleotide synthesis 
via the dTMP synthase reaction. McGaughey et al. (1996) have explored protein-protein 
interactions of the phage-coded forms of these two enzymes. An extract of radiolabelled 
T4 proteins was passed through a column of immobilised enzyme (either dTMP synthase 
or dCMP deaminase) and the specifically bound proteins were identified. In addition to 
binding strongly to each other several other proteins were identified which include 
dihydrofolate reductase and the single-stranded DNA-binding protein (McGaughey et al.,
1986). As protein affinity chromatography experiments on T4 phage TS have identified 
protein-protein interactions, a similar study was performed on immobilised VZV TS to 
identify interacting proteins. It was expected that several enzymes involved in dNTP 
biosynthesis might be identified.
4.1. Detection of proteins interacting with TS
Protein affinity chromatography was used to look for any specific interactions 
between TS and other proteins involved in dNTP synthesis. VZV TS was purified (refer 
to Chapter 3, 3.10) and covalently attached to an NHS-activated Sepharose Hi-Trap 
affinity column. Confluent 35S-methionine labelled MeWo cells were infected with VZV- 
infected cells and incubated for 2-3 days, cell extracts were then prepared. As a 
comparison 35S-methionine labelled mock infected cell extracts were also prepared. The 
extracts were then applied separately to the column and bound proteins were eluted using 
a linear salt gradient. Fractions obtained from the column were examined by scintillation 
counting and revealed that most of the radiolabelled proteins had come through the 
column in the buffer wash and only a small amount of radioactivity was present in the 
0.1-0.4M NaCl washes (Figure 4.1). The samples containing radioactivity were 
precipitated with BSA and examined by SDS-PAGE (refer to Chapter 3, 3.13). The 
autoradiographs in Figures 4.2 and 4.3 reveal that for VZV and mock infected cells no 
proteins appeared to bind to TS on the column and all of the proteins came through in the 
buffer wash. Autoradiographs were exposed for periods of up to three weeks but there 
were still no bands.
4.2. Coupling and activity of bound TS
There are several possible explanations for the absence of any detectable protein- 
protein interactions. Firstly it could be that TS had not coupled to the column efficiently. 
To test the efficiency of the coupling procedure, the concentration of TS protein in the 
load on and flow through were examined by the Bradford assay. TS protein loaded onto
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Figure 4.1. Radioactivity present in proteins eluted from HiTrap column.
3^ S labelled Mock infected and VZV infected cells were loaded onto a HiTrap affinity 
column which had TS covalently coupled to it. Proteins that were found bound to the 
column were eluted by a salt gradient and radioactivity in samples were analysed to 
give an indication of binding.
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0.1-1M NaCl
Figure 4.2. Autoradiograph of fractions eiuted from a Hi-Trap affinity column 
containing bound TS.
35S-methionine labelled mock infected cells were applied to an NHS-activated Hi-Trap 
affinity column containing covalently bound TS. Following elution from the column in an 
increasing salt gradient, fractions were precipitated with BSA and resolved by SDS- 
PAGE. Lane 1 shows a 10pl sample of the protein extract that was loaded onto the 
column and the proteins coming through the column in the buffer wash are shown in lane 
2. Apart from one protein band the subsequent lanes showed that no labelled proteins 
were eluted.
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Figure 4.3. Autoradiograph of fractions eluted from a Hi-trap affinity column 
containing bound TS.
X5S-methionine labelled VZV infected cells were applied to an NHS-activated Hi-Trap 
affinity column containing covalently bound TS. Following elution from the column in an 
increasing salt gradient, fractions were precipitated with BSA and resolved by SDS- 
PAGE. Lane 1 shows a 1 OjliI sample of the protein extract that was loaded onto the 
column and the proteins coming through the column in the buffer wash are shown in lane 
2. The subsequent lanes show that no labelled proteins were eluted.
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the column contained 1.2mg/ml of protein. Several buffer washes were performed on the 
column and the flow through was examined by eye using Bradford reagent which 
changed from brown to blue in the presence of protein. One fraction was blue in colour 
and this was assayed in the Bradford reaction. This sample contained 0.1 mg/ml protein 
indicating that 1.1 mg/ml of protein must be coupled to the column.
A second theory was that TS bound to the column was not present in an active 
conformation. To establish whether TS on the column was active, a tritium release assay 
was carried out. 3H-dUMP (700,000 cpm) and excess folate were added to the column, 
which was then incubated at 37°C for 30 minutes and a buffer wash and salt gradient 
were applied as before. The product from the tritium release assay, 3H20 ,  was expected to 
come through in the buffer wash but the salt gradient was added to reproduce the 
experimental procedure that had been used previously. Charcoal was added to the 
collected fractions to absorb any unreacted 3H-dUMP which was removed by 
centrifugation and the samples were subjected to scintillation counting. In the presence of 
charcoal approximately twice as much activity was present in a 200/d sample obtained 
from the buffer wash than when charcoal was absent. These results indicate that a 
significant amount of 3H-dUM P had reacted to form tritiated water (Figure 4.4).
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Figure 4.4. Activity of bound TS
700,000 cpm of 3H-dUMP and excess folate were added to TS which was covalently 
bound onto a HiTrap affinity column and incubated at 37°C for 30 minutes. The column 
was washed with buffer and fractions were eluted in 0.1-1M NaCl. 200/71 fractions from 
the column were measures for activity in the presence and absence of charcoal. The 
blue line indicates the amount of reacted dUMP in fractions whereas the red line shows 
the unreacted dUMP in fractions.
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Therefore, having established that TS was efficiently coupled to the column and it 
was present in the active conformation the experiments were then repeated. Several 
attempts were made to identify any proteins binding to TS. In addition to infecting the 
MeWo cells with VZV for varying durations of time (1-3 days), the infected cells were 
also loaded onto the column which was incubated at various temperatures (room 
temperature, 37°C). All attempts, however failed to demonstrate that any proteins were 
binding to TS.
4 .3 .D iscu ssion
These experiments have shown that no other VZV or cellular proteins could be 
detected specifically bound to the TS immobilised on the column. These results could be 
due to the experimental procedure used, it could be that there was a problem with the VZV 
infected cells or that the protein precipitation steps used were not effective. Alternatively 
the radiolabelled proteins could have formed a complex with 35S-labelled TS prior to 
being loaded onto the column and as a result there was no binding to the cold TS on the 
column. One way of overcoming this problem would be to load purified proteins, which 
are expected to bind to TS, onto the column one by one.
There are several other techniques available which allow protein interactions to be 
detected and it may be that one of these methods could be used to detect the interactions of 
VZV TS. Typically, co-immunoprecipitation experiments have been applied in which 
antibody to a known protein is used to precipitate associated proteins, at present there is 
no antibody against VZV TS available. More recently the yeast two hybrid system has 
been described, this is an in vivo method which identifies protein-protein interactions 
through reconstitution of the GAL4 yeast transcriptional activator protein (Fields & Song, 
1989). This protein is a transcriptional activator required for the expression of genes 
encoding enzymes of galactose utilisation. It consists of two domains: an N-terminal 
domain which binds to specific DNA sequences and a C-terminal domain which contains 
acidic regions which are necessary to activate transcription. This procedure involves the 
construction of two hybrid proteins containing parts of GAL4: the GAL4 DNA-binding 
domain fused to a protein "X" and a GAL4 activating domain fused to a protein "Y". If 
"X" and " Y" can form a protein-protein complex and reconstitute proximity of the GAL4 
domains then this can lead to transcriptional activation of a reporter gene containing a 
binding site for GAL4.
A second technique for examining protein-protein interactions is the BIAcore 
machine (Schuck, 1997). This monitors biomolecular interactions using non-invasive 
optical detection principle based on surface plasmon resonance (SPR). The reactant is 
covalently attached to the sensor surface and a mobile second reactant at a constant
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concentration is introduced into the buffer flow above the sensor surface, and the 
progress of complex formation at the sensor surface is monitored. This procedure is 
followed by a dissociation phase in which mobile reactant is absent from the buffer. The 
SPR response reflects a change in mass concentration at the detector surface as molecules 
bind or dissociate. No labelling of interacting components is required and the technology 
is applicable to a wide range of experimental situations. This technique could be applied to 
detect interactions in VZV TS. Biotinylated TS could be bound to an avidin-coated chip 
and fractions from nuclear extracts passed across. Samples showing a detectable 
interaction could be further fractionated. However this line of investigation was not 
pursued in order to concentrate on the mutagenesis studies described in the following 
chapters.
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C h a p t e r  5 .  P u r i f i c a t i o n  o f  T S  v a r i a n t s
Purification of TS proteins
In the following chapters several mutants have been produced by region directed 
mutagenesis. Further characterisation of these mutants requires large amounts of purified 
protein. This chapter deals with the problems that were encountered in the purification 
procedure.
5.1. M utant enzymes tested for solubility
In the purification experiments only three of the mutant enzymes were examined 
as it was thought that these would give an indication of what would happen in the others 
(Table 5.1). AZ42 and JB88 are temperature sensitive mutants. AZ42 contains three point 
mutations in buried regions of the protein and JB88 has a 14 amino acid deletion at the C- 
terminus. The third enzyme examined contains a point mutation at position 214 and is 
referred to as N214D. All mutations were introduced into the TS gene in the plasmid 
pAD768 backbone. Plasmid pAD768 (Harrison, 1992; see Chapter 3 section 3.1) is a 
pBS backbone vector containing VZV TS, this vector confers ampicillin resistance and 
contains the bacteriophage fl origin of replication to allow ssDNA isolation. TS is under 
the control of the tac promoter in this plasmid (Figure 5.1).
AZ42 and JB88 contain sufficient enzyme activity to complement Thy' bacteria 
and N214D had been found to be Thy (refer to Chapters 6, 7 & 8). Protein extracts from 
all three mutants had shown a significant amount of activity in the tritium release assay 
(Table 5.1).
Mutant Amino acid 
change
Secondary
structure
% Wild type activity 
of crude extract
AZ42 D206Y Loop 29.2
M207L Helix J
N214S Helix J
JB88 284-301 C-terminus 8.8
14 a.a.deletion
N214D N214D Helix J 0.06*
Table 5.1. Mutants examined for solubility.
This table summarises the mutants which were examined for solubility. The amino acid 
changes are given and the regions of mutation. The table also provides the activ ity 
found in protein extracts of each of the mutants relative to a wild type value of 100%.
* implies that N214D is a purified extract.
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5.2. Solubility of TS
To obtain large amounts of variant TS enzymes, the TS genes were subcloned 
from their original pAD768 backbone (using N col and EcoRI) into the pET-23d 
expression vector (Figure 5.1).
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Figure 5.1. Cloning of VZV TS into the pET 23d vector
The TS gene was EcoRI/Ncol digested from original pAD768 backbone and cloned into 
pET23d expression vector under the control of T7 promoter.
The plasmids were initially transformed into an NM522 Thy' host as these cells 
are highly transformable. Candidate clones were digested to ensure they had the correct 
restriction profile. Those containing the correct profile were retransformed into BL21 
(DE3) Thy' cells which contain a copy of the gene for T7 RNA polymerase and should 
induce expression from the T7 promoter after addition of IPTG. Again the clones 
produced were analysed by restriction digestion and those containing the correct profile
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were test-induced with IPTG. Clones that were induced produced a protein band of 
around 32KDa.
Initially large cultures of AZ42 were grown (4x700mls) at 30°C and protein 
expression induced from the T7 promoter by addition of IPTG for 2-3 hours. Samples 
from the induced and uninduced cultures were removed and analysed by SDS-PAGE. An 
intense band was seen in the induced samples at around 32K, the position at which 
purified TS is known to run. This band indicated that high levels of TS protein had been 
induced. Protein extracts were prepared from the induced culture by sonication and 
centrifugation and samples were removed from both the supernatant and pellet. 
Examination of the samples by SDS-PAGE revealed that a significant proportion of TS 
was present in the pellet in an insoluble form (not shown but refer to Figure 5.2). These 
are inclusion bodies which are often formed when the protein is overproduced resulting in 
the aggregation of partially folded proteins in the cytoplasm.
The initial procedure used to try to overcome the problem of protein insolubility 
was to change the growth temperature and induce the protein at lower temperatures as this 
had previously been found to overcome certain solubility problems (Lin et al., 1990). 
350ml cultures of the C-terminal mutant JB88 and the buried mutant AZ42 were grown at 
30°C and the samples split in two, one half of the sample was induced at 26°C for 4 
hours and the other half was induced overnight at 15°C. Protein extracts were prepared 
and fractions from both the supernatant and pellet were analysed by SDS-PAGE. Figure 
5.2 shows that both pellet and supernatant samples of the mutants can be seen at the 
various induction temperatures. From the gel it looks as though 15°C is better than 26°C 
for JB88 but in all cases the largest proportion of the TS protein was present in the 
insoluble pellet
A time course was then set up to establish if there was a certain point during 
induction that the protein started to form insoluble inclusion bodies. A 350ml culture of 
the buried mutant AZ42 was grown at 30°C and protein expression was induced. 
Following induction samples were removed at 30 minute intervals from between 1-3 
hours. Protein extracts were prepared and samples from the supernatant and the pellet 
were examined by SDS-PAGE. Figure 5.3 shows a Coomassie stained gel with pellet 
and supernatant fractions obtained after the varying intervals of induction. The results 
revealed that even after one hour most of the protein appeared to be present in the 
insoluble pellet.
A further possible method for the preparation of soluble protein is to express the 
target gene in a host strain containing a compatible plasmid that provides a small amount 
of T7 lysozyme, a natural inhibitor of T7 RNA polymerase (Moffatt & Studier, 1987; 
Studier, 1991). T7 lysozyme is a bifunctional protein: it cuts a specific bond in the 
peptidoglycan layer of the E.coli cell wall and it binds to T7 RNA polymerase, inhibiting
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Figure 5.2. Investigation of the induction temperature on the solubility of TS
A Coomassie stained SDS-polyacrylamide gel of protein extracts from the buried mutant 
AZ42 and the C-terminal mutant JB88. 350 ml cultures of the mutants were grown and 
TS expression was induced by the addition of IPTG for either 4 hours at 26°C or 
overnight at 15°C. Protein extracts were prepared and samples from the pellet (p) and 
supernatant (s/n) were analysed by SDS-PAGE. The position at which purified TS 
runs is denoted by an arrow. Protein size markers (M) are present on the right. Note that 
the 14 amino acid deletion causes the JB88 protein to run faster than the multiple point 
mutant AZ42.
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Figure 5.3. Time course of induction
A Coomassie stained SDS-polyacrylamide gel of protein extracts from the buried mutant 
AZ42. A 350ml culture of AZ42 was grown and TS expression was induced by IPTG. 
50ml samples were removed from the culture at 30 minute intervals, 1-3 hours post 
induction. Protein extracts were prepared and the pellet (p) and supernatant (s/n) 
fractions were analysed by SDS-PAGE for the presence of TS. The position at which 
purified TS runs is denoted by an arrow. Protein size markers are not present on the gel.
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transcription. The pET vectors containing the mutants were transformed into BL21 pLysS 
as this strain contains a plasmid that provides a small amount of T7 lysozyme.
The mutants AZ42, JB88 and N214D were grown at 30°C and protein extracts 
were prepared. Samples from the pellet and supernatant were examined by SDS-PAGE. 
Figure 5.4 reveals that TS is present in the insoluble pellet for the deletion mutant JB88 
and the buried mutant AZ42. An exception was found with the N214D point mutation 
which appeared to have the protein present in equal amounts in the pellet and supernatant 
indicating that this mutant produces more soluble TS when it is expressed in the BL21 
pLysS cells.
Therefore expression of the TS protein from the pET vector seemed to be 
producing large amounts of protein very quickly which was resulting in the formation of 
insoluble protein. Changing the variables such as growth temperature, induction time and 
host cell did not appear to affect the solubility of the mutant enzymes with the exception 
of N214D.
5.3. Recovery of insoluble protein from inclusion bodies
Occasionally it is possible to solubilise the inclusion body protein in strong 
denaturing solutions such as urea or guanidine-HCl and then refold by slowly diluting out 
the denaturant at low protein concentrations. As the inclusion bodies can be easily isolated 
by low speed centrifugation this procedure was carried out on the mutants AZ42, JB88 
and N214D. 350ml cultures of the mutants were grown up and the cells harvested by 
centrifugation. The cells were then lysed and the inclusion bodies were spun down 
(section 3.11.1). The inclusion bodies were solubilised in 8M urea, spun down and the 
jelly-like pellet was resuspended in urea containing buffer and spun down once again. At 
each stage the supernatants were retained and these were analysed by SDS-PAGE. Figure 
5.5 shows a gel containing samples from the pellet of the solubilised inclusion bodies and 
also fractions from the supernatants. The results reveal that a significant amount of the 
protein is still remaining in the pellet but now a larger amount is found in the 
supernatants. Having established that the protein was present in the supernatant the aim 
was to refold it to its native form by dialysis. The protein was dialysed, for 1 hour at a 
time, against 8M urea-containing buffer at room temperature, 4M urea-containing buffer 
at 4°C and 2M urea-containing buffer at 4°C. Finally the supernatants were dialysed 
overnight against buffer containing no urea. Following dialysis the protein appeared to 
have come out of solution and so the samples were spun down and the pellet and 
supernatant analysed by SDS-PAGE. Figure 5.6 demonstrates that all of the protein was 
found in the pellet and so the proteins must have aggregated during dialysis and once 
again formed insoluble structures.
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32KDa
Figure 5.4. Solubility of TS expressed in BL21 (DE3) pLysS
A Coomassie stained SDS-polyacrylam ide gel of protein extracts of the buried mutant 
AZ42, the C-terminal mutant JB88 and the point mutant N214D. 350ml cultures of the 
mutants were grown and TS expression was induced by the addition of IPTG for 2-3 
hours. Protein extracts were prepared and samples from the pellet (p) and supernatant 
(s/n) were analysed by SDS-PAGE. The position at which purified TS runs is denoted 
by an arrow. Protein size markers (M) are given on the right. The size difference 
between JB88 and the point mutants AZ42 and N214D is evident.
AZ42 JB88 N214D
94KDa
67KDa
43KDa
30KDa
20KDa
14KDa
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Figure 5.5. Solubilisation of inclusion bodies
A Coomassie stained SDS-polyacrylam ide gel showing solubilisation of inclusion 
bodies from the buried mutant AZ42, the C-terminal deletion mutant JB88 and the point 
mutant N214D. Inclusion bodies were dissolved in 8M urea, spun down and the 
supernatant collected. This process was repeated and the pellet (p) and supernatants 
from each step (s/n 1&2) were analysed by SDS-PAGE. The position at which purified 
TS runs is denoted by an arrow. Protein size markers (M) are given on the right.
32KDa
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Figure 5.6. Renaturation of TS
Coomassie stained SDS-polyacrylam ide gel of protein extracts from the buried mutant 
AZ42, the C-terminal deletion mutant JB88 and the point mutant N214D. Solubilised 
inclusion bodies were renatured by dialysing against decreasing concentrations of urea. 
Following overnight dialysis in phosphate buffer containing no urea, the sample w as 
spun down and protein extracts from the pellet (p) and supernatant (s/n) were prepared 
and analysed by SDS-PAGE. The position at which purified TS runs is denoted by an 
arrow. Protein size markers (M) are present on the right.
32KDa
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5.4. Purification of mutant proteins from pAD768 vector
One final variable that could be changed to allow for the production of soluble 
protein is the expression vector, as the use of strong promoters often results in the 
formation of inclusion bodies and the pET vector contains the strong T7 promoter. The 
use of weak promoters sometimes favours the production of lower amounts of protein in 
a more soluble form. Therefore the mutant genes were used in their original bluescript 
vector which contains the weaker tac promoter, to allow for the production of lower 
amounts of protein which could be more soluble.
A five litre culture of the deletion mutant JB88, in the original pAD768 backbone, 
was grown at 30°C. A protein extract was prepared and was loaded onto a 
hydroxyl apatite column. TS probably binds to hydroxyl apatite due to its phosphate 
'binding' pocket, which co-ordinates the phosphate of dUMP in the active site. This 
column is disposable and prevents the potential cross contamination of one mutant with 
another that can occur when columns are re-used.
Once the protein had been loaded onto the column it was washed with 60mls of 
50mM phosphate buffer to remove any unbound protein, followed by lOOmM phosphate 
buffer and the TS protein was eluted in 60mls of 300mM phosphate buffer. The 300mM 
wash was precipitated with ammonium sulphate and dialysed overnight against 1 litre of 
50mM phosphate buffer. Each step of the purification was monitored by protein mini-gel 
analysis of the appropriate collected fractions. The dialysate was then loaded onto an S- 
sepharose column and the column was washed in 50mM phosphate buffer. TS protein 
was eluted from the column with an increasing salt gradient and 1ml fractions were 
collected. A Bradford assay was carried out on the fractions obtained from the column to 
determine whether they contained protein and the fractions containing protein were 
analysed by SDS-PAGE. Figure 5.7 shows that a TS band was present at around 32K in 
fractions 13-18. The TS containing fractions were pooled together and stored at -70°C 
prior to use.
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Figure 5.7. Purification of JB88 from S-sepharose column
Coomassie stained gel of fractions collected from purification of JB88 by S-sepharose 
chromatography. The partially purified protein extract obtained from the hydroxylapatite 
column was bound to the S-sepharose column, the column was washed with 
phosphate buffer and the TS protein was eluted from the column with an increasing salt 
gradient. Lanes 12-20 are fractions eluted from the column which are found to contain TS 
protein. The position at which purified TS runs is denoted by an arrow. Protein markers 
(M) are present on the right.
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S-sepharose chromatography produced a protein that was partially pure. Two 
distinct contaminating bands can be seen in Figure 5.7 which migrated more slowly than 
the TS band. Analysis of the partially purified protein confirmed results that had 
previously been obtained from crude extracts. The enzyme showed TS activity in the 
tritium release assay, with the specific activity of the purified extract being 0 .10% of 
activity of the wild type enzyme (see Chapter 7). Although the TS activity of the mutant 
was low there was sufficient activity present to complement Thy' bacteria.
Several attempts have been made to purify other C-terminal and buried mutants of 
VZV TS in their original pAD768 backbones. Purified protein recovered from the column 
was found to be inactive in the tritium release assay which could be the result of a loss in 
activity during the purification procedure. A possible solution for cutting down the length 
of time involved in purification would be to purify the mutants using FPLC 
chromatography.
5.5. Discussion
Purification of wild type TS is achieved through high level expression in the pET 
vector followed by hydroxylapatite and S-sepharose chromatography. This procedure 
produced sufficient amounts of protein on which experimental work could be carried out. 
The same purification procedure, when applied to the TS variants, proved to be 
unsuccessful. Low amounts of protein were recovered from the chromatography steps 
and on examination of the extract which had been applied to the column it was found that 
a large quantity of the protein was present in the insoluble pellet as inclusion bodies. It 
may be that a large portion of the wild type enzyme is found in the insoluble pellet but 
sufficient remains soluble (J.Scott & R. Thompson, personal communication).
The conditions used in the purification procedure were varied and it appeared that 
the only means of purifying the C-terminal mutant JB88 was to express the TS gene in 
the original bluescript backbone and purify it from there. The 14 amino acid deletion may 
expose sufficient underlying hydrophobic amino acids to severely reduce the solubility of 
the protein. Problems were encountered when this procedure was applied to the other C- 
terminal mutants and the buried mutant AZ42. In contrast, the point mutant N214D was 
purified following expression in the pET-23d vector and induction from BL21(DE3) 
pLysS cells.
Many of the problems with the purification procedure still remain to be resolved 
however sufficient material was obtained for the kinetic and other characterisation 
described in the following chapters.
Single amino acid substitutions have been shown to have dramatic effects on the 
properties of other proteins. The mutation producing sickle cell anaemia results in an 
adenine to thymine substitution in the sixth codon of the (3-globin gene which reduces the
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solubility of haemoglobin causing increased destruction of red cells and sickle cell disease 
(Ingram, 1956). In this sense even single amino acid variants can be considered to be 
"new" proteins and the problems encountered in purifying the variant TSs while not 
predictable should not be too surprising.
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Chapter 6. Region directed mutagenesis of buried residues 
in VZV TS
Region directed random mutagenesis ofVZV TS
Mutagenesis studies of TS from L.casei and E.coli have shown that many of the 
highly conserved residues can be readily substituted without compromising enzyme 
activity (reviewed in Carreras & Santi, 1995). This means that conventional site-directed 
mutagenesis of residues selected on the basis of their conservation is of limited value. 
These studies have however identified at least four residues that are critically important for 
enzyme function, including the completely conserved cysteine residue that forms a 
covalent adduct with the substrate. The high degree of sequence conservation within the 
TS family makes these enzymes an ideal test bed for the development of species-specific 
inhibitors.
This section deals with the development of a technique to randomly mutagenise 
selected regions of the protein. Several different methods have been devised for the 
random mutagenesis of cloned genes, these include in vivo methods such as the use of 
mutator strains, in vitro enzyme dependent approaches and procedures that use chemicals 
to damage the DNA. Mutagenesis by these procedures can result in an uneven distribution 
of mutations because of the presence of mutagenic "hot spots" in the DNA. Therefore the 
spiked oligo approach was developed to introduce single amino acid changes scattered 
throughout the whole of a targeted region of the gene of interest (section 3.5.2). The 
oligonucleotides were synthesised by a protocol that gives a defined probability of 
incorporating one of three "wrong" nucleotide bases at each position along the 
oligonucleotide (Ner et al., 1988; McNeil & Smith, 1985). The strand selection procedure 
of Kiinkel for mutant enrichment was used for random mutagenesis with these spiked 
oligonucleotides (Kiinkel, 1985; Kiinkel et a l, 1987). This method uses a single stranded 
phage M l3 DNA (ssDNA) template that contains a number of uracil residues instead of 
thymine. The uracil-enriched ssDNA (U-ssDNA) is produced in an E.coli dut' ung' strain 
which lacks the enzymes dUTPase and uracil N-glycosylase. Lack of dUTPase activity 
leads to raised levels of dUTP and results in an increased incorporation of uracil into 
DNA instead of thymine. The absence of uracil N-glycosylase, which normally removes 
uracil from DNA, means that uracil is stably incorporated. The double stranded molecules 
produced from the mutagenesis have a parental strand which is uracil rich, whilst the 
newly synthesised mutant strand contains only thymine. When E.coli dut+ung+ are 
transformed with this DNA, there is a strong biological selection against the replication of 
the parental template strand which is degraded. This results in the production of 
predominantly mutant double stranded DNA molecules.
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The spiked oligo approach was used to generate a series of temperature sensitive 
mutants as these are an efficient way of identifying amino acid positions which are critical 
for the correct folding and activity of the protein. Temperature sensitive proteins will only 
be active at the permissive temperatures. Screening was facilitated by the ability of VZV 
TS to genetically complement Thy' bacteria, allowing screening for catalytically active 
VZV TS at three different temperatures, 31°C, 37°C and 42°C on solid minimal growth 
media which only permits the growth of Thy+.
6.1. Construction of buried region mutants
Fifteen spiked oligonucleotides (ROl-15) were synthesised spanning the entire TS 
gene and were then used as primers in the Kiinkel method of site-directed mutagenesis to 
introduce mutations into the cloned VZV TS gene (Figure 6.1). Initially spiked oligos 
were used that were targetted to buried regions of the protein structure, since it was 
anticipated that residues involved in stability would be found there.
Following mutagenesis the plasmids were transformed into NM522 cells which 
had a point mutation in their TS gene, rendering the cells Thy*. Colonies obtained from 
the transformation were screened for temperature sensitivity (Table 6.1). Temperature 
sensitive mutants are capable of complementing Thy' bacteria on M9 plates at 30°C but not 
at 37°C or 42°C. At 30°C these mutants are able to form the closed conformation of the 
enzyme and perform the complete reaction whereas at higher temperatures the enzyme is 
inactive. Table 6.2 provides a summary of the temperature sensitive mutants which had 
previously been produced in the laboratory (J. Scott, personal communication).
Random oligo Colonies
screened
Temperature
sensitive
Mutant name
R 09 73 12 AZ18-22, 41-47
RO10 100 10 AZ24-27, 48-53
R011 100 13 AZ28-36, 54-57
R015 70 14 AZ23, 58-70
RQ16 100 10 AZ37-40, 71-76
Table 6.1. Mutations created in the buried region of TS
The table summarises the colonies screened for mutations and the number of 
temperature sensitive mutants obtained.
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GAGCGGCGATTTCTATATGTGTATACCCTATATATGCCTAGCTCGTTTAAAGATTTATCC 
R04 ( 5 7m er ) , , , , , , , , ,  I I M i l  I I " * '  R014 (5 7 m e r)
|  H E L IX  G — |
N G F B K R H T G D L G P I Y G F Q W R  
AATGGCTTCCATAAAAGACACACGGGGGACCTTGGCCCCATTTACGGCTTCCAGTGGAGA 
TTACCGAAGGTATTTTCTGTGTGCCCCCTGGAACCGGGGTAAATGCCGAAGGTCACCTCT 
..........................., , , , R015 ( 5 7 m e r ) , , , , , , , , , , , , , ,
H E L IX  H
N E S
R 0 1 6  ( 5 4 m e r )  '
| SH EET v
M S
CTGCAAACTGTTATAGATACAATTAAAACAAACCCAGAAAGCCGACGAATGATTATATCG
GACGTTTGACAATATCTATGTTAATTTTGTTTGGGTCTTTCGGCTGCTTACTAATATAGC
............................................................  , , , , , , ,  R 0 5  ( 4 8 m e r ) , , , , ,
« « « « « « « <  ( 6 1 )
|  H E L IX  I  1 | * * * * * *  SH EET i v  A
S W H P K D  I  P  L M V L P P  *C* H T L C Q 
TCTTGGAATCCAAAGGATATCCCCTTAATGGTACTACCTCCATGTCACACGTTATGTCAG 
AG AAC C T TAGG T T TC C TA T AGGGG AA TTAC C A TG A TGG AGG T AC AG TG TGC AA T AC AG TC 
RQ6 (4 8m e r)  . , , , R0 7 ( 4  5 m er)
SH EET i i i I — -
TTTTACGTTGCAAACGGTGAATTATCCTGCCAAGTATACCAGAGATCGGGGGATATGGGC
AAAATGCAACGTTTGCCACTTAATAGGACGGTTCATATGGTCTCTAGCCCCCTATACCCG
, , , , , , , , , ,  I RQ8 (4  8 m e r )
L G V P F  H I A G Y A L L T Y  I V A H V  
CTTGGGGTACCGTTCAACATTGCTGGATATGCACTTCTTACCTACATAGTAGCGCATGTT 
GAACCCCATGGCAAGTTGTAACGACCTATACGTGAAGAATGGATGTATCATCGCGTACAA 
, , , , , , ,  R 0 9  ( 5 4 m e r ) , RO 10
SH EET
ACAGGACTTAAAACCGGAGATTTAATTCATACAATGGGGGATGCACATATTTACTTGAAT 
TGTCCTGAATTTTGGCCTCTAAATTAAGTATGTTACCCCCTACGTGTATAAATGAACTTA 
( 5 4 m e r )  R O l l  ( 5 4 m e r )
( 6 0 )« « « « « « « <
|  H E L IX  K  1
CATATAGATGCTTTAAAAGTGCAGCTAGCTCGATCCCCAAAACCTTTTCCTTGCCTTAAA
GTATATCTACGAAATTTTCACGTCGATCGAGCTAGGGGTTTTGGAAAAGGAACGGAATTT
, , ,| [|M I I.................................  R O l7  ( 5 4 m e r  )  MINI
ATTATTCGAAATGTAACAGATATAAACGACTTTAAATGGGACGATTTTCAGCTTGATGGA
TAATAAGCTTTACATTGTCTATATTTGCTGAAATTTACCCTGCTAAAAGTCGAACTACCT
, , , , , , , , , , , ,  R 0 1 8  ( 5 7  m e r )  , , , ,  # , , , , ,  | | | | | |  .....................
N H M M
TATAATCCACACCCCCCCCTAAAAATGGAAATGGCTCTTTAATGGATTTTTAAATGTTGT 
ATATTAGGTGTGGGGGGGGATTTTTACCTTTACCGAGAAATTACCTAAAAATTTACAACA 
R O l9 ( 5  7 m e r )
, , , , , , , , ,  R O 20 ( 5 l i n e r  ) , , , , , , , , , , , , ,
CAAGACAGTAGATGTGTTGCGAATGTAATAAAATGATATACACAGACGCGTTTGGTTGGT 
GTTCTGTCATCTACACAACGCTTACATTATTTTACTATATGTGTCTGCGCAAACCAACCA 
« « « « « « « <  ( 5 9 )
1 0 8
1 3 0 0
1 3 0 0
1 2 8
1 3 6 0
1 3 6 0
1 4 8
1 4 2 0
1 4 2 0
1 6 8
1 4 8 0
1 4 8 0
1 8 8
1 5 4 0
1 5 4 0
2 0 8
1 6 0 0
1 6 0 0
2 2 8
1 6 6 0
1 6 6 0
2 4 8
1 7 2 0
1 7 2 0
2 6 8
1 7 8 0
1 7 8 0
2 8 8
1 8 4 0
1 8 4 0
3 0 8
1 9 0 0
1 9 0 0
Figure 6.1. Spiked oligonucleotides covering the VZV TS gene
Oligonucleotides used for region directed mutagenesis are indicated in red. Primers used 
in sequencing are given in blue. The active site cysteine is shown as *C*.
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A total of 59 temperature sensitive clones were produced from the random 
mutagenesis and base changes were identified by sequencing with primers spanning the 
various regions of the gene (J. Scott, personal communication). 12 of the potential 
mutants had an unreadable sequence. 47 of the mutants contained a readable sequence, of 
these 35 had point mutations and 4 had deletions. The spiked oligonucleotide approach 
should have generated between one and three base changes and from Table 6.2 it can be 
seen that for the enzymes with point mutations, the most common number of changes is 
two, which is the expected number.
1 base 2 base 3 base 4 base 5 base
change changes changes changes changes
5 19 9 2 0
Table 6.2. Sequenced tem perature sensitive mutants from buried regions of TS
The table summarises the number of base changes present in the various temperature 
sensitive mutants.
6.2. Mutants from buried regions
Eight of the mutants, which had been previously isolated were double checked for 
temperature sensitivity before they were characterised further. Colonies were again 
examined for their ability to complement Thy' cells at 3 1°C, 37°C and 42°C. All mutants 
showed growth on M9 plates at 30°C but no growth at 37°C and 42°C .
Table 6.3 provides a summary of the random oligonucleotides used in the region 
directed mutagenesis procedure and the base changes in these mutants. The results show 
that base changes were found in various buried regions of the secondary structure. AZ41 
contains a silent mutation (G210G) which produced a temperature sensitive phenotype, 
this suggests that a mutation is present in the TS gene outwith the region targetted by 
spiked oligo R09. Figure 6.2 shows the positions in the enzyme structure where these 
mutations are found.
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Mutant Random oligo Amino Acids Amino acid 
change
Secondary
structure
AZ28 R011 234-251 Y 246 N p-strand ii
AZ29 R011 234-251 L 236 I p-strand ii
AZ41 R 09 205-222 G 210 G Helix J
AZ42 R 09 205-222 D 206 Y Loop
M 207 L Helix J
N 214 S Helix J
AZ47 R 09 205-222 G 210 V Helix J
AZ65 R015 114-132 F 125 I Helix G
G 124 Y Helix G
AZ66 R015 114-132 Y 123 I Helix G
AZ69 R015 114-132 G 124 C Helix G
Table 6.3. Buried region mutants of VZV TS.
The buried mutants were constructed using region-directed mutagenesis with randomly 
spiked oligonucleotides. Eight of the buried mutants from the 76 produced are given in 
the table. These mutants contain between one and three base changes.
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Figure 6.2. Thymidylate synthase monomer
This is a model of the monomer of VZV TS which shows the positions of the buried 
mutants. In green are (3-strands, a-helices are red, turns are ye llow  and the ligands are 
grey. The amino acid residues in the mutants are shown in blue space-filling. G124 and 
G210 are not shown.
AZ28 contains the mutation Y246N in p-strand ii, this is a completely conserved 
tyrosine and is one of the four residues that are thought to be critical for enzyme activity 
(refer to Figure 1.13 and pull-out). A G210V mutation is found in AZ47 which is the 
mobile region of helix J, this is the core helix around which other structural elements fold. 
It packs diagonally across the (3-sheet and is flanked by several other helices. AZ42 
contains three base changes, Asp206 is a completely conserved residue and Met207 
shows high conservation. Asp206 is in the turn between strand iii and the J helix which 
begins with Met207. The point mutation of most interest in AZ42 is N214S (refer to 
Figure 1.13). This asparagine residue is fully conserved and is found in helix J of the 
protein, it is the only residue that makes direct contact between a protein side chain and
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the dUMP pyrimidine ring. Studies on Lcasei have revealed that N229D (N214 in VZV) 
mutations decrease the enzymes ability to discriminate between dUMP and dCMP (Liu & 
Santi, 1992). This topic will be explored further in Chapter 8 . AZ65, 66 and 69 contain 
mutations in helix G, this helix forms part of the hydrophobic protein core (refer to Figure 
1.13).
The mutants AZ28, AZ42 and AZ47 were chosen for further examination as these 
enzymes contain mutations in highly conserved residues (see Figure 1.13 and pull-out). 
Having established that the mutants were active in the in vivo complementation assay, the 
mutants were examined in vitro by the tritium release assay which measures the release of 
tritiated water from 2'-deoxy[5'3H]uridylate. This assay is performed under conditions of 
linear kinetics as less than 30% of the 3HdUMP put into the reaction produces soluble 
counts and it is optimised for the wild type enzyme. The assay is highly sensitive 
detecting as little as 10'8 U/mg TS activity.
Crude protein extracts of the mutants and wild type VZV TS were prepared and 
assayed at 30°C. The results from the assays are given in Table 6.4 and reveal that AZ47 
(G210V) retained 45.8% activity, demonstrating that glycine is important though not 
essential for catalytic activity. The triple mutant AZ42 (D206Y, M207L, N214S), which 
contains the important N214S mutation retains significant activity (29.2%). Mutation of 
the completely conserved tyrosine 246 to asparagine in AZ28 results in a modest 2-fold 
reduction in activity.
Enzyme Tritium release 
pmol dTMP/min/iLigprotein
% Wild type
Wild type 0.024 100
AZ28 0.012 50
AZ42 0.007 29.2
AZ47 0.011 45.8
Table 6.4. TS assays
TS activity of crude extracts from the buried region and wild type TS enzymes 
measured by the tritium release assay at 30°C. All enzymes were expressed in E.coli 
NM522 Thy.
118
Chapter 6. Region directed mutagenesis o f buried residues in VZV TS
Having established that the buried mutants were temperature sensitive in vivo the 
mutants were then examined in vitro. Crude protein extracts of the mutants were held at 
42°C, 5/d aliquots removed at 5 minute intervals and assayed in the tritium release assay 
at 30°C. Comparison of the temperature profiles of both mutant and wild type enzymes 
are given in Figure 6.3. When held at 42°C the mutant extracts show a rapid decrease in 
TS activity. In contrast the wild type extract only produces a decrease to 86% activity 
revealing that the enzyme is not intrinsically temperature sensitive.
'A
 □ -----  AZ 28
 O  AZ42
 O   AZ47
 A   WT
O
o
Time at 42°C (mins)
Figure 6.3. Temperature profiles of buried region mutants
Crude protein extracts of the buried mutants were incubated at 42°C and at 5 minute 
intervals samples were removed and assayed at 30°C in the tritium release assay. The 
graph show s the decrease in activity of the mutants corresponding to the length of time 
incubated at 42°C.
6 .3 . Phenolphthalein  inh ib ition  o f bu ried  TS m utants
To further characterise this set of mutants phenolphthalein was examined in the 
tritium release assay. This compound had been identified as an inhibitor of TS by the 
DOCK computer programme, the programme identifies compounds that fit into the active 
site of enzymes and so inhibit their reactions (Schoichet et al., 1993). Phenolphthalein has
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concentrations of approximately 200pM  (J.Scott & R.Thompson, personal
communication).
Crude extracts of the wild type enzyme and the three buried mutants have been 
examined for phenolphthalein inhibition in the tritium release assay at 50, 100 and 500pM  
concentrations of inhibitor (Figure 6.4).
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Phenolphthalein concentration (pM)
Figure 6.4 Phenolphthalein inhibition
Crude extracts of buried mutants and wild type TS were assayed for phenolphthalein 
inhibition in the tritium release assay at30°C. Phenolphthalein was examined at 50, 100 
and 500pM concentrations and was added to the reaction prior to the enzyme. The 
graph shows the activity present in the mutants relative to no inhibitor.
The results indicate that at concentrations of 50pM the wild type enzyme retains 
90% activity whereas the mutant enzymes possess around 50-60% activity. 
Phenolphthalein concentrations of lOOpM result in the wild type extract being inhibited to 
71% of its initial activity while the buried mutants AZ28, AZ42 and AZ47 have been 
inhibited to 29.6% , 28.8% and 51.4% activity respectively. Concentrations of 500pM - 
lOmM result in the enzyme becoming almost totally inactive. These results suggest that 
the mutant enzymes are more sensitive to phenolphthalein than the wild type.
WT 
□  AZ28
M  AZ42
Az47
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6.4. dCMP inhibition of AZ42
As AZ42 contained the N214S mutation, this enzyme was examined for dCMP 
inhibition. Ordinarily dCMP is a poor competitive inhibitor of TS and binds to the wild 
type enzyme with a 1000 fold lower affinity than the substrate dUMP. Replacement of 
Asn 229 in L.casei TS with aspartic acid resulted in the enzyme losing TS activity 
toward dUMP and becoming a dCMP methylase (Liu & Santi, 1993). Addition of 
dCMP to the tritium release assay of such a mutant results in the competitive inhibition of 
the enzyme. AZ42 does not contain an asparagine to aspartic acid mutation but an 
asparagine to serine mutation. The N214S mutation in Lcasei has been found to have 
modest TS activity but dCMP inhibition of this mutation has not been examined. 
Therefore AZ42 was examined for inhibition by adding 50jnM-10mM concentrations of 
dCMP to the tritium release assay. The activity of the mutant was found to be unaltered 
by the presence of the dCMP which indicates that an asparagine to serine mutation does 
not affect the enzyme’s dicrimination of dCMP and dUMP whereas a corresponding 
asparagine to aspartic acid mutation does (see results Chapter 8 .).
6.5. Discussion
The initial region directed mutagenesis studies to produce temperature sensitive 
mutants focused on buried regions of the TS protein as it was expected that residues 
involved in protein stability would be found there. From the results it can be seen that this 
idea proved to be correct as a number of mutants were produced in these buried regions 
which contained between one and three base changes. Although this approach proved to 
be successful, it had the drawback that many of the clones produced appeared to be 
temperature sensitive but upon restriction digestion they did not produce the correct 
restriction pattern. In addition some of the clones which did produce the correct restriction 
pattern had a wild type sequence within the region of the spiked oligonucleotide. Despite 
this, the method proved to remarkably efficient at generating temperature sensitive 
mutants (46 of the 443 colonies screened were temperature sensitive mutants). The 
mutants selected for further characterisation had all been fully sequenced across the TS 
region to confirm the absence of additional mutations.
Molecular modelling was performed on the mutants to determine the effects of the 
amino acid substitutions on enzyme structure (see section 3.14). The substitutions have 
been illustrated with the mutant residues superimposed on the original residues.
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Figure 6.5. Temperature sen sitive  mutant AZ28 showing the point mutation 
Y246N
The mutant residue can be seen in yellow superimposed on the original tyrosine residue. 
Additional residues labelled in green are those in close proximity to the mutated residue. 
In cyan is a H-bond that is formed between the original tyrosine residue and the 
substrate dUMP.
AZ28 has the Y246N substitution. Tyr246 is a completely conserved residue and 
is present in p-strand ii of TS. It is located in a buried pocket surrounded by Thr39, 
His244 and Asp206. The hydroxyl group of tyrosine makes a hydrogen bond with an 
oxygen of dUMP with a bond length of 2.35A. It was thought that if Tyr246 was mutated 
it would lead to the disruption of the hydrogen bond and affect enzyme activity. This 
mutant retains sufficient activity to complement NM522 Thy' bacteria at 30°C. The
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mutation in L.casei TS, Y261N, does not result in complementation of the bacteria, 
however if the tyrosine residue is mutated to a methionine then the enzyme is capable of 
complementing Thy bacteria (Climie et al., 1990).
CU3717
Y206D
1201VI
Figure 6.6. Temperature sen sitive mutant AZ42 showing the point mutations 
D206Y, M207L and N214S
Panel A shows D206Y and M207L and panel B shows N214S. The mutant residues can 
be seen in yellow superimposed on the original residue. Additional residues labelled in 
green are those in close proximity to the mutated residue. In cyan are H-bonds that are 
formed between D206 and CB3717 and N214 and dUMP.
Three point mutations are present in AZ42; D206Y, M207L and N214S. Asp206 
is a fully conserved residue of TS which has been shown to be mutated to a tyrosine 
residue. This residue makes a H-bond to N3 of CB3717 and substitution of this residue 
to a tyrosine would result in the loss of this hydrogen bond. It is thought, however that 
the enzyme could tolerate this change if the histidine residue at 249 moves to 
accommodate the tyrosine. A similar situation was found in L.casei, as the side chain of 
the corresponding residue (D221) forms a hydrogen-bond network with N-3 of folate. 
Substitutions at this position in L.casei, however generally give enzymes that do not 
complement Thy E.coli (D. Santi, unpublished reviewed in Carreras & Santi, 1995). The 
analogous residue in E.coli Asp 169, could not be restored to Thy+ by any of the 
substitutions made (Michaels et al., 1990).
The second mutation produced in AZ42 was in Met207 which is highly conserved 
in all but one of the eukaryote enzymes and in the bacterial enzymes it is one of several 
conserved hydrophobic residues (Figure 1.13 and pull-out). It is present in helix J of the
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enzyme in a fairly hydrophobic pocket surrounded by Ile245, Ala252 and Leu253. No 
mutations have been produced in Lcasei or E.coli which correspond to M207L.
The third mutation present in AZ42 is in the fully conserved Asn214, this residue 
is found in the highly conserved hydrophobic J-helix which forms the core ofTS. It is the 
only residue that makes direct contact between a protein side chain and the dUMP 
pyrimidine ring. Hydrogen bonds are formed from Asn214 to N3 and 04  of dUMP, the 
oxygen of Asn214 forms a hydrogen bond to N3 dUMP with a bond length of 2.86A and 
the nitrogen forms a hydrogen bond with a length of 3.01 A. Substitution of this residue 
for a serine would result in the loss of the hydrogen bonds. This disruption in enzyme 
structure produces the temperature sensitive phenotype. In Lcasei it had been noted that 
N229 (N214 in VZV) mutations decrease the enzyme’s ability to discriminate between 
dUMP and dCMP. The N214S mutation was not affected when dCMP was added to the 
assay indicating that the mutant resulted in the enzyme still retaining TS specificity for 
dUMP. It was capable of complementing Thy' E.coli and participating in the tritium 
release assay. In Chapter 8 an N214D mutation was constructed in VZV TS and this 
resulted in an increase in sensitivity to dCMP competition for the dUMP binding site 
although dCMP methylase activity was not directly demonstrated.
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dUMP
V210G
Figure 6.7. Temperature sen sitive mutant AZ47 showing the point mutation 
G210V
The mutant valine residue can be seen in yellow  superimposed on the original glycine 
residue. Additional residues labelled in green are those in close proximity to the mutated 
residue. In cyan is a H-bond that is formed between asparagine 214 and the substrate 
dUMP.
AZ47 has the point mutation G210V. Gly210 is fully conserved in all organisms 
apart from L.lactis and is found in helix J (refer to Figure 1.13 and pull-out). Substitution 
of glycine for a valine resulted in the residue being in Van der Waals contact with dUMP. 
G210V was capable of complementing T h y E.coli at 30°C and had 42.8% activity in the 
tritium release assay. No comparison could be made with L.casei or E.coli as this 
mutation had not been produced.
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Further examination of the mutants for phenolphthalein inhibition has revealed that 
all of them appear to be more sensitive to the inhibitor than the wild type enzyme. This 
suggests that the active site of these enzymes is in a more open conformation than that of 
the wild type and as a result is more accessible to phenolphthalein.
126
Chapter 7. Mutagenesis o f highly mobile regions o f VZV TS
Chapter 7. Mutagenesis of highly mobile regions of VZV TS
Studies on the highly mobile regions of VZV TS
This section of the results involves examining the effects of mutations on highly 
mobile regions of the enzyme. Two areas were targeted; the C-terminal tail and the DRTG 
loop as these are the regions which show most movement upon ligand binding.
The initial studies were focused on the highly exposed DRTG surface loop region 
which lies between helix A and p-strand i. This region contains four residues; Asp37, 
Arg38, Thr39 and Gly40 which were thought to be critical for enzyme function (Carreras 
& Santi, 1995). These residues are conserved in 30 of the 35 TS sequences (Figure 1.13). 
Crystal structures from E.coli and Lcasei have shown that Arg23 (R38 in VZV) is one of 
four residues that is responsible for the co-ordination of the phosphate of dUMP in the 
active site. In Lcasei is was noted that upon substrate binding Arg23 (R38 in VZV) 
moves to interact with the phosphate moiety of dUMP, this action may be in preparation 
for the conformational change where Arg23 forms a salt bridge with the C-terminal 
carboxylate following folate binding (Climie et al., 1990). In E.coli three of these loop 
residues, Asp20 (Asp37 in VZV), Arg21 (Arg38 in VZV) and Thr23 (Thr39 in VZV) 
have limited tolerance to substitution (Michaels et al., 1990; Kim et al., 1992). At Asp20, 
Cys and Ser substitutions were tolerated. Asp20 could also tolerate substitution with Glu, 
a larger but electrochemically similar residue. In vitro biochemical assays of the Cys and 
Ser mutations show that the specific activity of the mutants is reduced by approximately 
20 fold which indicates that Asp20 plays a critical role. Arg21, however could not tolerate 
substitution by any other residue. The long positively charged side chain of Arg21 
reaches into the base of the substrate binding pocket to stabilise the negatively charged 
phosphate moiety of the substrate. The structurally similar lysine residue could not 
substitute for arginine at this position which is due to the fact that the terminal nitrogen 
groups of Arg21 also make H-bonds with the carboxyl oxygens of Ile264 at the C- 
terminus of the protein, as well as indirect H-bonds with the folate cofactor via a water 
molecule. This interaction with Ile264 is important for stabilising the conformational 
changes associated with formation of the ternary complex. The interaction is possible only 
by the presence of multiple nitrogens in the Arg residue. This inability of the Arg21 
mutants to complement Thy' bacteria is best explained by their poor binding to substrate 
which reduces K^/K^ below essential levels needed for cell growth. The large increase in 
folate value likely results from the inability of the mutant to form the salt bridge with 
the C-terminal carboxylate and effectively close the active site.
127
Chapter 7. Mutagenesis o f highly mobile regions o f VZV TS
7.1. Construction of DRTG loop region mutants
Mutagenesis of the DRTG loop region was performed using two randomly spiked 
oligonucleotides, ROl covering amino acids 37-55 and R013 covering 20-39 (see Figure 
6.1). Following mutagenesis the DNA was transformed into NM522 Thy" bacterial cells 
and colonies were screened for temperature sensitivity. The plasmids were recovered 
from the candidate temperature sensitive mutants and EcoRl digested to ascertain whether 
they contained the correct restriction profile. Having established that colonies contained 
the correct size of TS gene insert, the base changes were identified by sequencing. Table 
7.1 summarises the efficiency of the mutagenesis procedure.
Spiked oligo Colonies Temperature Restriction R eadable
screened sensitive profile point
colonies m utations
R 013 403 53 20 7
ROl 214 34 6 1
Table 7.1. Efficiency of m utagenesis of the DRTG loop region
The table shows the spiked oligonucleotides that were used in the mutagenesis and the 
results from screening and sequencing.
From Table 7.1 it was noted that a high proportion of the potential mutants 
screened did not produce the correct restriction profile upon enzyme digestion. EcoRI 
digestion of potential mutants should result in the TS gene being cleaved from the plasmid 
backbone to produce two distinct bands on an agarose gel, one band is the plasmid 
backbone and the other is the TS gene. The agarose gel in Figure 7.1 provides a typical 
example of temperature sensitive colonies that had been screened by EcoRI digestion. The 
first two lanes on the gel are control lanes indicating the bands that should appear with 
uncut and cut plasmid containing the wild type TS gene. Lanes numbered 1-7 contain the 
potential mutants. Many single bands appeared on the gel which could indicate that one of 
the EcoRI restriction sites has been affected by the filling in reaction of the mutagenesis 
procedure. Lane 6 provides an example of the correct digestion pattern for a potential TS 
mutant.
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Figure 7.1. Agarose gel showing restriction profiles of potential TS mutants
A 1% agarose gel of an EcoRI digest of DNA obtained from potential TS mutants. The 
first two lanes are controls with uncut and cut pAD768 plasmid containing the wild type  
TS gene. Lanes numbered 1-7 contain the potential TS mutant. Lane 6 demonstrates a 
mutant with the correct restriction profile.
Sequencing of the mutants that contained the correct restriction profile has shown 
that only eight contained a TS sequence with a mutation. The remainder, either had an 
unreadable sequence or a wild type sequence. The enzymes with the wild type sequence 
however, had been shown to be temperature sensitive. It appears, therefore that such 
mutants may contain two copies of the TS gene, one with the wild type sequence and one 
with a mutation. A dominance effect can occur in such cases which results in the mutant 
gene producing a temperature sensitive phenotype over that of wild type. When 
sequenced both wild type and mutant DNA primes and the sequence can look like that of 
wild type but weaker bands can also be seen which correspond to the mutant sequence.
7.1.1. C haracterisation of DRTG loop m utants
Following the mutagenesis procedure eight candidate clones were identified in 
vivo and were then further characterised by examining their catalytic activity in vitro. The 
in vivo assay involved the genetic complementation of NM522 cells which have a 
mutation in their TS gene. This was performed by patching colonies of the mutants onto 
M9 and M9T plates at 30°C, 37°C and 42°C. All eight mutants appeared to be temperature
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sensitive as they could complement the bacterial cells on M9 plates at 30°C but not at 37°C 
or 42°C (Table 7.2).
Enzyme
31 °C
M9 plates 
37°C 42°C 31 °C
M9T plates 
37°C 42°C
JB 28 + - - + +/-- +/-
JB 29 +/- - - +/- - +/-
JB 33 +/- - - + +/- +/-
JB 35 + - - + +/-- +/—
JB 36 +/- - - +/» +/-- +/--
JB 38 + - - + + +
JB 47 + - - + + +/—
JB 15a + - - + + +/-
Table 7.2. Phenotypes of DRTG loop mutants
Mutants obtained from region directed mutagenesis were screened for temperature 
sensitivity by patching on minimal media plates with and without thymidine at three 
temperatures. Growth was scored as + for growth, +/- partial growth, +/-- little growth 
and +/--- very little growth.
Several of the mutants also showed very weak growth on M9T plates. As the 
NM522 Thy' cells used in the genetic complementation assay contain a point mutation and 
not a deletion in their TS gene they can still produce E.coli TS subunits. When a mutant 
enzyme with a defective VZV TS gene is transformed into the cells then growth of the 
bacterial strain can slow down as the TS subunits are interacting. This may be why poor 
growth was seen on M9T plates at varying temperatures. The lack of growth for JB29 on 
M9T plates could be due to inadequate transfer of cells.
Sequencing of the eight temperature sensitive DRTG loop region mutants revealed 
that all contained between one and three base changes (Table 7.3). JB28, JB29, JB36 and 
JB15a are the only mutants which contain point mutations in the DRTG loop residues 
themselves, the remainder contain mutations in helix A, strand-i and the G loop. In the 
mutagenesis procedure Tyr31 has been hit four times, Arg34 twice, Asp27 three times 
and D37 twice. Ochre stop codons (TAA) were found in JB33, JB35, JB36 and JB38.
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NM522 cells contain an ochre suppressor which results in the insertion of a tyrosine at the 
position of the stop codon.
The method of mutant isolation was such that sibling mutants could be found and 
it is likely that JB 13a, JB15a and JB21a, all of which contained the same mutation within 
the same background could be siblings. Only JB15a was further characterised.
Random oligo Mutant Amino acid 
substitution
Secondary structure
R 013 JB 28 Y 21 S Helix A
Y 31 N Helix A
R 34 P Strand -i
R013 JB 29 R 34 L Strand -i
K 35 E Strand-i
D 37 A DRTG loop
R 013 JB 33 L 29 F Helix A
R 30 M Helix A
Y 31 Oc Helix A
R 013 JB35 L 22 V Helix A
D 27 E Helix A
Y 31 Oc Helix A
R 013 JB 36 L 22 Oc Helix A
D 27 G Helix A
D 37 N DRTG loop
ROI JB 38 D 27 E Helix A
Y 31 Oc Helix A
R 013 JB 47 G 32 E G loop
R 013 JB 13a R 38 Q DRTG loop
JB 15a
JB 21a
Table 7.3. DRTG loop region mutants
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Figure 7.2. Thymidylate synthase monomer
This is a model of the monomer of VZV TS which show s the positions of the DRTG loop 
region mutants. In green are p-strands, ex-helices are red, turns are yellow  and the 
ligands are grey. The amino acid residues in the mutants are shown in blue space-filling. 
G32 is not shown.
The activity present in the mutants was quantified in vitro by the tritium release 
assay, crude protein extracts were prepared and the assay was performed at 30°C. The 
results reveal that a significant amount of TS activity was found in all of the mutants with 
a 2-3 fold reduction from wild type activity (Table 7.4). Previous studies on DRTG loop 
residues in E.coli and L.casei had indicated that three of the DRTG loop residues tolerated 
certain substitutions which resulted in up to 20-fold reduction in activity. Asp20 from 
E.coli (Asp37 in VZV) could be substituted to cysteine, serine or glutamic acid. Thr22 
from E.coli (Thr39 in VZV) could tolerate substitutions to proline, serine, tyrosine,
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glutamine and lysine. Gly23 from E.coli (G40 in VZV) could be substituted to any other 
amino acid. In E.coli the fourth DRTG loop residue, Arg21 (R38 in VZV) could not 
withstand any kind of substitution (Michaels et al., 1990; Kim et al., 1992). Crucially, 
however these studies had been performed at 37°C.
Enzyme Tritium release 
pmol dTMP/min/ug 
protein
% Wild Type
Wild type 0.0240 100
JB 28 0.0080 33.3
JB 29 0.0110 45.8
JB 33 0.0150 62.5
JB 35 0.0087 36.3
JB 36 0.0093 38.8
JB 38 0.0067 27.9
JB 47 0.0092 38.3
JB 15 0.0071 29.6
Table 7.4. Enzyme activity of DRTG loop mutants
Crude extracts of the loop mutants and the wild type enzyme were prepared and TS 
activity was measured by the tritium release assay at 30°C. All enzymes were 
expressed in E.coli NM522 Thy' cells.
Temperature profiles of the loop mutants were examined in vitro as it had already 
been established that the mutants were temperature sensitive in vivo. Fractions of the 
crude extracts were held at 42°C and at 5 minute intervals aliquots were removed and 
assayed at 30°C by the tritium release assay. The loop mutants all produced a steady 
decrease in activity over time indicating that the longer the extracts were held at 42°C the 
less TS activity is present (Figure 7.3). By comparison the wild type extract only showed 
a slight decrease in activity verifying that this enzyme is not affected significantly by 
temperature.
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Figure 7.3. Temperature profiles of DRTG loop mutants
Crude protein extracts were held at 42°C and at 5 minute intervals aliquots were 
removed and assayed for TS activity at 30°C in the tritium release assay.
7 .1 .2 . D iscussion
Having established that the spiked oligonucleotide approach could produce a 
variety of temperature sensitive mutants targeted to various buried regions of TS, the 
same approach was used to successfully generate eight temperature sensitive mutant in the 
DRTG loop region.
Examination of the VZV TS ternary complex model reveals several things about 
the DRTG loop region. Firstly the loop is held in place by a number of hydrogen bonds 
which are formed between amino acids 32-35 from p-strand -i and residues 42-54 in (V 
strand i. In addition there are a number of residues which can tolerate mutations as they 
are surface exposed residues, these are Leu 19, Lys23, Asp26, Asp27, Arg30 and T yr31. 
Molecular modelling of the mutants was then used to explain the effects the amino acid 
substitutions were having on TS structure and function.
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Figure 7.4. Temperature sen sitive mutant JB28 showing the point 
mutations Y21S, Y31N and R34P
The mutant residue can be seen in yellow superimposed on the original residues. 
Additional residues given in green are those in close proximity to the mutated residue.
Mutant JB28 has three amino acid substitutions Y21S, Y31N and R34P. Tyr21 
is conserved in 34 out of 35 species of TS (see Figure 1.13 and pull-out sheet) the sole 
exception is L.lactis TS. It is found in helix A in a hydrophobic pocket surrounded by 
Met207, Val211 and Leu62. In JB28 this residue was mutated to a serine which
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introduces a cavity into the pocket which would be expected to destabilise the protein. 
Arg34 is present in strand -i and is a solvent exposed residue and should tolerate amino 
acid substitutions. It is not very highly conserved and appears in only 4 out of 35 TS 
sequences (VZV, EHV-2, human and S.aureus). Tyr31 is in helix A and is found in only 
two of the 35 TS species (VZV, HVS). The side chain of this residue is surface exposed 
and so the position can easily accommodate amino acid substitutions. We conclude that 
the significant change leading to the temperature sensitive phenotype of JB28 is Y21S.
L34R
A 37D
dUMP
Figure 7.5. Temperature sen sitive  mutant JB29 showing the point mutations 
R34L, K35E and D37A
The mutant residues can be seen in yellow superimposed on the original residues. 
Residues given in green are those in close proximity to the mutated residue. In cyan is a 
H-bond that is formed between the original aspartic acid residue at position 37 and 
threonine at position 39.
Three amino acid substitutions are found in JB29, R34L, K35E and D37A. 
Asp37 is conserved in 33 of the 35 TS species and forms part of the DRTG loop. This 
residue forms a hydrogen bond with Thr39, which maybe important in the structure of the
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loop. The O of the aspartate H-bonds to the Oy of threonine with a favourable bond length 
of 2.9A . Mutation of this residue to an alanine results in the loss of the H-bond.
The residues at positions 34 and 35 form part of the short -i jTstrand between 
helix A and (Tstrand i. Arg34 is not very highly conserved occurring in only 4 out of 35 
TS sequences (VZV, EHV-2, human and S.aureus). As mentioned above this residue is 
exposed to solvent and the position should tolerate amino acid substitutions. By contrast 
Lys35 is more highly conserved being present in 19 sequences across the full range of the 
TS family. The charge reversal which accompanies the substitution of lysine by glutamic 
acid might be expected to have more profound affects on the protein structure. It may be 
that the combination of the loss of the hydrogen bond from Asp37 and the charge reversal 
at position 35 together contribute to the destabilisation of the protein resulting in the 
temperature sensitive phenotype. It would require a site-directed mutagenesis approach 
changing these residues individually to fully resolve this issue.
Figure 7.6. Temperature sen sitive  mutant JB33 showing the point mutation 
L29F, R30M and Y 310c
The mutant residues can be seen in yellow  superimposed on the original residues. 
Residues given in green are those in close proximity to the mutated residue.
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Mutant JB33 has three sequence changes two of which result in an amino acid 
substitution. The changes are L29F, R30M and Y310c. Leu29 is in helix A and is present 
in 15 of the 35 sequences across the full range of the TS family. It is found in a 
hydrophobic pocket composed of Val25, Leu253, Ile245, Leu44 and Ile28. From the 
VZV TS model it would appear that phenylalanine, may be accommodated in this pocket 
but it may be that the increased bulk of the phenylalanine side chain which has a volume 
of 135A3 compared to leucine which is 124A3 destabilises the enzyme (Creighton, 1993). 
Arg30 is in helix A and occurs in only 5 TS sequences from 35, all of which are from 
eukaryotes. This residue is solvent exposed and so should tolerate the R30M substitution. 
Tyr31 has been mutated to an ochre stop codon, which is read as a tyrosine by the 
NM522 bacterial cells and as a result this residue remains the same. These considerations 
lead to the conclusion that L29F is the change leading to the temperature sensitive 
phenotype.
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Figure 7.7. Temperature sen sitive mutant JB35 showing the point mutation 
L22V, D27E and Y 310c
The mutant residues can be seen in yellow superimposed on the original residue. 
Residues given in green are those in close proximity to the mutated residue.
Mutant JB35 has three sequence changes two of which results in an amino acid 
substitutions. The changes are L22V, D27E and Y 310c. All three amino acids are present 
in helix A. Asp27 is found in only 8 TS sequences from both prokaryotes and 
eukaryotes. It is an exposed residue and so can accommodate a change to glutamate. 
Leu22 is in 28 from the 35 species and is fully conserved amongst the eukaryotic TS 
enzymes. It is buried in a non-hydrophobic pocket. Mutation of Leu22 to a valine residue 
results in a decrease in side chain volume from 124A3 to 105A3, this could produce a hole
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in the enzyme and lead to destabilisation. Again Tyr31 has been mutated to an ochre stop 
codon, which is read as a tyrosine by the NM522 bacterial cells and as a result this 
residue remains the same and would not affect enzyme structure. These findings lead to 
the conclusion that L22V is the change which is producing the temperature sensitive 
phenotype.
Figure 7.8. Temperature sen sitive  mutant JB36 showing the point mutations 
L220C and D27G
The mutant residues can be seen in yellow superimposed on the original residues. 
Residues given in green are those in close proximity to the mutated residue.
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L 220c, D27G and D37N are the three amino acid substitutions found in JB 3 6 . 
Asp37 is a highly conserved residue which is present in 35 from 37 TS sequences, the 
exceptions being H.influenzae and M.genitalium  (both of which are entries from genome 
sequencing projects). It forms part of the DRTG loop and is found H-bonded to Thr39. 
Mutation of this residue to an asparagine would result in a change to a residue of similar 
size which would be a conservative change. The hydrogen bond would be maintained and 
the substitution would not be expected to affect enzyme structure. For this reason this 
mutation is not shown on Figure 7.8.
Leu22 is present in 28 from the 35 species and is fully conserved amongst the 
eukaryotic enzymes. It forms part of helix A and is in a pocket which is not hydrophobic. 
This residue has been mutated to a tyrosine residue and results in an increase in side chain 
volume from 124A1 to 141 A ' which would be too big to fit into the pocket occupied by 
leucine (Creighton, 1993). The tyrosine residue however can adopt a conformation in 
which it can point out to solvent and this could then be accommodated by the enzyme. 
Asp27 is present in only 8 TS sequences from both prokaryotes and eukaryotes. This 
residue is found in helix A and is exposed to solvent. The mutation of aspartic acid to 
glycine at position 27 would not be expected to cause any problems. This D27G mutation 
cannot be seen in Figure 7.8 as glycine does not have a side chain. The conformational 
change required to accommodate tyrosine at position 22 would appear to destabilise the 
protein.
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Figure 7.9. Temperature sen sitive  mutant JB38 showing the point mutation 
D27E and Y 310c
The mutant residue can be seen in yellow superimposed on the original tyrosine residue. 
Residues given in green are those in close proximity to the mutated residue.
Mutant JB 38 has two sequence changes only one of which results in an amino 
acid substitutions, D27Eand Y 3lO c. Asp27 and Tyr31 are both surface exposed residues 
which are present in helix A. As stated previously Asp27 is present in 8 TS species from 
both prokaryotes and eukaryotes and Tyr31 is present in only 2 eukaryotic sequences. 
The tyrosine again has been mutated to an ochre stop codon which should have no effect 
on enzyme structure. The aspartic acid to glutamate change results in an increase in side 
chain volume from 91A3 to 109A3. Although Asp27 is a surface exposed residue this 
change in side chain volume could affect the interactions of aspartic acid with surrounding 
surface residues and could lead to protein stability.
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Figure 7.10. Temperature sen sitive mutant JB47 showing the point mutation 
G32E
The mutant glycine residue can be seen in yellow superimposed on the original 
glutamate. Residues given in green are those in close proximity to the mutated residue. 
In cyan are the hydrogen bonds formed.
Mutant JB 47 has the amino acid substitution G32E. Gly32 is a fully conserved 
residue of TS present in what could be called the G loop of the enzyme (refer to Figure 
1.13 and pull-out). It has a role in terminating helix A and allowing the enzyme flexibility 
to switch into strand -i and the DRTG loop. The single proton side chain of glycine points 
into a hydrophobic region composed of Leu22 and Ile23. In addition Leu44 makes close 
Van der Waals contacts with Gly32. This glycine residue is one of several that form
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hydrogen bond interactions with (3-strand i and hold the DRTG loop in place. From these 
considerations it is unlikely that Gly32 can tolerate any kind of substitution. It is 
interesting to note therefore that G32E is active at 30°C and this mutant deserves further 
study.
Figure 7.11. Temperature sen sitive  mutant JB15a showing the point mutation 
R38Q
The mutant glutamine residue can be seen in yellow superimposed on the original 
arginine residue. Residues given in green are those in close proximity to the mutated 
residue. There are two hydrogen bonds formed between Arg38 and the substrate 
dUMP, these are shown in cyan.
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JB15a has the amino acid substitution R38Q. Arg38 is found in 32 of the 35 TS 
species and is present in the DRTG loop structure. Upon ligand binding, the C-terminus 
and DRTG loop move to form a lid over the active site and Arg38 forms a direct hydrogen 
bond with the C-terminal carboxylate (Leu301). This hydrogen bond is thought to 
stabilise the packing of the loop and C-terminus after ternary complex formation.
In addition Arg38 is one of four highly conserved arginines that form a hydrogen 
bond network around the 5'-phosphate of dUMP, the other residues involved in forming 
this network are Argl64, Argl65, Arg203 and Ser204. It is the NH2 of Arg38 that 
hydrogen bonds to the oxygen of dUMP with a bond length of 3.3A and the nitrogen 
group hydrogen bonds to a second oxygen of dUMP with a bond length of 2.9A. The H- 
bonds formed by Arg203 to the phosphate of dUMP and the position of Ser204 are 
shown Figure 7.11. Mutating Arg38 to glutamine would allow the nitrogen group of 
glutamine to form a hydrogen bond to one of the oxygens of dUMP and so only one of 
the hydrogen bonds would be destroyed. The decrease in enzyme activity found in this 
mutant can perhaps better be explained more by the loss of the hydrogen bond to the 
carboxylate group of the C-terminal leucine residue.
7.2. The C-terminus of VZV TS
Crystallographic studies show that, upon ligand binding, the C-terminus 
undergoes a large conformational change to form an active-site lid and part of the folate 
binding site (Montfort et al., 1990). Carboxypeptidase cleavage of the terminal valine 
from one subunit of L.casei leads to complete loss of activity, although dUMP still binds 
with wild type affinity (Galivan et a l, 1976). Likewise, removal of the C-terminal residue 
from both subunits of Lcasei or E.coli TS also renders the enzyme unable to complement 
TS-deficient E.coli hosts (Climie et al., 1990, Michaels et al., 1990). This has been 
presumed to be due to the disruption of H-bonds between the C-terminal carboxyl group 
and the side chains of Trp85, Arg23 and Thr24, and to PABA ring of the cofactor 
(Montfort et al., 1990; Finer-Moore et al., 1990; Matthews et al, 1990b).
The L.casei TS mutants were inactive in the complete TS reaction but they were 
still able to participate in the partial reaction, catalysis of the dehalogenation of BrdUMP 
(Carreras et al., 1992). This suggests that the C-terminal interactions are independent of 
the first stage of the covalent binding of dUMP, and the activation of the C5-H.
VZV TS appears to be unique in that following removal of the C-terminal amino 
acid to produce the mutant L301A it has slighly elevated debromination activity and 3% of 
the wild type activity when measured in the tritium release assay at 37°C (Harrison et al., 
1995).
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Unique interactions occurring at C-terminus of VZV
Harrison et al., (1995) compared the C-terminal tail of VZV to that of E.coli and 
Lcasei to establish whether the differences in activity in the C-terminal deletion mutants 
could lie in the C-terminal tail itself, a region with which C-terminal tail interacts or a 
combination of both. Investigation of the final 6 amino acids from the various enzymes 
revealed that VZV has 4 amino acid substitutions (refer to Figure 1.13). The most 
significant is Glu298 in VZV which is replaced by a proline in Lcasei and E.coli. 
Construction of a VZV TS mutant containing a proline at this position resulted in an 
enzyme with a 15-20 fold decrease in tritium release activity. Removal of the C-terminal 
residue from the E298P protein did not affect activity indicating that neither mutant acts as 
an accurate mimic of the Lcasei TS C-terminal tail. Structural differences between VZV 
and Lcasei were therefore not thought to reside solely in the C-terminal tail.
Further studies on the C-terminus involved examination of models from VZV and 
Lcasei TS. In Lcasei TS four hydrogen bonds are formed between the C-terminal 
residue and Arg23, Thr24, Trp85 and the PABA ring of the cofactor (Matthews et al., 
1990; Finer-Moore et al., 1990; Montfort et al., 1990). Four identical interactions were 
found in the E.coli enzyme but only two equivalent bonds are formed in VZV between the 
C-terminal residue and Arg38 and Thr39 (equivalent to Arg23 and Thr24). The third 
interaction in Lcasei which involves Trp85 cannot occur in VZV TS as it has a tyrosine 
residue (TyrlOO in VZV) in place of the tryptophan. This residue cannot be positioned in 
the VZV enzyme such that its OH group could form a H-bond with the carboxylate group 
of the C-terminal residue without steric clashes. Removal of the C-terminal residue from 
L.casei (V316A) results in the disruption of the hydrogen bond network and leads to the 
inactivation of the enzyme.
As VZV retains a significant amount of activity when the C-terminus is removed it 
has been predicted that a further interaction must occur which closes down the enzyme 
sufficiently to allow catalysis. It has been suggested (Harrison et al., 1995) that 
hydrophobic interactions may occur between the side chains of Ile99/Tyrl00, the C- 
terminal residue and Met299 (Figure 7.12). This would result in VZV being stabilised 
more by hydrophobic contacts across the face of the enzyme between the C-terminus and 
helix D rather than H-bond contacts observed in Lcasei and E.coli. In addition the 
aromatic ring structure of TyrlOO may also help stabilise the binding of the cofactor in an 
analogous manner seen by tryptophan. The small amount of activity observed in the C- 
terminal deletion mutant of VZV (L301A) is due to the decrease but not the abolition of 
these hydrophobic contacts, as the three remaining residues can still interact to hold the 
two sides of the active site together.
TS from E.coli and Lcasei have a valine residue at the antepenultimate position in 
their C-terminus compared to methionine in VZV. They also contain the hydrophilic 
amino acid glutamate at the position equivalent to Ile99 of VZV. These residues may be
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Figure 7.12. Interactions occurring at the C-terminus of thymidylate synthase
The C-terminal interactions of L.casei, E.coli, VZV  and human TSs. Hydrophobic 
interaction are given as solid black lines and hydrogen bonds are dashed lines. The C- 
terminal residues are in bold.
sufficient to prevent significant hydrophobic interactions in L.casei and E.coli. These 
observations further support the importance of the hydrophobic interactions in VZV TS.
Examination of other eukaryotic TS sequences shows that they do not contain a 
tyrosine residue at the position equivalent to TyrlOO but an asparagine residue (refer to 
Figure 1.13). An asparagine has been modelled in place of tryptophan in E.coli TS such 
that its N-H group could form a H-bond to the carboxylate group of the C-terminal 
residue. This suggests that the asparagine residue in eukaryotes may play an analogous
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role to the conserved tryptophan in TS from prokaryotes and these TSs could also be 
inactive if their C-terminal residue is removed (P.T. Harrison, PhD thesis, Glasgow 
University 1992). Therefore it appears that it is the tyrosine residue in VZV TS, which is 
uniquely found in place of a conserved tryptophan or asparagine residue, that is in part 
responsible for the residual activity in VZV L301A.
7.2.1. Mutagenesis of the C-terminal region
Region-directed mutagenesis was performed on the C-terminus of VZV TS using 
spiked oligonucleotides R019 and RO20 which covered amino acids 284-301 and 284- 
300 respectively. The efficiency of the mutagenesis procedure is given in Table 7.5.
Spiked oligo Colonies Temperature Restriction R eadable
screened sensitive profile point
colonies m utations
R 019 716 65 24 0
RO20 230 56 9 4
Table 7.5. Efficiency of m utagenesis procedure
The table shows the spiked oligonucleotides that were used in the mutagenesis and the 
results from screening and sequencing.
The results demonstrated that a large number of the potential temperature sensitive 
mutants did not produce the correct restriction profiles and had similar profiles to those 
seen in Figure 7.1. Single stranded DNA was extracted from the mutants that did contain 
the correct restriction pattern and these were sequenced. Mutations were initially identified 
by sequencing across the C-terminal region using primer 59. As before the absence of 
further changes introduced during the mutagenisis step was confirmed by sequencing the 
complete TS gene with primers 59-62. The mutants are shown in Table 7.6.
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Proteins C-terminal sequence
Wild type 283 D FQ L D G Y N P H P P LKMEM A L 301
JB 73 283 D FQ L M D I I H T P P 294
JB 79 283 D FQ H H D G Y N P H P P L K ME M A L 301
JB 88 283 D FQ L D 287
JB102 283 D FQ L D G Y N P H P P L K E W L FN
G F L N V V K T V D V L R M 316
Table 7.6. C-Terminal mutants
C-terminal mutants produced by region-directed mutagenesis using spiked 
oligonucleotide RO20 which covered amino acids 284-300. Mutated residues are shown 
in red.
JB79 contained a L286H point mutation and the other three mutants produced 
major reconstructions of the C-terminus. JB73 has a deletion in Leu286 which changes 
the reading frame of the remaining amino acids and produces an amber stop codon at 
position 284, resulting in a seven amino acid deletion. JB88 contains a point mutation in 
Gly288 which produces an amber stop codon at position 288 resulting in a 14 amino acid 
deletion. In contrast JB102 carries a deletion in Glu298 which changes the frame of the 
amino acids and results in an amber stop codon being present at position 316 rather than 
301, resulting in a 15 amino acid extension. The C-terminus of VZV TS with the 
positions of mutations and deletion are shown in Figure 7.13.
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Figure 7.13. Thymidylate synthase monomer
A model of the monomer of VZV TS showing the positions of the C-terminal mutants. In 
green are p-strands, a-helices are red, turns are yellow and the ligands are grey. The 
amino acid residues in the mutants are shown in blue space-filling. The C-terminus is 
present as a thick yellow strand with the positions of the deletions shown as white zig 
zag lines.
As C-terminal mutants from other TS enzymes had shown no activity in the 
complete reaction, the four C-terminal mutants produced were assayed for activity. All 
four mutants had been shown to be catalytically active in vivo  as they could complement 
the growth of NM522 Thy' cells at 30°C. Crude protein extracts were prepared of the 
mutants and the tritium release assay was performed at 30°C to quantify the TS activity of 
the mutant enzymes. The specific activity of the crude extracts are given in Table 7 .7 .
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Enzyme Tritium release 
pmol/min/ug protein
% Wild type
Wild type 0.0205 100
JB 73 0.0021 10.2
JB 79 0.0013 6.3
JB 88 0.0018 8.8
JB 102 0.0037 18.0
Table 7.7. TS activity of C-terminal mutants
Crude extracts of the C-terminal mutants and wild type enzyme were prepared and the 
activity was measured by the tritium release assay. All enzymes were expressed in 
E.coli NM522 Thy at 30°C
Analysis of the crude extracts from the C-terminal mutants show that they contain 
significant activity. Although these experiments were performed on crude extracts at 30°C 
they complement previous studies on the C-terminus of VZV TS which revealed that 
removal of the C-terminal residue L301 resulted in a significant decrease in enzyme 
activity but not complete inactivation (Harrison et al., 1995). In contrast, similar studies 
performed on L.casei TS revealed that deletion of 4 or 8 amino acids from the C-terminus 
of this enzyme resulted in complete inactivation of the enzyme as the enzyme could not 
form a covalent complex with the substrate and cofactor (unpublished data cited in 
Carreras & Santi, 1995).
From the crude extracts temperature profiles of the mutants were determined to 
establish whether the mutants were temperature sensitive in vitro as it had already been 
established that they were temperature sensitive in vivo (Figure 7.14).
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Figure 7.14. Temperature profiles of the C-terminal mutants
Crude protein extracts of the mutants were prepared and samples from the extracts 
were held at 42°C. At 5 min intervals 5/vl aliquots were removed and assayed for TS 
activity in the tritium release assay at 30°C. The graph show s the decrease in activity of 
the mutants in response to the length of time incubated at 42°C.
All of the mutants displayed a sharp decrease in activity the longer they were held 
at 42°C, in contrast the wild type extract shows only a slight decrease in activity. 
Therefore the mutants were temperature sensitive in vitro as well as in vivo.
7 . 2 . 2 .  C haracterisation  o f p u rified  JB 88
In order to purify the C-terminal deletion mutant JB88, the TS gene was digested 
from its original pAD768 backbone and ligated into the pET23d vector which is a high 
expression vector under the control of the T7 promoter (refer to Figure 5.1). The protein 
was insoluble when produced in such large amounts and so it was recloned into the 
original backbone under the control of the toe promoter (refer to Chapter 5). Following 
expression of JB88 from the pAD768 vector, the enzyme was purified by hydroxyl apatite 
and S-sepharose chromatography. Figure 7.15 is a Coomassie stained polyacrylamide gel 
demonstrating the purity of the mutant following S-sepharose chromatography.
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Figure 7.15. Purification of JB88 on an S-sepharose column
Coomassie stained gel of fractions collected from purification of JB88 by S-sepharose 
chromatography. The partially purified protein extract obtained from the hydroxylapatite 
column was bound to the S-sepharose column, the column was washed with 
phosphate buffer and the TS protein was eluted from the column with an increasing salt 
gradient. Lanes 12-20 are fractions eluted from the column which are found to contain TS 
protein. TS is present at 32KDa and is denoted by an arrow. Protein markers (M) are 
present on the right.
JB88 was found to have 0.10% of wild type activity (Table 7.8). This is very low 
but is sufficient to complement Thy' NM522 cells. In contrast the crude extract had 8.8% 
activity, this may reflect loss of activity during the purification process.
Enzyme Tritium release assay % Wild type
pmol/min/ug protein
Wild type 8.34
JB 88 0.0084
14 a.a. deletion___________________
Table7.8. TS activity of the deletion mutant JB88
The C-terminal mutant JB88 and the wild type enzyme were purified and the activities 
were measured by the tritium release assay. All enzymes were expressed in E.coli 
NM522 T h y .
100
0.10
32KDa
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Further characterisation of the deletion mutant required kinetic analysis. 
Spectrophotometric assays, which measure the increase in absorbance at 340nm 
concomitant with dihydrofolate production were carried out on purified JB88. The protein 
extract was added to a microtitre plate containing spectro assay buffer and either varying 
concentrations of substrate or cofactor (S). Graphs were generated of the increase in 
absorbance over time at the varying concentrations of substrate and from these the 
velocity (V) of the enzyme at the different concentrations could be calculated. This 
allowed a graph to be drawn of 1/V against 1/S from which a Km value could then be 
obtained. This procedure was performed several times for both dUMP and folate and the
mean Km values are given in Table 7.9
Enzyme dUMP Km (pM) Folate Km (pM)
Wild type 5.00 ±0.31 25.77 ± 2.20
JB 88 1.41 ±0 .34 523 ± 87.2
14 a.a. deletion
Table 7.9. Kinetic analysis of purified TS enzymes
Spectrophototmetric assays were performed on purified wild type enzyme and the C - 
terminal deletion mutant JB88. The assays measure the increase in absorbance at 
340nm concomitant with dihydrofolate production and allow Km values for dUMP and 
folate to be evaluated. The Km results are given as the mean Km value ± the standard 
error.
The Km value for dUMP was found to be 3 fold lower than the wild type enzyme 
which would suggest that the active site of the mutant enzyme is in a more open 
conformation allowing the substrate to enter more readily (Table 7.9). In contrast the 
folate Km value for the C-terminal mutant has dramatically increased by around 25 fold 
which suggests that reduced folate binding must play a part in the diminished activity of 
the mutant enzyme. This very high folate value could possibly be the result of the failure 
of the active site to close down upon ligand binding. Therefore it appears that in the C- 
terminal mutant JB88, removal of the 14 amino acids from the C-terminus results in an 
enzyme which has difficulty forming a closed complex. These data are consistent with 
that obtained from the C-terminal deletion mutant L301A which had a dUMP Km value of
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0.65 ± 0.09(liM and a folate Km value of 514 ± 83 .12|iM at room temperature (Harrison et 
a l., 1995).
7.2.3. Kinetic analysis of C-term inal extracts
The remaining three C-terminal mutants; JB73, JB79 and JB102 could not be 
purified which resulted in them being characterised more fully from crude extracts. Fresh 
crude extracts of the C-terminal mutants were prepared, dialysed and assayed for enzyme 
activity (Table 7.10). Having established that the extracts were active, spectrophotometric 
assays were performed to obtain a Km value for dUMP.
Enzyme dUMP Km (pM)
Wild type -
JB 73 1.79 ± 0.29
JB 79 1.27 ±0 .17
JB 88 -
JB102 1.53 ±0 .32
Table 7.10. Kinetic analysis of C-terminal mutants
Crude extracts of C-terminal mutants were prepared and analysed 
specrophotometrically to initially obtain a Km value for dUMP. Spectrophotometric 
analysis involves the examination of the increase in absorbance at 340nm concomitant 
with dihydrofolate production. The results for the Km for dUMP are given as the mean Km 
value ± the standard error.
The C-terminal mutants JB73, JB79 and JB102 produced low dUMP Km values 
but inconsistent results were obtained from the crude extracts of the wild type enzyme and 
JB88 and so no conclusive result could be drawn. Determination of the folate Km also 
presented a few problems. It appeared that when the concentration of folate in the assay 
was increased then the TS response appeared to get lower and when folate was omitted 
from the assay the extracts produced the highest response. These results indicated that the 
crude extracts must contain an agent that interferes with absorbance.
155
Chapter 7. Mutagenesis o f highly mobile regions o f  VZV TS
7 .2 .4 . Inh ib ition  o f C -term inal m utant enzym es 
P henolph thalein  inh ib ition
Phenolphthalein inhibition was examined initially on crude preparations of all four 
C-terminal mutants by the tritium release assay. Phenolphthalein was added to the assay at 
50, 100 and 500//M concentrations. Inhibition of the enzymes can be seen in Figure 7.16.
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Figure 7.16. Phenolphthalein inhibition of C-terminal mutants
Crude extracts of C-terminal mutants and wild type TS were assayed for 
phenolphthalein inhibition in the tritium release assay. Phenolphthalein was examined at 
50, 100 and 500jt/M concentrations. The graph shows the activity present in the mutants 
relative to no inhibitor.
The results from the assay are shown in Figure 7.16 and reveal that at 
concentrations of 500//M, phenolphthalein drives down TS activity in all of the mutants 
as well as the wild type enzyme, although the mutant enzymes show slightly more 
resistance. JB73, JB79 and JB88 were much more sensitive to phenolphthalein than the 
wild type extract at 50 and 100//M concentrations. JB102, however showed more 
resistant to phenolphthalein than the wild type enzyme at 50/<M and 500pM  and was only 
slightly more sensitive at 100//M.
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The tritium release assay was then repeated with purifed JB88, again using 50, 
100 and 500pM  concentrations of the inhibitor. The results are shown graphically in 
Figure 7.17.
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Figure 7.17 Phenolphthalein inhibition of JB88
A purified extract of the C-terminal deletion mutant JB88 was examined for inhibition by 
phenolphthalein at 50, 100 and 500pM concentrations. The graph shows the results 
from an experiment of the activity present in the mutant enzyme relative to no inhibitor.
Therefore, JB88 is more sensitive than the wild type enzyme to phenolphthalein 
irrespective of whether it is present as a crude or purified extract. These findings support 
the results obtained from the spectrophotometric assays on this mutant where a low 
dUMP and high folate Km values were produced which indicated the more open 
conformation of the enzyme. The greater sensitivity to phenolphthalein also demonstrates 
that the mutant enzyme is in a more open configuration and so is more accessible to 
phenolphthalein.
■  WT 
□  JB88
k
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Folate analogue inhibition
Folate analogues that inhibit TS were developed modelled on the structure of 5,10 
methylenetetrahydrofolate. The folate analogues ICI 1-8 were developed based on the lead 
compound CB3717. This compound allows the formation of a covalent bond between TS 
and dUMP. However, CB3717 cannot form a covalent bond with dUMP and so 
methylene transfer cannot occur. The folate analogues ICI 1, ICI 4 and ICI 5 were 
examined in the tritium release assay to determine whether they could inhibit purified 
JB88 (Table 7.11)
Inhibitor
concentration
WT
ICI 1 
JB88 WT
ICI 4 
JB88 WT
ICI 5 
JB88
0.5ng/p! 73.2% 62.5% 96.2% 100% 86.5% 67.2%
5ng/pl 29.5% 51.1% 86.7% 100% 80.1% 79.9%
50ng/p! 8.2% 17.6% 36.0% 100% 47.1% 89.6%
500ng/pl 3.0% 5.5% - - - -
5pg/pl 0.5% 2.5% - - - -
Table 7.11 Folate analogue inhibition
Purified extracts of the C-terminal mutant and wild type enzyme were prepared. The 
tritium release assay was performed with varying concentrations of the folate analogue 
compounds ICI 1 ,4  and 5 which had been added prior to the addition of the enzyme. 
The figures are a mean of two values. They are expressed as a percentage of activ ity 
in the absence of inhibitor.
JB88 was more resistant to ICI 1 than the wild type enzyme at concentrations of 
5ng/gl and above. ICI 4 had no effect on the activity of the mutant enzyme but did affect 
the wild type. The folate analogue ICI 5 inhibited both the mutant enzyme and wild type at 
0.5ng/pl but at higher concentrations it appeared to stimulate the activity of the mutant 
whereas the wild type was still inhibited. This result requires further investigation.
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7.2.5. Discussion
Examination of the 35 TS sequences shows a lack of alignment at the N-terminus 
and indeed the bifunctional enzymes have an N-terminal DHFR domain. By contrast the 
C-terminal regions precisely align in all species, indicating the importance of this region. 
In all cases the five amino acids at the most extreme C-terminal region are small and 
hydrophobic. 27 of the 37 sequences have a valine as the C-terminal residue, 7 of the 
remaining 8 sequences have either isoleucine or alanine and VZV TS is unique in that it 
has a leucine.
Previous studies on L.casei and E.coli TS have revealed the importance of the C- 
terminus for enzyme function. Removal of the solvent exposed and highly mobile 
carboxy-terminal residue results in the complete inactivation of the enzyme in the tritium 
release assay. In contrast, deletion of Leu301 from VZV TS does not completely 
inactivate the enzyme, implying structural differences between the viral and bacterial 
enzymes (Harrison e ta l,  1995). This thesis has shown that major reconstructions can be 
produced in the C-terminal region of VZV TS without a complete loss in enzyme activity.
The mutants JB73 and JB88 contain deletions of 7 amino acids and 14 amino 
acids respectively. Figure 7.13 demonstrates that removal of these amino acids would 
significantly decrease the length of the C-terminal tail which forms the lid over the active 
site upon ligand binding. This may result in the enzyme adopting a more open 
conformation. The deletion mutants have been shown to be functional but they are 
compromised. The mutant enzymes can complement bacterial cells deficient in TS on 
minimal media at 30°C and crude extracts have produced ~8-10% wild type activity in the 
tritium release assay. JB88 which had the 14 amino acid deletion was the only C-terminal 
mutant to be purified, this was shown to have 0.10% of wild type activity. Kinetic 
analysis of this mutant revealed a 3 fold reduction in dUMP Km and 25 fold increase in 
folate indicating that the mutant enzyme was in a more open conformation and could 
not form the closed complex as efficiently as that of the wild type enzyme. These findings 
were supported further by the phenolphthalein results which demonstrated that the mutant 
enzymes were more sensitive to phenolphthalein than the wild type enzyme and so must 
be more accessible for the inhibitor which was designed to fit into the active site cavity.
The results from the deletion mutants suggest that the previous model for the C- 
terminal region may not hold as it was thought that the activity in the Leu301 deletion 
mutant was due to hydrophobic interactions between Met200, Ile99 and TyrlOO. The 
deletion mutants however do not have Met299 present to form these hydrophobic 
interactions. The experimental evidence obtained in this thesis suggests that for the 
deletion mutant JB88 the enzyme does not close down upon ligand binding. In order to 
determine whether this is the case the crystal structure of the ternary complex of JB88 
would have to be solved.
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JB79 has a point mutation present in Leu286 which is positioned between a 13- 
strand and the C-terminal tail (refer to Figure 7.13). A leucine to histidine change at this 
residue produces an enzyme with drastically reduced TS activity ( -6% of wild type). This 
reduction in activity can be explained by the change from an uncharged hydrophobic side 
chain to a positively charged one which presumably prevents active site closure.
Mutant JB102 has a C-terminal extension resulting from a frame shift. This 
mutant cannot be modelled in Figure 7.13 as it is impossible to speculate what orientation 
this extension will take on the surface of the protein. Although this extension is present in 
an exposed region of the protein and should be readily accommodated it was found to 
produce a dramatic decrease in enzyme activity. This reduction in enzyme activity can be 
explained in several ways: if the C-terminal extension docks on the surface of the protein 
it can pull the C-terminal tail from its normal orientation and this could drastically affect 
enzyme structure and function. In contrast, the C-terminal extension may not find a 
position on which to dock and it will move around on the surface, this again will result in 
the normal orientation of the C-terminal tail being affected. In addition the DRTG loop 
may also play a role as it packs against the C-terminus upon ligand binding and a 
hydrogen bond is formed between Arg38 and the C-terminal carboxylate. This bond may 
limit the orientation the additional residues can adopt.
Phenolphthalein data from JB102 suggests that this enzyme shows more 
resistance to the inhibitor than the other three C-terminal mutants and the wild type 
extract. This could suggest that the tail is covering the active site and so phenolphthalein 
cannot enter as readily. The results on this mutant are from crude protein extracts and the 
result have to be corroborated with purifed enzyme.
The C-terminal residue of human TS is a valine. In addition this enzyme has an 
asparagine at position 112 which forms a hydrogen bond with the carboxylate of valine. 
Asnl 12 was proposed to play a role similar to Trp85 in E.coli as an asparagine can be 
modelled in place of tryptophan in E.coli TS such that its N-H group could form a H- 
bond to the carboxylate group of the C-terminal residue. This suggests that the asparagine 
residue in eukaryotes may play an analogous role to the conserved tryptophan in TS from 
prokaryotes and these TSs could also be inactive if their C-terminal residue is removed 
(Harrison et al., 1995). It was predicted that removal of this C-terminal valine residue 
would completely inactivate the enzyme but subsequent work in our laboratory has shown 
that the removal of this residue produces an enzyme (-50% pure) which can perform the 
partial debromination reaction at wild type levels but has 0.042% wild type activity in the 
tritium release assay (J. Scott, R. Thompson, personal communication). This level of 
activity is 100 fold lower than that found in VZV L301A and is not sufficient to 
complement Thy" bacteria. Thus there remains a significant difference between the human 
and viral enzymes.
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Analysis of the completely conserved residue asparagine 214
As an approach to understanding the structure function relationship of TS, the 
properties of “replacement sets” of key amino acid residues of the enzyme by all or most 
possible substitutions were investigated (Michaels et al., 1990, Kim et al., 1992). One 
such key residue was Asn229 (.Lcasei numbering), this residue is conserved in all 
sequenced TSs (Asn214 in VZV) and provides the only side chain that directly hydrogen 
bonds with the pyrimidine ring of the substrate dUMP. The carboxamide moiety forms a 
cyclic hydrogen bond network with the NH-3 and 0-4 of the base and is a prime 
candidate for assisting proton transfer reactions that occur at 0-4 of the pyrimidine ring of 
dUMP (Figure 8.1)
Glu 60
H is 199
Asn 229
d eoxyrib ose
Figure 8.1. Schematic diagram of the hydrogen bond interactions among the pyrimidine 
ring of the substrate dUMP and the amino acid residues at the active site (Montfort et al., 
1990; Montfort etal., 1993). The numbering is from Lcasei TS.
It has recently been proposed that the substrate specificity of TS for dUMP versus 
dCMP resides in the single amino acid residue Asn229 (Asn214 in VZV TS). The
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complete replacement set of L.casei TS mutants were catalytically active indicating that 
that Asn229 assists but is not essential for dUMP binding and catalysis. In addition the 
results demonstrated that the N229D mutant altered the pyrimidine specificity of the 
enzyme and resulted in it becoming a dCMP methylase (Liu & Santi, 1993a). The wild 
type enzyme can effectively discriminate between the related deoxyribonucleotides dUMP 
and dCMP as substrates. dUMP is a relatively tight binding substrate with a Km of ~5pM, 
in contrast dCMP is not a substrate but is a poor competitive inhibitor with a K; of 
3000//M (Liu & Santi, 1993b). With the exception of TS N229Q, most of the mutants 
bind dCMP as well as or tighter than dUMP. In particular the N229D mutant has a dUMP 
Km value of 50pM and a dCMP Kj value of 150//M. The mutants were assayed to identify 
those which could catalyse dCMP methylation and it was found that in addition to 
N229D, N229E also catalyses the reaction (Liu & Santi, 1993b). The aim of the 
experiments described in this section was to produce a corresponding mutation in 
asparagine 214 of VZV TS. The mutant enzyme was then examined for sensitivity to 
dCMP which would indicate a change in pyrimidine recognition.
8 .1 . Construction o f  N214D
Previously an asparagine to serine mutation (AZ42) had been produced in residue 
214 by region directed mutagenesis (Chapter 6 ), however in addition this mutant also 
contained D206Y and M207L mutations. Therefore a single asparagine to aspartic acid 
change was produced in residue 214. Construction of the N214D mutation in VZV TS 
required an oligonucleotide to be synthesised which contained the corresponding 
asparagine to aspartic acid mutation at residue 214 (Figure 8.2). Site directed mutagenesis 
was performed using the Ktinkel strand selection procedure and the mutation was initially 
identified by sequencing using primer 62. Sequencing the whole gene with primers 57-62 
revealed that there were no nucleotide changes apart from that introduced by mutagenesis. 
The N214D mutant was initially characterised by genetic complementation using a Thy' 
strain of E.coli and was shown to be unable to complement NM522 Thy'.
Amino acid Val Pro Phe Asn lie Ala Gly Tyr
211 212 213 214 215 216 217 218
Wild type sequence GTA CCG TTC AAC ATT GCT GGA TAT
Mutated sequence GTA CCG TTC GAC ATT GCT GGA TAT
Val Pro Phe Asp lie Ala Gly Tyr
Figure 8.2. A point mutation constructed in asparagine 214 of VZV TS by site directed 
mutagenesis to produce N214D. In red is the mutated residue.
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8 .2 . Expression of N 214D
Detailed studies of the N214D mutant required large amounts of the enzyme which 
were obtained by cloning the mutant into the pET-23d high level expression vector. The 
mutant gene was digested from the original bluescript backbone with EcoR\ and N c o \ ,  
the digest was run on an agarose gel and the TS fragment was extracted. The pET-23d 
plasmid was digested with the same enzymes and a ligation reaction was set up to ligate 
the TS construct into the expression vector. The target gene was initially cloned into 
NM522 Thy' cells that do not contain T7 RNA polymerase gene, once established in this 
non-expression host the plasmid was transferred into a BL21 pLysS expression host and 
protein expression was induced by the addition of IPTG. Purification was achieved by 
hydroxylapatite and S-sepharose chromatography (Figure 8.3).
94KDa
67KDa
43KDa
30KDa
20KDa
14KDa
Figure 8.3. Purification of TS from S-sepharose column
Coomassie stained gel of fractions collected from purification of N214D by S-sepharose 
chromatography. The partially purified protein extract obtained from the hydroxylapatite 
column was bound to the S-sepharose column, the column was washed with 
phosphate buffer (F) and the TS protein was eluted from the column with an increasing 
salt gradient. The position at which purified TS runs is denoted by an arrow. Protein size 
markers(M) are present on the right.
A tritium release assay was carried on the purified extract to quantify the TS 
activity present. The specific activity of the mutant protein was found to be 0.06% of that 
of the wild type enzyme, this very low specific activity confirmed the Thy' phenotype of 
the mutant which had been shown by an inability to complement Thy' bacteria (Table 
8 .1). Previous studies (Liu & Santi, 1993) have shown that an N229D mutation in 
Lcasei produces a Thy' phenotype with similar TS activity to the VZV N214D mutant.
Fractions from column
32KDa
..
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Enzyme Tritium release % Wild type
pmol/min/ug protein
Wild type 8.34 100
N214D 0.0047 0.06
Table 8.1. Enzyme activity of N214D mutant
TS activity of purified extracts of the N214D mutant and wild type TS enzymes 
measured by the tritium release assay. All enzymes were expressed in E.coli BL21 
pLysS.
8.3. dCMP inhibition of N214D
Ordinarily dCMP is a poor competitive inhibitor of TS and binds to the wild type 
enzyme with a 1000 fold lower affinity than the substrate dUMP. Replacement of Asn229 
in L.casei TS with aspartic acid resulted in the enzyme losing TS activity toward dUMP 
and becoming a dCMP methylase (Liu & Santi, 1993).
The purified N214D enzyme of VZV was assayed for dCMP inhibition in a tritium 
release assay in which dCMP was present at concentrations of 500p.M-10mM. The results 
are presented graphically (Figure 8.4) and reveal that high concentrations of dCMP have 
no effect on the wild type enzyme. However the mutant enzyme shows a large decrease in 
enzyme activity at concentrations of ImM dCMP and above indicating that the dCMP is 
inhibiting the enzyme by competing with the substrate dUMP.
164
Chapter H. Pyrimidine discrimination hy VZV TS
Wild type 
N214D
Figure 8.4. dCMP inhibition of N214D
TS activity of N214D and the wild type  enzyme examined in the presence of increasing 
concentrations of dCMP (500^M-10mM) with a fixed dUMP concentration of 23.4pmoles.
8 .4 . K inetic stud ies
It did not prove possible to measure the kinetic parameters of N214D. Alteration 
of the substrate concentration in the spectrophotometric assays did not appear to affect the 
velocity of the reaction. It may be that the low sensitivity of the spectrophotometric assay 
and the low activity of the N214D extracts combined to frustrate accurate measurements. 
Studies in L.casei TS have shown that an asparagine to aspartic acid mutation at residue 
229 resulted in a ten fold increase in dUMP K m value implying that there is a decrease in 
affinity for dUMP. With the exception of N229Q, the complete replacement set of 
mutants of L.casei bind dCMP as well as or tighter than dUMP and bind dCMP 300- 
3,000 fold tighter than wild type TS (Liu & Santi, 1993).
8 .5 . D iscussion
Previous studies on Asn229 of L.casei has shown that mutations in this residue 
result in the enzyme having an increased affinity for dCMP, in particular the N229D 
mutation resulted in the enzyme converting to a dCMP methylase. The corresponding
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mutation produced in VZV TS could not complement E.coli NM522 Thy' cells in vivo, 
similar results had been noted in L.casei. The N214D mutant enzyme did produce a low 
but measurable amount of activity in the tritium release assay which is comparable with 
the activity present in the N229D mutant of Lcasei TS(Liu & Santi, 1993a). When dCMP 
inhibition was examined in this assay, the wild type enzyme did not appear to be inhibited 
by the presence of dCMP whereas the mutant enzyme showed inhibition at concentrations 
of ImM and above. These results suggest that the substrate specificity of the mutant 
enzyme has been altered and the dCMP is now competing with the dUMP. values 
were not obtained for the VZV mutant enzyme but similar studies of the Lcasei enzyme 
revealed that in the N229D mutant the for dUMP was increased by 10 fold from that 
of the wild type enzyme. Further characterisation of the N214D mutant from VZV would 
require the analysis of both dUMP and dCMP as substrates in the tritium release assay. 
The E.coli mutant N177D gave an initial velocity with dCMP which was 35 fold faster 
than that obtained with dUMP indicating that the mutant enzyme is more active on dCMP 
than dUMP (Hardy & Nalivaika, 1992).
Therefore the wild type TS enzymes discriminate binding of dUMP versus dCMP 
by the exclusion of dCMP from the active site. This exclusion is thought to be the result 
of untoward interactions between the carboxamide group of Asn or Gin at position 214 
and dCMP. If dUMP was replaced by dCMP in the active site of either of the two 
enzymes, this would place the carboxamide oxygen of the side chain adjacent to the 
heterocycle nitrogen of dCMP and the amide nitrogen adjacent. This close proximity of 
the relatively negative groups of the enzyme and dCMP would lead to a repulsion of the 
ligand from the enzyme and account for poor binding. Rotation of the Asn or Gin 
carboxamide group at 214 to better accommodate the dCMP binding would require 
disruption of the H-bond network with other amino acids.
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GIu 60
O----------- His 199
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Asn 229 -
deoxyribose
dCMP
Figure 8.5. Schematic diagram showing that the hydrogen bonding once formed 
between dUMP and N229 is disrupted between dCMP and N229 (Liu & Santi, 1993b). 
The numbering is from Lcasei TS.
These findings have important ramifications as there are a large number of 
enzymes that bind uracil nucleotides in preference to cytosine nucleotiodes and these 
enzymes may employ a similar mechanism for discrimination. One such enzyme which 
recognises uracil is deoxyuridine 5'-triphosphate nucleotidehydrolase (dUTPase), this 
enzyme catalyses the hydrolysis of dUTP to dUMP and pyrophosphate. The enzyme 
serves two biological functions: it contributes to the pool of dUMP an essential precursor 
in the biosynthesis of thymidylate nucleotides via the TS reaction and it maintains the 
intracellular concentration of dUTP at a low level thereby reducing the incorporation of 
uracil into DNA. E.coli dUTPase is highly specific for its substrate and discriminates not 
only different bases and sugar moieties but also the phosphate group. NH-3 of the 
pyrimidine ring makes a H-bond with the main chain of the enzyme, while the carbonyl 
group at C-4 makes a weak H-bond with Asn84 (Larsson et al., 1996). It is thought that 
this asparagine group may contribute to discrimination of cytosine in a similar manner to 
TS. This asparagine residue however, is not an evolutionary conserved residue and is 
only found in E.coli dUTPase. Crystallographic studies of human dUTPase (Mol et al.,
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1996) have demonstrated that a hairpin loop is responsible for specific recognition: uracil 
is inserted into the distorted antiparallel hairpin and dUTPase main-chain hydrogen bonds 
recognise 02, N3 and 04 atoms. These interactions mimic DNA base pairing, selecting 
uracil over cytosine and sterically precluding thymine and ribose binding.
A second class of enzyme which discriminate against cytosine are uracil DNA 
glycosylases (UDGases), which are a ubiquitous, highly conserved and extremely 
specific class of DNA repair enzymes. Their biological function is the specific removal 
from DNA of the RNA base uracil. In the human UDG-6 amino uracil complex, uracil 
binds at the base of the groove within a rigid preformed pocket that confers selectivity for 
uracil over other bases by the shape complementarity and by main chain and Asn204 side 
chain hydrogen bonds (Mol et al., 1995). Site-directed mutagenesis of this residue has 
identified it as the most critical residue for the recognition of uracil (Mol at al., 1995). 
This asparagine residue was found to be highly conserved throughout all UDGases and 
has been identified in HSV-1 (McGeoch et al., 1988) and VZV (Davison & Scott, 1986) 
and must serve a similar function to that of the human Asn204 residue.
The phenomenon of uracil acceptance and cytosine exclusion by Asn or Gin can 
also be examined in reverse. In dCMP hydroxymethylase of bacteriophage T4, whose 
natural substrate is dCMP, an aspartate residue is naturally present in the position of this 
asparagine. An analogous Asp 179 to Asn 179 mutation in this enzyme changes the 
substrate specificity to a dUMP hydroxymethylase (Graves et al., 1992). The alteration in 
substrate preference is specific to the D179N mutation, since D179A lacks nucleotide 
specificity, and D179S is completely inactive. The enzyme Hhal methyltransferase also 
discriminates against uracil. It is involved in a variety of biological processes and 
catalyses the transfer of a methyl group from S-adenosyl-L-methionine to the C-5 position 
of cytosine. In this enzyme there is a direct interaction between a glutamate residue 
G lull9  and the N3 and N4 atoms of the cytosine ring again indicating the specificity of 
either glutamate or aspartic acid for cytosine rather than uracil.
Therefore, it seems likely that the highly conserved nature of Asn229 was not 
simply to stabilise dUMP in the active site but to prevent the binding of dCMP. These 
interactions of asparagine or glutamine with uracil, and aspartic acid or glutamate with 
cytosine may represent a general theme in protein nucleic acid recognition
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9.1. Protein-protein interactions in VZV TS
Affinity chromatography experiments were performed in order to identify proteins 
interacting with VZV TS. In these studies no other proteins were found to interact with 
VZV TS. This however, was not a fully exhaustive search and it could be that if the 
experimental approach used had been improved in several areas then interacting proteins 
may have been identified. It is likely that such interactions do occur. Co- 
immunoprecipitation studies have shown that replication complexes exist in the nucleus of 
HSV-1, all seven of the virally-encoded replication proteins, along with the components 
of the cellular replication machinery, localise to the nucleus in replication compartments 
(Olivio et a l, 1989; Goodrich et al., 1990; Lukonis & Weller, 1996). To pursue this idea 
we would require an antibody for VZV TS.
9.2. Mutagenesis studies
The original aim of this study was to examine the structural/functional 
relationships in VZV TS by producing a series of temperature sensitive mutants targeted 
to various regions of the protein. A conservation paradox exists for members of the TS 
family as there are many fully conserved residues which can be substituted without loss 
of catalytic activity. Previous work has centred on replacing these conserved residues one 
by one and observing the affect they have on catalysis, these studies however tended to be 
non-informative. A region directed mutagenesis approach was therefore used to generate 
temperature sensitive mutants in both buried and solvent exposed region of the enzyme. 
Unlike other approaches which had specifically targeted conserved residues this approach 
randomly identified residues that were important for protein stability in targeted regions of 
the protein. Many of the temperature sensitive mutants had previously been generated in 
E.coli and Lcasei and had been shown to be inactive when examined for activity at 37°C. 
We have shown that these mutations can be accommodated at 30°C when there is more 
order to the enzyme structure. Detailed examination of these mutants on the VZV model 
have provided some insight into what may be happening at the structural level. The region 
directed mutagenesis approach can be applied to any protein for which an expression 
system and in vivo assay are available.
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9.3. Unique interactions at the C-terminus of VZV TS
Much work has centred on the C-terminus, because it has been implicated heavily 
in catalysis and closing down the active site. Our studies have shown that VZV TS can 
retain a small amount of activity even without the C-terminal tail, which moves to form a 
lid over the active site upon ligand binding. Although the mutants can complement Thy' 
bacteria they cannot form a tightly closed ternary complex upon ligand binding as 
reflected by their high folate values. The mutants have a lower dUMP values 
which indicate the enzyme is present in a more open conformation allowing the substrate 
to enter more readily. These findings have been confirmed by the increased sensitivity to 
phenolphthalein again indicating that the inhibitor can access the active site more readily.
It had previously been proposed that the C-terminus of VZV has hydrophobic 
interactions rather than the hydrogen bond network which is present in the bacterial 
enzymes. These hydrophobic interactions were thought to involve Met299, but this 
residue has been removed in two of the C-terminal deletion mutants. Clearly our 
understanding of the full range of interactions is incomplete.
9.4. Protein-nucleic acid interactions
The interactions between asparagine or glutamine and aspartic acid or between 
glutamic acid and cytosine could be a general theme in protein-nucleic acid recognition. 
We have shown that Asn214 discriminated between dUMP and dCMP as a substrate. 
When this residue is mutated to an aspartic acid then the enzyme becomes sensitive to 
dCMP inhibition. Further work on this residue would involve examining dCMP as a 
substrate for TS in a modified assay. In E.coli the N177D mutant has activity on both 
dUMP and dCMP, with dCMP being a considerably more reactive substrate. In the 
tritium release assay, the N177D variant has an initial velocity with dCMP which is 35 
fold faster then that obtained with dUMP.
A clearer understanding of the results in this thesis can only be obtained when the 
crystal structure of VZV TS has been solved. This work is now underway in 
collaboration with Adrian Lapthome. At present all predictions have been made on the 
VZV TS model which has been produced from the E.coli crystal structure.
170
References
References
Ace, C.I., McKee, T.A., Ryan, J.M., Cameron, J.M. and Preston, C .M .
(1989). Construction and characterisation of a herpes simplex virus type 1 mutant 
unable to transinduce immediate-early gene expression. J. Virol. 63, 2260-2269.
Albani, D., Parisi, B., Carbonera, D. and Celia, R. (1985). Dihydrofolate 
reductase from Daucas carota cell suspension cultures: purification, molecular and kinetic 
characterization. Plant Molecular Biology 5, 363-372.
Allen, J.R., Reddy, G.P.V., Lasser, G.W. and Matthews, C.K. (1 9 8 0 ).
T4 ribonucleotide reductase. J. Biol. Chem. 255, 7583-7588.
Arvin, A.M., Kushner, J.H., Feldman, S., Baehner, R.I., Hammond, D . 
and Merigan, T.C. (1982). Human leukocyte interferon for treatment of varicella in 
children with cancer. N. Engl. J. Med. 306, 761-767.
Aull, J.L., Lyon, J.A. and Dunlap, R.B. (1974). Gel electrophoresis as a 
means of detecting ternary complex formation of thymidylate synthetase. Microchemistry 
Journal 19, 210-218.
Ayusawa, D., Shimizu, K., Koyama, H., Kaneda, S., Takeishi, K. and 
Seno, T. (1986). Cell-cycle directed regulation of thymidylate synthase messenger 
RNA in human diploid fibroblasts stimulated to proliferate. J. Mol. Biol. 190, 559-567.
Bachmann, B.J. (1983). Linkage map of E.coli K12, edition 7. Microbiol. Reviews 
47, 180-230.
Bachman, B. and Follman, H (1987). Deoxyribonucleotide biosynthesis in green 
algae: characterization of thymidylate synthase-dihydrofolate reductase in Scenedesmus 
obliquus. Arch. Biochem. Biophys. 256, 244-252.
Baer, R., Bankier, A.T., Biggin, M.D., Deninger, P.L., Farrell, P .J .,  
Gibson, T.J., Hatfull, G., Hudson, G.S., Satchwell, S.C., Seguin, C ., 
Tuffnell, P.S. and Barrell, B.G. (1984). DNA sequence and expression of B95- 
8 Epstein-Barr virus genome. Nature 310, 207-211.
Balestrazzi, A., Branzoni, M., Carbonera, D., Parisi, B. and Celia, R . 
(1995). Biochemical evidence for the presence of a bifunctional dihydrofolate reductase- 
thynidylate synthase in plant species. J. Plant Physiol. 147, 263-266.
Balfour, H.H. (1993). Current management of VZV-infection. J.Med. Virol. Suppl. 
1, 74-81.
Barr, P.J., Nolan, P.A., Santi, D.V. and Robins, M.J. (1981). Inhibition of 
thymidylate synthetase by 5-alkynyl-2'-deoxyuridylate. J. Med. Chem. 24, 1385-1388.
Baskin, F., Carlin, S.C., Kraus, P., Friedkin, M. and Rosenberg, R .N . 
(1975). Experimental chemotherapy of neuroblastoma II. Increased thymidylate 
synthetase activity in a 5-fluoro-2'-deoxyuridine resistant vriant of mouse neuroblastoma. 
Molec. Pharm. 11, 105-117.
Beauchamp, I.M., Orr, G.F., Demiranda, P., Burnette, T. and K renitsky, 
T.A. (1992). Amino-acid ester prodrugs of acyclovir. Antiviral Chemistry and 
Chemotherapy 3(3), 157-164.
Beaudette, N.V., Langerman, N. and Kisliuk, R.L. (1980). A calometric 
study of the binding of 2'-deoxyuridine-5'-phosphate and its analogues to thymidylate 
synthetase. Arch. Biochem. Biophys. 200, 410-417.
Bellisario, R.L., Maley, G.F, Galivan, J.H. and Maley, F. (1976). Proc.
Natl. Acad. Sci. USA. 13, 1848.
Ben-Porat, T. and Rixon, F.J. (1979). Replication of herpesvirus DNA. Analysis
of concatamers. Virology. 94, 61-70.
Beverley, S.M., Ellenberger, T.E. and Coordingley, J.S . (1986). Primary 
structure of the gene encoding the bifunctional dihydrofolate reductase-thymidylate 
synthase of Leishmania major. Proc. Natl. Acad. Sci. USA.. 83, 2584-2588.
Blakley, R.L. (1963). The biosynthesis of thymidylic acid IV. Further studies on
thymidylate synthase. J. Biol. Chem. 238, 2113-2118.
Boehmer, P.E. and Lehman, I.R. (1993). Physical interaction between the herpes
simplex virus 1 origin-binding protein and single stranded DNA-binding ptrotien ICP8 . 
Proc. Natl. Acad. Sci. USA 90, 8444-8448.
References
Booy, F.P., Newcomb, W.W., Trus, B.L., Brown, J.C., Baker, T .S .  
and Steven, A.C. (1991). Liquid-crystalline, phage-like packing of encapsidated
DNA in herpes simplex virus. Cell 64, 1007-1015.
Brock, B.V., Selke, M.A., Benedetti, J., Douglas, J.M and Corey, L .
(1990). Frequency of assymptomatic shedding of HSV in women with genital herpes. 
JAMA. 263, 418-420.
Brown, M.D. (1993). Distribution and characterisation of mutations induced by the 
nitrous acid or hydroxylamine in the intron-containing thymidylate synthase gene of 
bacteriophage T4. Biochem. Genetics. 31, 507.
Bugg, C.E., Carson, W.M. and Montgomery J.A. (1993). Drugs by design.
Scientific American 269(6), 92-98.
Burdeska, A., Ott, M., Bannwarth, W. and Then, R.L. (1990). Identical 
genes from trimethoprim-resistant dihydrofolate reductase from Staphylococcus aureus in 
Australia and Central Europe. FEBS. 266, 159-162.
Bures, A.K., Daron, H.H. and Aull, J.L. (1991). Inhibition of thymidylate 
synthase by glyceraldehyde-3-phosphate. International Journal o f Biochemistry 23, 733- 
736.
Bzik, D.J., Li, W., Horii, T. and Inselburg, J. (1987). Molecular cloning and 
sequence analysis of the Plasmodium flaciparum dihydrofolate reductase-thymidylate 
synthase gene. Proc. Natl. Acad. Sci. USA..
Calabresi, P. and Chabner, B.A. (1990). Antineoplastic agents. In Goodman and 
Gilman's The Pharmacological Basis of Therapeutics pp 1223-1227. A. Goodman. T.W. 
Rail, A.S. Nies and P. Taylor. New York: Pergamon Press.
Calvert, A.H., Newell, D.R., Jackman, A.L., Gumbrell, L.A., Sikora, 
E., Grzelakowska-Sztabert, B., Bishop, J.A.M., Judson, I.R., Harland, 
S. and Harrap, K.R. (1987). Recent preclinical and clinical studies with the TS 
inhibitor Nl0-propargyl-5,8 ,dideazafolic acid (CB3717). Natl. Cancer. Inst. Monogr. 5 ,  
213-218.
Cantwell, B.M.J., MacAulay, V., Harris, A.L., Kaye, S.B., Smith, I .E .,  
Milsted, R.A. and Calvert, A.H. (1988). Phase II study of the antifolate N 10-
propargyl-5,8-dideazafolic acid (CB3717) in advanced breast cancer. Eur. J. Cancer Clin. 
Oncol. 24, 733-736.
Capco, G.R., Krupp, T.L. and Matthews C.K. (1973). Bacteriophage-coded 
thymidylate synthetase: characteristics of the T4 and T5 enzymes. Archives Biochem. 
Biophys. 158, 726-775.
Carreras, C.W., Costi, P.M. and Santi, D.V. (1994). Heterodimeric
thymidylate synthases with a C-terminal deletion on one subunit. J. Biol. Chem. 
269(17), 12444-12446.
Carreras, C.K., Climie, S.C. and Santi, D.V. (1992). Thymidylate synthase 
with a C-terminal deletion catalyses partial reactions but is unable to catalyse thymidylate 
formation. Biochemistry 31, 6038-6044.
Carreras, C.W. and Santi, D.V.(1995). The catalytic mechanism and structure of 
thymidylate synthase. Ann. Rev. Biochem. 64, 721-762.
Casey, T.A., Ruyechan, W.T., Flora, M.N., Reinhold, W., Straus, S .E .  
and Hay, J. (1985). Fine mapping and sequencing of a variable segment in the 
inverted repeat region of varicella-zoster virus DNA. J. Virol. 54, 639-642.
Castro, M.G., Spruce, B.A., Savva, D. and Lowry, P.J. (1 9 9 0 ).
Expression of biologically active human pre-procorticotropin releasing hormone in E.coli: 
characterisation and purification. Int. J. Biochem. 22(11), 1341-1349.
Celia, R., Nielsen, E., and Parisi, B. (1988). Daucus-carota cells contain a
dihydrofolate-reductase-thymidylate synthase bifunctional polypeptide. Plant Molecular 
Biology 10(4), 331-338.
Celia, R., Carbonera, D., Orsi, R., Ferri, G, Iadarola, P. (1 9 9 1 ).
Proteolytic and partial sequencing studies of the bifunctional dihydrofolate reductase- 
thymidylate synthase from daucus-carota. Plant Molecular Biology 16(6), 975-982.
Celia, R. and Parisi, B. (1993). Dihydrofolate reductase and thymidylate synthase 
in plants: an open problem. Physiologia Plantarum 88 , 509-521.
References
Chang Y, Cesarman E, Pessin M, Lee F, Culpepper, J Knowles D. and 
Moore P. (1994). Identification of herpesvirus-like DNA in AIDS-associated Kaposi’s 
sarcoma. Science 266, 1865-1869.
Chee, M.S., Bankier, A.T., Beck, S., Bohni, R., Brown, C. M., Cerny, 
R., Horsnell, T., Hutchinson, C.A., Kouzarides, T., Martigetti, J .A .,  
Preddie, E., Satchwell, S.C., Tomlinson, P., Weston, K.M. and Barrell, 
B.G. (1990). Analysis of the protein-coding content of the sequence of the human 
cytomegalovirus strain AD 169. Curr. Tops. Micro. Immun. 154, 125-169.
Chen, S., Daron, H.H. and Aull, J.L. (1988). Inhibition of thymidylate
synthase by pyridoxal phosphate. FASEB Journal 2, A1546.
Chen, S., Daron, H.H. and Aull, J.L. (1989). Inhibition of thymidylate 
synthase by pyridoxal phosphate. International Journal of Biochemistry 21, 1217-1221.
Chen, D. and Olivio, P.D. (1994). Expression of the VZV origin-binding protein 
and analysis of its site-specific DNA-binding properties. J. Virol. 68 (6), 3841-3849.
Cheng, Y.-C. Tsou, T.Y., Hackstadt, T. and Mallavia, L.P. (1979).
Induction of thymidine kinase and DNase in varicella-zoster virus-infected cells and 
kinetic properties of the virus induced thymidine kinase. J. Virol. 31, 172-177.
Cheung, A.K. (1989). DNA-sequence and comparative analyses of the equine 
herpesvirus type-1 immediate early gene. Nucl. Acid Res. 17(12), 4637-4646.
Chiu, C.-S., Cook, K.S. and Greenberg, G.R. (1982). Characteristics of 
bacteriophage T4-induced complex synthesizing deoxyribonucleotides. J. Biol. Chem. 
257, 15087-15097.
Chothia, C., Levitt, M. and Richardson, D. (1977). Structures of proteins: 
packing of a-helices and pleated sheets. Proc. Natl. Acad. Sci. USA 74, 4130-4134.
Chu, E., KoeUer, D.M., Casey, J.L., Drake, J.C., Chabner, B .A .,  
Elwood, P.C., Zinn, S. and Allegra, C.J. (1991). Autoregulation of human TS
mRNA translation by TS. Proc. Natl. Acad. Sci. USA 88 , 8977-8981.
Chu, E., Voeller, D., Koeller, D.M., Drake, J.C., Takimota, C .H .,  
Maley, G.F., Maley, F. and Allegra, C.J. (1993). Identification of an RNA 
binding site for human thymidylate synthase. Proc. Natl. Acad. Sci. USA. 90, 517-521.
Chung C.T. and Miller, R.H. (1988). A rapid and convenient method for the 
preparation and storage of competent bacterial cells. Nucl. Acids Res. 16, 3580.
Cisneros, R.J., Zapf, J.W. and Dunlap, R.B. (1993). Studies of 5- 
fluorodeoxyuridine-5'-monophosphate binding to carboxypeptidase A-inactivated 
thymidylate synthase from Lactobacillus casei. J. Biol. Chem. 268(14), 10102-10108.
Clements, J.B., Watson, R.J. and Wilkie, N.M. (1977). Temporal regulation 
of herpes simplex virus type 1 transcription: location of transcripts on the viral genome. 
Cell 12, 275-285.
Climie, S., Ruiz-Perez, L., Gonzalez-Pacanowska, D., Prapunwattana, 
P., Sung-Woo, C., Stroud, R. and Santi, D.V. (1990). Saturation site- 
directed mutagenesis of thymidylate synthase. J. Biol. Chem. 265 (31), 18776-18779.
Cohen, F.E., Sternberg, M.J.E. and Taylor, W.R. (1981). Analysis of the 
tertiary structure of protein (3-sheet structures. J. Mol. Biol. 148, 253-272.
Cohen. J.I. and Seidel, K.E. (1993). Generation of varicella-zoster virus (VZV) 
and viral mutants from cosmid DNAs - VZV thymidylate synthetase is not essential for 
replication in vitro. Proc. Natl. Acad. Sci. USA 90(15), 7376-7380.
Conrad, A.H. (1971) Thymidylate synthetase activity in cultured mammalian cells. J. 
Biol. Chem. 246, 1318-1328.
Conrad, A.H. and Ruddle, F.H. (1972). Regulation of thymidylate synthetase 
activity in cultured mammalian cells. J. Cell Science 10, 471-486.
Courtney, R.J., Schaffer, P.A. and Powell, K.L. (1976). Synthesis of virus 
specific polypeptides by temperature sensitive mutants of herpes simplex virus type 1. 
Virology IS, 306-318.
Creighton, T.E. (1993). Proteins. Structure and Molecular Properties (second 
edition). W.H. Freeman and Company.
References
Croen, K.D., Ostrove, J.M., Dragovic, L.J. and Straus, S.E. (1 9 8 8 ).
Patterns of gene expression and sites of latency in human nerve ganglia are different for 
varicella-zoster and herpes simplex viruses. Proc. Natl. Acad. Sci. USA. 85, 9773- 
9777.
Croen, K.D., Ostrove, J.M., Dragovic, L.J., Smialek, J.E. and Straus, 
S.E. (1987). Latent HSV in human trigeminal ganglia. N. Eng. J. Med. 317, 1427- 
1432.
Crusberg, T.C., Leary, R. and Kisluik, R.L. (1970). Properties of 
thymidylate synthetase from dichloromethotrexate-resistant Lactobacillus casei. J. Biol. 
Chem. 245, 5292-5296.
Danenberg, K.D. and Danenberg, P.V. (1979). Evidence for a sequential 
interaction of the subunits of thymidylate synthase. J. Biol. Chem. 254, 4345-4348.
Danenberg, K.D. and Danenberg, P.V. (1989). Activity of thymidylate 
synthetase and its inhibition by 5-fluorouracil in highly enzyme-overproducing cells 
resistant to 10-propargyl-5,8-dideazafolate. Molec. Pharm. 36, 219-223.
Danenberg, P.V., Langenbach, R.J. and Heidelberger, C. (1974). Structure 
of the reversible and irreversible complexes of thymidylate synthetase and fluorinated 
pyrimidine nucleotides. Biochemistry 13, 926-933.
Darby, G. (1993). The acyclovir legacy: Its contribution to antiviral drug discovery. 
J. Med. Virol. Suppl. 1, 134-138.
Daron, H. and Aull, J.L. (1978). A kinetic study of thymidylate synthetase from 
L.casei. J. Biol. Chem. 253, 940-945.
Davison, A.J. (1984). Structure of the genome termini of VZV. J. Gen. Virol. 65, 
1969-1977.
Davison, A.J. (1991). Varicella-Zoster Virus.(The 14th Fleming Lecture). J. Gen. 
Virol. 72, 475-486.
Davison, A.J. (1992). Channel catfish virus: a new type of herpesvirus. Virology. 
186, 9-14.
Davison, A.J. and McGeoch, D.J. (1986). Evolutionary comparisons of the S 
segments in the genomes of herpes simplex virus type 1 and varicella-zoster virus. J. 
Gen. Virol. 67, 597-611.
Davison, A.J. and Scott, J.E. (1985). DNA sequence of the major inverted repeat 
in the varicella-zoster virus genome. J. Gen. Virol. 66, 207-220.
Davison, A.J. and Scott, J.E. (1986). The complete sequence of varicella-zoster 
virus. J. Gen. Virol. 67, 1759-1816.
Davison, A.J. and Wilkie, N.M. (1981). Nucleotide sequence of the joint 
between the L and S segments of herpes simplex virus types 1 and 2. J. Gen. Virol. 55, 
315-331.
Davison, A.J. and Wilkie, N.M. (1983). Location and orientation of homologous 
sequences in the genomes of five herpesviruses. J.Gen. Virol. 64, 1927-1942.
DeLuca, N.A., McCarthy, A.M. and Schaffer, P.A. (1985). Isolation and 
characterisation of the deletion mutants of herpes simplex virus type 1 in the gene 
encoding the immediate-early regulatory protein ICP4. J. Virol. 56, 558-570.
Deluca, N.A. and Schaffer, P.A. (1988). Physical and functional domains of the 
herpes simplex virus transcriptional regulatory protein ICP4. J. Virol. 62, 732-743.
Dev, I.K., Yates, B.B., Atashi, J. and Dallas, W.S. (1989). Catalytic role of 
histidine 147 in Escherichia coli thymidylate synthase. J. Biol. Chem. 264, 19132- 
19137.
Dev, I.K., Yates, B.B., Leong, J. and Dallas, W.S. (1988). Functional role 
of cysteine 146 in E.coli thymidylate synthase. Proc. Natl. Acad. Sci. 85, 1472-1476.
Disney, G.H. and Everett, R.D. (1990). A herpes simplex type 1 recombinant 
with both copies of Vmw 175 coding sequences replaced by the homologous varicella- 
zoster virus open reading frame. J. Gen. Virol. 71, 2681-2689.
Disney, G.H., McKee, T.A., Preston, C.M. and Everett, R.D. (1 9 9 0 ).
The product of varicella-zoster virus gene 62 autoregulates its own promoter. J. Gen. 
Virol. 71, 2999-3003.
References
Dixon, R.A.F. and Schaffer, P.A. (1980). Fine-structure mapping and analysis 
of temperature sensitive mutants in the gene encoding the herpes simplex virus type 1 
immediate early protein VP 175. J. Virol. 36, 189-203.
Donato, H., Aull, J.L., Lyon, J.A., Reinsch, J.W. and Dunlap, R .B . 
(1976). Formation of the ternary complexes of thymidylate synthetase as followed by 
absorbance, fluorescence and circular dichroism spectra and gel electrophoresis. J. Biol. 
Chem. 251, 1303-1310.
Duch, D.S., Banks, S., Dev, I.K., Dickerson, S.H., Ferone, R., Heath, 
L.S., Humphreys, J., Knick, V., Pendergast, W., Singer, S., Smith, G .,  
Waters, K. and Wilson, R. (1993). Biochemical and cellular pharmacology of 
1849U89, a novel benzoquinazoline inhibitor of thymidylate synthase. Cancer Res. 53, 
810-818.
Dumas, A.M., Geelan, J.L.M.C., Weststrate, M.W. and Van Der 
Noordaa, J. (1981). Xbal, PstI and Bglll restriction exonuclease maps of the two 
orientations of the varicella-zoster virus genome. J. Virol. 39, 390-400.
Duncan, C.H., Wilson, G.A. and Young, F.E. (1979). Transformation of 
Bacillus subtilis and Escherichia coli by a hybrid plasmid pCDI. Gene 1, 153-167.
Ecker, J.R and Hyman, R.W. (1982). Varicella zoster virus DNA exists as two 
isomers. Proc. Natl. Acad. Sci. USA. 70, 156-160.
Eckstein, J.W., Foster, P.G., Finer-Moore, J. S., Wataya, Y and Santi, 
D.V. (1993). Mechanism-based inhibition of thymidylate synthase by 5- 
(Trifluoromethyl)-2'-deoxyuridine 5'-monophosphate. Biochemistry 33, 15086-15094.
Ehrlich, S.D. Bursztyn-Pettigrew, A., Stroynowski, I. and Lederberg, J . 
(1976). Expression of thymidylate sytnthase gene of Bacillus subtilis bacteriophage phi- 
3-T in Escherichia coli. Proc. Natl. Acad. Sci. USA 73, 4145-4149.
Elion, G.B. (1983). The biochemistry and mechanism of action of acyclovir. J. 
Antimicrob. Chemo. 12, 9-17.
Elion, G.B. (1993). Acyclovir: Discovery, mechanism of action, and selectivity.
(1993). J. Med. Virol. Suppl. 1, 2-6.
Evans, S.V. (1993). “Setor”: hardware lighted three dimensional solid model 
representations of macromolecules. J. Mol. Graphics 11, 134-138.
Everett, R.D. (1984). Transactivation of transcription by herpesvirus products. 
Requirements for two HSV-1 immediate early polypeptides for maximum activity. EMBO 
Journal 3, 3135-3141.
Everett, R.D. and Dunlop, M. (1984). Transactivation of plasmid bome 
promoters by adenovirus and several herpes group viruses. Nuc. Acid. Res. 12, 5969- 
5978.
Fauman, E.B., Rutenber, E.E., Maley, G.F., Maley, F. and Stroud, R.M.
(1994). Water-mediated substrate/product discrimination: the product complex of
o
thymidylate synthase at 1.83A. Biochemistry 33, 1502-1511.
Felser, J.M., Kinchington, P.R., Ichauspe, G., Straus, S.E. and 
Ostrove, J.M. (1988). Cell lines containing varicella-zoster virus open reading frame 
62 and expressing the “IE” 175 protein complement ICP4 mutants of herpes simplex type 
1. J. Virol. 62, 2076-2082.
Ferone, R. and Roland, S. (1980). Dihydrofolate reductase: thymidylate synthase, 
a bifunctional polypeptide from Crithidia fasiculata. Proc. Natl. Acad. Sci. USA. 77, 
5802-5806.
Fields, S. and Song, O-K. (1989). A novel genetic system to detect protein- 
protein interactions. Nature 340, 245-246.
Finer-Moore, J.S., Montfort, W.R. and Stroud, R.M. (1990). Pairwise 
specificity and sequential binding in enzyme catalysis: thymidylate synthase.
Biochemistry 29, 6977-6986.
Finer-Moore, J.S, Fauman, E.B., Foster, P.G., Perry, K,M., Santi, D.V. 
and Stroud, R.M. (1993). Refined structures of substrate-bound and phosphate 
bound TS from L.casei. J. Mol. Biol. 232, 1101-1116.
Finer-Moore, J.S., Fauman, E.B., Morse, R.J., Santi, D.V. and Stroud, 
R.M. (1996). Contribution of a salt bridge to binding affinity and dUMP orientation to 
catalytic rate: mutation of a substrate-binding arginine in thymidylate synthase. Protein 
Engineering 9(1), 69-75.
References
Frasca, V., LaPat-Polaska, L., Maley, G.F. and Maley, F. (1988). Site- 
directed mutagenesis of the T4-phage thymidylate synthase gene. In Proceedings o f the 
1988 Miami Bio/Technology Winter Symposium, P I49 (K. Brew et al., Editors). IRL 
Press, Washington, D.C.
Freemantle, S.J., Lunec, J., Jackman, A.L., Kelland, L.R., Ahem e, 
G.W. and Calvert, A.H. (1993). Molecular characterisation of three cell lines 
selected for resistance to folate-based thymidylate synthase inhibitors. Brit J. Cancer. 
67(20), 79.
Friedkin, M., Crawford, E., Humphreys, S.R. and Goldin, A. (1 9 6 2 ).
The association of increased dihydrofolate reductase with amethopterin resistance in 
mouse leukemia. Cancer Res. 22, 600-606.
Furlong, D., Swift, H. and Roizman, B. (1972). Arrangement of the
herpesvirus DNA in the core. J. Virol. 10, 1071-1074.
Furuta, Y., Takasu, T. and Fukuda, S. (1992). Detection of VZV DNA in
human geniculate ganglia by PCR. J. Infect. Dis. 166, 1157-1159.
Fyfe, J.A., Kellar, P.M., Furman, P.A., Miller, R.L. and Elion, G .B . 
(1978). Thymidine kinase from herpes simplex virus phosphorylates the new antiviral 
compound 9-(2-hydroxymethyl)guanine. J. Biol. Chem. 253, 8721-8727.
Gabel, C.A., Dubey, L., Steinberg, S.P., Sherman, D. Gershon, M .D .
and Gershon, A.A. (1989). Varicella-zoster virus glycoprotein oligosaccharides are 
phosphorylated during post-translational maturation. J. Virol. 63, 4264-4276.
Galivan, J.H., Maley, G.F. and Maley, F. (1975). The effect of substrate 
analogues on the circular dichroic spectra of thymidylate synthetase from Lactobacillus 
casei. Biochemistry 14, 3338-3344.
Galivan, J.H., Maley, G.F. and Maley, F. (1976a). Demonstration of separate 
binding sites for the folate coenzymes and deoxynucleotides with inactivated L.casei 
thymidylate synthetase. Biochem. Biophys. Res. Comm. 71, 527-534.
Galivan, J.H., Maley, G.F. and Maley, F. (1976b). The effect of substrate 
analogues on the circular dichroism spectra of thymidylate synthetase from Lactobacillus 
casei. Biochemistry 15, 356-362.
Garrett, C., Wayata, Y. and Santi, D.V. (1979). Thymidylate synthetase 
catalysis of dehalogenation of5-bromo- and 5-iodo-2'-deoxyuridylate. Biochemistry 18, 
2798-2804.
Garrett, C.E., Coderre, J.A., Meek, T.D., Garvey, E.P., Claman, D .M ., 
Beverley, S.M. and Santi, D.V. (1984). A bifunctional thymidylate synthase- 
dihydrofolate reductase in protozoa. Molec. Biochem. Parisitol. 11, 257-265.
Garvey, E.P. and Santi, D.V. (1985). Limited proteolysis of the bifunctional 
thymidylate synthase-dihydrofolate reductase from Leishmania tropica. Proc. Natl. Acad. 
Sci. USA. 82, 7188-7192.
Garvey, E.P. and Santi, D.V. (1987). A stable binary complex between 
Leishmania major thymidylate synthase and the substrate deoxyuridylate: A slow-binding 
interaction. J. Biol. Chem. 262, 9068-9074.
Gershon, A.A., Cosio, L. and Brunell, P.A. (1973). Observations on the
growth of varicella-zoster vims in human diploid cells. J. Gen. Virol. 18, 21-31.
Gershon, A.A., Sherman, D.L., Zhu, Z., Gabel, C.A., Ambron, R.T. and 
Gershon, M.D. (1994). Intracellular transport of newly synthesised varicella-zoster 
virus: final envelopment in the trans-Golgi network. J. Virol. 68, 6372-6390.
Gerster, T. and Roeder, R.G. (1988). A herpesvirus trans-activating protein 
interacts with transcription factor OTF-1 and other cellular proteins. Proc. Natl. Acad. 
Sci. USA 85(17), 6347-6351.
Gilden, D.H., Rosenman, Y., Murray, R., Devlin, A. and Vafai, A .
(1987). Detection of varicella zoster vims nucleic acid in neurons of normal human
thoracic ganglia. Ann. Neurol. 22, 377-380.
Gokhale, R.J., Agarwalla, S., Francis. V.S., Santi, D.V. and Balaram, 
P. (1994). Thermal stabilization of thymidylate synthase by engineering two disulphide 
bridges across the dimer interface. J. Mol. Biol. 235, 89-94.
Goodrich, L.D. Schaffer, P.A., Dorsky, D.I., Crumpacker, C.S. and 
Parris, D.S. (1990). Localisation of the herpes simples vims type 1 65-kilodalton 
DNA-binding protein and DNA polymerase in the presence and absence of viral DNA
References
synthesis. J. Virol. 64, 5738-5749.
Graves, K.L., Butler, M.M. and Hardy, L.W. (1992). Roles of Cys198 and 
Asp179 in catalysis by deoxycytidylate hydroxymethylase from bacteriophage examined by 
site-directed mutagenesis. Biochemistry 31, 10315-21.
Grivell, A.R. and Jackson, J.F. (1968). Thymidine kinase: evidence for its 
absence from Neurospora crassa and some other microoragnisms and the relevance of this 
to the specific labelling of deoxyribonucleic acid. J. Gen. Micro. 54, 307-317.
Grumont, R., Washtien, W.L., Caput, D. and Santi, D.V. (1 9 8 6 ).
Bifunctional thymidylate synthase-dihydrofolate reductase from Leishmania tropica: 
sequence homology with the corresponding monofunctional proteins. Proc. Natl. Acad. 
Sci. USA. 83, 5387-5391.
Hardy, L.W., Finer-Moore, J.S., Montfort, W.R., Jones, M.I., Santi, 
D.V. and Stroud, R.M. (1987). Atomic structure of thymidylate synthase: target for 
rational drug design. Science 235, 448-455.
Hardy, L.W. and Nalivaika, E. (1992). Asn177 in Escherichia coli thymidylate 
synthase is a major determinant of pyrimidine specificity. Proc. Natl. Acad. Sci. USA. 
89, 9725-9729.
Harrap, K.R., Jackman, A.L., Newell, D.R., Taylor, G.A., H ughes, 
L.R. and Calvert, A.H. (1989). Thymidylate synthase: a target for anticancer drug 
design. Adv. Enz. Reg. 29, 161-179.
Harrison, P.T., Scott, J.E., Hutchinson, M.J. and Thompson, R. (1 9 9 5 ).
Site-directed mutagenesis of varicella-zoster virus thymidylate synthase - analysis of 2 
highly conserved regions of the enzyme. European Journal Of Biochemistry 2 3 0 (2 ),  
511-516.
Hayakawa, Y. and Hyman, R.W. (1987). Isomerization of the UL region of 
varicella zoster virus DNAs of clinical isolates by endonuclease Hpal. J. Gen. Virol. 67, 
1817-1829.
Heidelberger, C., Kaldor, G., Mukherjee, K.L., and Danenberg, P .B .  
(1960). Studies on fluorinated pyrimidines XI. In vitro studies on tumour resistance. 
Cancer Research 20, 903-909.
Helene, C. and Tolume, J.-J. (1990). Specific regulation of gene expression by 
antisense, sense and antigene nucleic acids. Biochimie et Biophysica Acta 1049, 99-125.
Hoffbrand, A.V., Tripp, E., Houlihan, C.M. and Scott, J.M. (1990).
Studies on the uptake of synthetic conjugated folates by human marrow cells. Blood 42, 
141-146.
Hondo, R. and Yogo, Y. (1988). Strain variation of R5 direct repeats in the right- 
hand portion of the long unique segment of varicella zoster virus DNA. J. Virol. 62, 
2916-2921.
Honess, R.W., Bodemer, W., Cameron, K.R., Niller, N .H .,  
Fleckenstein, B. and Randall, R.E. (1986). The A+T rich genome of
herpesvirus saimiri contains a highly conserved gene for thymidylate synthase. Proc. 
Natl. Acad. Sci. USA. 83, 3604-3608.
Honess, R.W. and Roizman, B. (1974). Regulation of herpesvirus
macromolecular synthesis I. Cascade regulation of the synthesis of three groups of viral 
proteins. J. Virol. 14, 8-19.
Honess, R.W. and Roizman, B. (1975). Regulation of herpesvirus
macromolecular synthesis: sequential transition of polypeptide synthesis requires 
functional viral polypeptides. Proc. Natl. Acad. Sci. USA 72, 1276-1280.
Horie, N., Chimoto, M., Nozawa, R. and Takeishi, K. (1 9 9 3 ).
Characterisation of regulatory sequences and nuclear factors that function in co-operation 
with the promoter of the human thymidylate synthase. Biochem. Biophys. Act. 1219, 
409-416.
Huang, W. and Santi, D.V. (1994). Isolation of a covalent steady-state
intermediate in Glutamate 60 mutants of thymidylate synthase. J. Biol. Chem. 269(50), 
31327-31329.
Hughes, D.E., Opeolu, A., Shonekan, E.A. and Simpson, L. (1 9 8 9 ).
Structure, genomic organization and transcription of the bifunctional dihydrofolate 
reductase-thymidylate synthase gene from Crithidia fasiculata. Mol. Biochem. Parisitol. 
34(2), 155-166.
References
Hyman, R.W., Ecker, J.R. and Tenser, R.B. (1983). Varicella zoster virus 
RNA in human trigeminal ganglia. Lancet 83, 814-816.
Inchauspe, G., Nagpal, S. and Ostrove, J.M. (1989). Mapping of two 
varicella zoster virus-encoded genes that activate the expression of viral early and late 
gene. Virology 173, 700-709.
Ingram V.M. (1956). Nature 792.
Ivanetich, K.M. and Santi, D.V. (1990). Thymidylate synthase-dihydrofolate 
reductase in protozoa. Exper. Parasitol. 70, 367-371.
Iwakura, M., Kawata, M., Tsuda, K. and Tanka, T. (1988). Nucleotide
sequence of the thymidylate synthase B and dihydrofolate reductase genes cloned in one 
Bacillus subtilis operon. Gene 64, 9-20.
Jacob, R.J., Morse, L.S. and Roizman, B. (1979). Anatomy of herpes simplex 
virus DN A. Accumulation of head-to-tail concatemers in nuclei of infected cells and their 
role in the generation of the four isomeric arrangements of viral DNA. J. Virol. 29, 448- 
457.
Jackers, P., Defechereux, P., Baudoux, L., Lambert, C., Massaer, M ., 
Merville-Louis, M-P., Rentier, B. and Piette, J. (1992). Characterisation of 
regulatory functions of the varicella zoster virus gene 63-encoded protein. J. Virol. 
66(6), 3899-3903.
Jackman, A.L., Jodrell, D.I., Gibson, W. and Stephens, T.C. (1991). ICI
D1694, an inhibitor of thymidylate synthase for clinical study. In: R.A. G.B Elion and N. 
Zollner (eds), Purine and Pyrimidine metabolism in man, Vol VII, Part A pp 19-23. New 
York: Plenum press.
Jackman, A.L., Aherne, G., Kimbell, R., Brunton, L., Hardcastle, A .,  
Wardleworth, J.W., Stephens, T.C. and Boyle, F. (1994). ZD 9331, a non- 
polyglutamatable quinazoline thymidylate synthase inhibitor. Proc. Am. Cancer. Assoc. 
Res. 35, 301.
Jackman, A.L., Kelland, L.R., Brown, M., Gibson, W., Kimbell, R .,  
Aherne, W. and Judson, I.R. (1992). ICI D1694 resistant cell lines. Proc. Am.
Assoc. Cancer Res. 33, 406
Jackman, A.L., Marsham, P.R., Moran, R.J., Kimbell, R., O ’Connor,
B.M., Hughes, L.R. and Calvert, A.H. (1991). Thymidylate synthase 
inhibitors: the in vitro activity of a set of heterocyclic benzoyl ring modified 2-desamino- 
2-methyl-N10-substituted-5,8,-dideazafolates. Adv. Enz Reg. 31, 13-27.
Jackman, A.L., Marsham, P.R., Thornton, T.J., Bishop, J .A .M ., 
O'Connor, B.M., Hughes, L.R., Calvert, A.H. and Jones, T.R. (1 9 9 0 ).
Quinazoline antifolate thymidylate synthase inhibitors: 2'-fluoro-N10-propargyl-5,8- 
dideazafolic acid and derivatives with modifications in the C2 position. J. Med. Chem. 
33, 3067-3071.
Jansen, G., Westerhof, G.R., Jarmuszewski, M.J., Kathmann, I . ,  
Rijksen, G. and Schornagel, J.H. (1990). Methotrexate transport in variant 
human crf-cem leukemia cells with elevated levels of the reduced folate carrier. Selective 
effect on carrier mediated transport of physiological concentrations of reduced folate. J. 
Biol. Chem. 265, 18272-18277.
Jastreboff, M., Kedzierska, B. and Rode, W. (1983). Altered thymidylate 
synthetase in 5-fluorodeoxyuridine-resistant Erhlich ascites carcinoma cells. Biochem. 
Pharm. 32, 2259-2267.
Jazwinski, S.M. and Endelman, G.M. (1984). Evidence for participation of a 
multiprotein complex in yeast DNA-replication in vitro. J. Biol. Chem. 259, 6852-6857.
Jenh, C.H., Geyer, P.K. and Johnson, L.F. (1985). Control of thymidylate 
synthase messenger RNA content and gene transcription in an overproducing mouse cell 
line. Mol. Cell. Biol. 5, 2527-2532.
Johnston, P.G., Lenz, H.J,. Leichman, C.G., Danenberg, K.D., A llegra,
C.J., Danenberg, P.V. and Leichman, L. (1995). Thymidylate synthase gene 
and protein expression correlate and are associated with response to 5-fluorouracil in 
human colorectal and gastric tumors. Cancer Research 55(7), 1407-1412.
Jones, T.R., Calvert, A.H., Jackman, A.L., Brown, S.J., Jones, M. and 
Harrap, K.R. (1981). A potent antitumour quinazoline inhibitor of thymidylate 
synthase: synthesis, biological properties and therapeutic results in mice. Eur. J. Cancer 
17, 11-19.
References
Jones, F. and Grose, C. (1988). Role of cytoplasmic vacuoles in glycoprotein 
trafficking and virion envelopment. J. Virol. 62, 2701-2711.
Kallen, R.G. and Jencks, W.P. (1966). The mechanism of condensation of 
formaldehyde with tetrahydrofolic acid. J. Biol. Chem. 241, 5821.
Kamb, A., Finer-Moore, J.S. and Stroud, R.M. (1992). Cofactor triggers the 
conformational change in thymidylate synthase: implications for an ordered binding 
mechanism. Biochemisrty 31, 12876-12884.
Katayama, C. (1990). A modified single-stranded DNA rescue protocol. Strategies in 
Mol. Biol. 4(4), 56-58.
Keyomarsi, K. and Moran, R.G. (1988). Quinazoline folate analogs inhibit the
catalytic activity of thymidylate synthase but allow binding of 5-fluorodeoxyuridylate. J. 
Biol. Chem. 265, 19163-19169.
Keyomarsi, K., Samet, J., Molnar, G. and Pardee, A.B. (1993). The
thymidylate synthase inhibitor, ICI-D1694, overcomes translational detainment of the 
enzyme. J. Biol. Chem. 268(20), 15142-15149.
Kim, C.W., Michaels, M.L. and Miller, J.H. (1992). Amino-acid substitution
analysis of Escherichia coli thymidylate synthase-the study of a highly conserved region 
at the N-terminus. Proteins-Structure Function And Genetics 13(4), 352-363.
Kinchington, P.R., Reinhold, W.C., Casey, T.A., Straus, S.E., Hay, J . 
and Ruyechan, W.T. (1985). Inversion and circularisation of the varicella-zoster 
virus genome. J. Virol. 56, 194-200.
Kinchington, P.R., Vergnes, J.P., Defecherux, P., Piette, J. and Turse, 
S.E. (1994). Transcriptional mapping of the varicella-zoster virus regulatory genes 
encoding open reading frames 4 and 63. J. Virol. 68, 3570-3584.
Knighton, D.R., Kan, C.C., Howland, E., Janson, C.A., Hostomska, Z., 
Welsch, K.M. and Matthews, D.A. (1994). Structure of and kinetic channeling 
in bifunctional dihydrofolate reductase-thymidylate synthase. Nature Struct. Biol. 1 (3 ), 
186-194.
Kobayashi, H., Takemura, Y., Miyachi, H., Skelton, L. and Jackman, 
A .L .(1995). Effect of hammerhead ribozyme against human thymidylate synthase on 
the cytotoxicity of thymidylate synthase inhibitors. Japanese Journal o f Cancer Research 
86(11), 1014-1018.
Koff, A. and Tegmeyer, P. (1988). Characteriztion of major recognition 
sequences for a herpes-simplex virus type 1 origin-binding protein. J. Virol. 6 2 (1 1 ),  
4096-4103.
Kost, R.G., Kupinsky, H. and Straus, S.E. (1995). Varicella-zoster virus gene 
63-transcript mapping and regulatory activity. Virology 209(1), 218-224.
Ktinkel, T.A., (1985). Rapid and efficient site-specific mutagenesis without
phenotypic selection. Proc. Natl. Acad. Sci. USA 82, 488-492.
Ktinkel, T.A., Roberts, J.D., and Zakour, R.A. (1987). Rapid and efficient 
site-specific mutagenesis without phenotypic selection. Methods in Enzymology 54, 367- 
382.
Lagosky, P.A., Taylor, G.R. and Haynes, G .R . (1987). Molecular
characterisation of the Saccharomyces cerevisiae dihydrofolate reductase gene (DHFR1). 
Nuc. Acid Res. 15, 10355-10371.
Langenbach, R. (1976). Thymidylate synthetase of in vitro chemically and virally 
transformed rat cell. Biochimie et Biophysica Acta. 422, 295-301.
Larsson, G., Svensson, L.A. and Nyman, P.O. (1996). Crystal structure of 
the Escherichia coli dUTPase in complex with a substrate analogue (dUDP). Nature 
Structural Biology 3(6), 532-538.
Lazar, G., Hong, Z. and Goodman, H.M. (1993). The origin of the 
bifunctional dihydrofolate reductase thymidylate isogenes of Arabidopsis thaliana. Plant 
Journal 3, 657-668.
Leary, R.P., Beadette, N. and Kisluik, R.L. (1975). Interaction of 
deoxyuridylate with thymidylate synthetase. J. Biol. Chem. 250, 4869-4878.
References
Liedtke, W., Opalka, B., Zimmermann, C.W. and Lignitz, E. (1993). Age
distribution of latent HSV-1 and varicella zoster virus genome in human nervous tissue. 
N. Neurol. Sci. 116, 6-11.
Lim, W.A. and Sauer, R.T. (1989). Alternative packing arrangements in the 
hydrophobic core lambda repressor. Nature 339, 31-36.
Liu, L,. and Santi, D.V. (1992). Mutation of asparagine-229 to aspartate in 
thymidylate synthase converts the enzyme to a deoxycy tidy late methylase. Biochemistry 
31(22), 5100-5104.
Liu, L. and Santi, D.V. (1993a). Exclusion of 2'-deoxcytidine 5'-monophosphate 
by asparagine 229 of thymidylate synthase. Biochemistry 32(36), 9263-9267.
Liu, L. and Santi, D.V. (1993b). Asparagine 229 in thymidylate synthase 
contributes to, but is not essential for catalysis. Proc. Natl. Acad. Sci. USA. 90, 8604- 
8608.
Lockshin, A. and Danenberg, P.V. (1980). Hydrodynamic behaviour of human 
and bacterial thymidylate synthetase and TS-5-fluorodeoxyuridylate-2'deoxyuridylate- 
5,10-methylenetetrahydrofolate complexes. Evidence for large conformational changes 
during catalysis. Biochemistry 19, 4244-4251.
Lu, Y.Z., Aiello, P. and Matthews, R. (1984). Studies on the polyglutamate 
specificity of thymidylate synthetase from fetal pig liver. Biochemistry 23, 6870-6876.
Ludwig, H., Haines, H.G., Biswal, N. and Benyesh-Melnick, M. (1972).
The characterisation of varicella-zoster virus DNA. J. Gen. Virol. 14, 111-114.
Luger, K., Mader, A.W., Richmond, R.K., Sargent, D.F. and Richm ond, 
T .J. (1997). Crystal structure of the nucleosome core particle at 2.8A resolution. 
Nature 389, 251-260.
Lukonis, C.J. and Weller, S.K. (1996). Characterisation of nuclear structures in 
cells infected with herpes simplex virus type 1 in the absence of viral DNA replication. J. 
Virol. 70, 1751-1758.
Mahalingam, R., Wellish, M.C. Dueland, A.N., Cohrs, R.J. and G ilden, 
D.H. (1992). Localisation of HSV and VZV DNA in human ganglia. Ann. Neurol. 
31, 444-448.
Maley, G.F., Maley, F. and Baugh, C.M. (1979). Differential inhibition of 
host and viral thymidylate synthase by folyl-polyglutamates. J. Biol. Chem. 254, 7485- 
7487.
Maley, G. and Maley, F. (1988). Properties of a defined mutant of Escherichia coli 
thymidylate synthase. J. Biol. Chem. 263, 7620-7627.
Manavalan, P., Mittelstaedt, D.M., Schimerlik, M.I. and Johnson, W .C . 
(1986). Conformational analysis of thymidylate synthase from amino acid sequence by 
circular dichroism. Biochemistry 25, 6650-6655.
Maniatis, T., Fritsch, E.F. and Sambrook, J. (1985). Molecular cloning. A 
Laboratory Manual. Cold Spring Harbour Laboratory, Cold Spring Harbour, New York.
Marsden, H.S., Campbell, M.E.M., Haarr, L., Frame, M.C., Parris,
D.S., Murphy, M., Hope, R.G., Muller, M.G. and Preston, C.M. (1987).
The 65,000 Mr DNA-bnding and virion trans-inducing proteins of herpes simplex virus 
type 1. J. Virol. 61, 2428-2437.
Marsden, H.S., Crombie, I.K. and Subak-Sharpe, J.S. (1976). Control of 
protein synthesis in herpes virus-infected cells: analysis of the polypeptides induced in the 
wild and sixteen temperature sensitive mutants of HSV strain 17. J. Gen. Virol. 31, 
347-372.
Marsham, P.R., Hughes, L.R., Jackman, A.L., Hayter, A.J., O ldfield, 
J., Wardelworth, J.M., Bishop, J.A.M., O'Connor, B.M. and Calvert, 
A.H. (1991). Quinazoline antifolate thymidylate synthase inhibitors: heterocyclic 
benzoyl ring modification. J.Med. Chem. 34, 1594-1605.
Matherly, L.H., Schuetz, J.D., Westin, E. and Goldman, I. D. (1989). A
method for the synchronization of cultured cells with aphidicolin: applications to the large- 
scale synchronization of L1210 cells and the study of the cell cycle regulation of 
thymidylate synthase and dihydrofolate reductase. Analytical Biochemistry 182, 338- 
345.
References
Matthews, C.K., North, T.W. and Reddy, G.P.V. (1978). Multienzyme 
complexes in DNA precursor biosynthesis. Adv. Enz. Reg. 17, 133-156.
Matthews, C.K., Moen, L.K., Wang, Y. and Sargent, R.G. (1 9 8 8 ).
Intracellular organisation of DNA precursor biosynthetic enzymes. T.I.B.S. 13, 394-
397.
Mathews, D.A., Appelt, K. and Oatley, S.J. (1989). Stacked beta-bulges in 
thymidylate synthase account for a novel right-handed rotation between opposing beta- 
sheets. J. Mol. Biol. 205, 449-454.
Mathews, D.A., Villafranca, J.E., Janson, C.A., Smith, W.W., W elsh, 
K. and Freer, S. (1990a). Stereochemical mechanism of action for thymidylate 
synthase based on the x-ray structure of the covalent inhibitory ternary complex with 5- 
fluoro-2'-deoxyuridylate and 5, 10-methylenetetrahydrofolate. J. Mol. Biol. 214, 937- 
948.
Mathews, D.A., Appelt, K., Oatley, S.J. and Xuong, N.H. (1990b ).
Crystal structure of Escherichia coli thymidylate synthase containing bound 5-fluoro-2'- 
deoxyuridylate and 10-propargyl-5,8-dideazafolate. J. Mol. Biol. 214, 923-936.
McGaughey, K.M., Wheeler, L.J., Moore, J.T., Maley, G.F., Maley, F . 
and Mathews C.K. (1996). Protein-protein interactions involving T4 phage-coded 
deoxycytidylate deaminase and thymidylate synthase. J. Biol. Chem. 271(38), 23037- 
23042.
McGeoch, D.J. and Davison, A.J. (1986). Alphaherpesviruses possess a gene 
homologous to the protein kinase gene family of eukaryotes and retroviruses. Nucl. Acids 
Res. 14, 1765-1777.
McGeoch, D.J., Barnett, B.C. and MacLean, C.A. (1993). Emerging
functions of alphaherpesvirus genes. Seminars in Virology 4, 125-134.
McGeoch, D.J., Cook, S., Dolan, A., Jamieson, F.E. and Telford,
E.A.R. (1995). Molecular phylogeny and evolutionary timescale for the family of 
mammalian herpesviruses. J. Mol. Biol. 247, 443-458.
McGeoch, D.J., Dalrymple, M.A., Davison, A.J., Dolan, A., Frame, 
M.C., McNab, D., Perry, L.J., Scott, J.E. and Taylor, P. (1988). The
complete DNA sequence of the long unique region in the genome of herpes simplex virus 
type 1. J. Gen. Virol. 69, 1531-1574.
McGeoch, D.J., Dolan, A., Donald, S. and Rixon, F.J. (1985). Sequence 
determination and genetic content of the short unique region in the genome of herpes 
simplex virus type 1. J. Mol. Biol. 181, 1-13.
McGeoch, D.J., Dolan, A., Donald, S. and Brauer, D.H.K. (1 9 8 6 ).
Complete DNA sequence of the short repeat region in the genome of herpes simplex virus 
type 1. Nucl. Acids Res. 14, 1727-1745.
McKee, T.A., Disney, G.H., Everett, R.D. and Preston, C.M. (1 9 9 0 ).
Control of expression of the varicella-zoster virus major immediate early gene. J. Gen 
Virol. 71, 897-906.
McNeil, J.B. and Smith, M. (1985). Saccharomyces cerevisiae CYC1 mRNA 5’- 
end positioning by in vitro mutagenesis, using synthetic duplexes with random mismatch 
base pairs. Mol. Cell Biol. 5, 3545-3551.
Mead, D.A., Szczesna-Skorupa, E. and Kemper, B. (1986). Single-stranded 
DNA “blue” T7 promoter plasmids: a versatile tandem promoter system for cloning and 
protein engineering. Protein Engineering 1, 67-74.
Meek, T.D., Garvey, E.P. and Santi, D.V. (1985). Purification and 
characterisation of the bifunctional thymidylate synthase-dihydrofolate reductase from 
methotrexate-resistant Leismania tropica. Biochemistry 24, 678-686.
Meier, J.L., Holman, R.P., Croen, K.D., Smialek, J.E. and Straus, S .E .  
(1993). VZV transcription in human trigeminal ganglia. Virology 193, 193-200.
Merigan, T.C., Rand, K.H., Pollard, R.B., Abdallah, P.S., Jordan,
G.W. and Fried R.P. (1978). Human leukocyte interferon for the treatment of 
herpes zoster in patients with cancer. N. Eng. J. Med. 298, 981-987.
Michaels, M.L., Mathews, D.A. and Miller, J.H. (1990). Escherichia coli 
thymidylate synthase: amino acid substitutions by suppression of amber nonsense 
mutations. Proc. Natl. Acad. Sci. USA 87, 3957-3961.
References
Moen, L.K., Howell, M.L., Lasser, G.W. and Matthews, C.K. (1 9 8 8 ).
Intracellular organization of DNA precursor biosynthetic-enzymes. Journal o f Molecular 
Recognition 1, 48-57.
Moffatt, B.A., and Studier, F.W. (1987). T7 lysozyme inhibits transcription by
T7 RNA-polymerase. Cell 49(2), 221-227.
Mol, C.M., Arvai, A.S., Slupphug, G., Kavli, B., Alseth, I., Krokan,
H.E. and Tainer, J.A. (1995). Crystal structure and mutational analysis of human 
uracil-DNA glycosylase: structural basis for specificity and catalysis. Cell 80, 869-878.
Mol, C.D., Harris, J.M., McIntosh, E.M. and Tainer, J.A. (1996). Human
dUTP pyrophosphatase: uracil recognition by a (3 hairpin and active sites formed by three 
separate subunits. Structure 4(9), 1077-1092.
Montfort, W.R., Perry, K.M., Fauman, E.B., Finer-Moore, J.S., M aley, 
G.F., Hardy, L., Maley, F. and Stroud, R.M. (1990). Structure, multiple site 
binding, and segmental accommodation in thymidylate synthase on binding dUMP and an 
anti-folate. Biochemistry 29, 6964-6977.
Moore, M.A., Ahmed, F. and Dunlap, R.B. (1986). Evidence for the existence 
of covalent nucleotide-thymidylate synthase complexes, identification of sites of 
attachment, and enhancement by folates. J. Biol. Chem. 261, 12745-12749.
Moore, P.S., Gao, S.-J., Dominguez, G., Cesarman, E., Lungu, O ., 
Knowles, D.M., Garber, R., Pellett, P.E., McGeoch, D.J. and Chang, Y . 
(1996). Primary characterisation of a herpesvirus agent associated with Kaposi's 
sacroma. J. Virol. 70, 549-558.
Moriuchi, H., Moriuchi, M., Smith, H.A., Straus, S.E. and Cohen, J .I .
(1992). Varicella-zoster virus open reading frame 61 protein is functionally homologous 
to herpes-simplex virus type 1 ICP0. J. Virol. 66(12), 7303-7308.
Moriuchi, H., Moriuchi, M., Straus, S.E. and Cohen, J.I. (1 9 9 3 ).
Varicella-zoster virus open reading frame 10 protein, the herpes simplex virus VP13 
homolog transactivates herpesvirus immediate early gene promoters. J. Virol. 67, 2739- 
2746.
Moriuchi, M., Moriuchi, H., Straus, S.E., and Cohen, J.I. (1 9 9 4 ).
Varicella-zoster virus open reading frame 62 protein enhances the infectivity of VZV 
DNA. Virology 220, 297-300.
Miiller-Dieckmann, H-J. and Schulz, G.E. (1995). Substrate specificity and 
assembly of the catalytic center derived from two structures of ligated uridylate kinase. J. 
Mol. Biol. 246, 22-530.
Navalgund, L.G., Rossana, C., Muench, A.J. and Johnson, L.F. (1 9 8 0 ).
Cell cycle regulation of thymidylate synthetase gene expression in cultured mouse 
fibroblasts. J. Biol. Chem. 255, 7386-7390.
Nelson, A.N. and St. Geme, M.W. (1966). The respiratory spread of VZV. 
Pediatrics 37, 1007-1009.
Ner, S.S., Goodin, D.B. and Smith, M. (1988). A simple and efficient 
procedure for generating random point mutations and for codon replacements using mixed 
oligonucleotides. DNA. 7, 127-134.
Neuhard, J., Price, A.R., Schack, L. and Thomassen, E. (1978). Two
thymidylate synthases in Bacillus subtilis. Proc. Natl. Acad. Sci. USA. 75, 1194-1198.
Newell, D.R., Siddik, Z.H., Calvert, A.H., Jackman, A.L., A lison , 
D.L., McGhee, G.K. and Harrap, K.R. (1982). Pharmacokinetics and toxicity
studies with CB3717. Proc. Am. Assoc. Cancer. Res. 23, 181.
Ogino, T., Otsuka, T. and Takahashi, M. (1977). Induction of 
deoxypyrimidine kinase activity in human embryonic lung cells infected with varicella- 
zoster virus. J. Virol. 21, 1232-1235.
Olivio, P.D., Nelson, N.J. and Chalberg, M.D. (1989). Herpes simplex virus 
type 1 gene products required for DNA replication: identification and overexpression. J. 
Virol. 63, 196-204.
Ostrove, J.M., Reinhold, W., Fan, C.H., Zorn, S., Hay, J. and Straus, 
S.E. (1985). Transcription mapping of the varicella-zoster virus genome. J. Virol. 56, 
600-606.
References
Ostrove, J.M. (1990). Molecular biology of varicella-zoster virus. Advan. Virus 
Res. 38, 45-98
O'Hare, P. and Hayward, G.S. (1985). Three trans acting regulatory proteins of 
herpes simples virus modulate immediate-early gene expression in a pathway involving 
positive and negative feedback regulation. J. Virol. 56, 723-733.
Park, J.S., Cheng, C.T.-C. and Mertes, M.P. (1979). 5-[(4-Methyl-l,2,3,4-
tetrahydroquinoxalyl)methyl]-2'-deoxyuridine 5'-phosphate: an analogue of a proposed 
intermediate in thymidylate synthetase catalysis. J. Med. Chem. 22, 1134-1137.
Paterson, T. and Everett, R.D. (1988). Mutational dissection of the HSV-1
immediate early protein Vmw 175 involved in transcriptional transactivation and 
repression. Virology 156, 186-196.
Perry. K.M., Carreras, C.W., Chang, L.C., Santi, D.V. and Stroud, 
R.M. (1993). Structures of thymidylate synthase with a C-terminal deletion: role of the 
C-terminus in alignment of 2'deoxyuridine 5'-monophosphate and 5,10- 
methylenetetrahydrofolate. Biochemistry 32, 7116-7125.
Perry, K.M., Fauman, E.B., Finer-Moore, J.S., Montfort, W.R., M aley, 
G.F., Maley, F. and Stroud, R.M. (1990). Plastic adaptation toward mutations 
in proteins: structural comparison of thymidylate synthases. Proteins: Struct. Fund. 
Genetics 8, 315-333.
Perry, L.J. and McGeoch, D.J. (1988). The DNA sequences of the long repeat 
region and adjoining parts of the long unique region in the genome of herpes simplex 
virus type 1. J. Gen. Virol. 69, 2831-2846.
Perry, L.J., Rixon, F.J., Everett, R.D., Frame, M.C. and McGeoch, D .J .
(1986). Characterisation of the IE 110 gene of herpes simplex virus type 1. J. Gen. 
Virol. 67, 2365-2380.
Piggot, P.J. and Hoch, J.A. (1985). Revised linkage map of Bacillus subtillus. 
Microb. Reviews 49, 158-179.
Plese, P.C. and Dunlap, R.B. (1977). Sulphydryl group modifications of 
thymidylate synthetase and its effects on activity and ternary complex formation. J. Biol. 
Chem. 252, 6139-6144.
Pogolotti, A.L.J., Danenberg, P.V. and Santi, D.V. (1986). Kinetics and 
mechanism of interaction of 10-propargyl-5, 8-dideazafolate with thymidylate synthase. 
J. Med. Chem. 29, 478-482.
Pookanjanatavip, M., Yuthavong, Y., Greene, P.J. and Santi, D .V .
(1992). Subunit complementation of thymidylate synthase. Biochemistry 31, 10303- 
10309.
Poon, P-P. and Storms, R.K. (1994). Thymidylate synthase is localised to the
nuclear periphery in the yeast Saccharomyces cerevisiae. J. Biol. Chem. 269(11), 8341 -
8347.
Preston, C.M. (1979a). Abnormal properties of an immediate early polypeptide in 
cells infected with the herpes simplex virus type 1 mutant tsK. J. Virol. 32, 357-369.
Preston, C.M. (1979b). Control of herpes simplex virus type 1 mRNA synthesis in 
cells infected with wild-type virus or the temperature-sensitive mutant taK. J. Virol. 29, 
275-285.
Purifoy, D.J.M., Beauchamp, L.M., Demiranda, P., Ertl, P., Lacey, S . ,  
Roberts, G., Rahim, S.G., Darby, G., Krenitsky, T.A. and Powell, K .L .
(1993). Review of research leading to new anti-herpesvirus agents in clinical 
development - valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 
882C, a specific agent for varicella-zoster virus. J. Med. Virol. Suppl. 1, 139-145.
Quinn, J.P. and McGeoch, D.J. (1985). DNA sequence of the region in the
genome of herpes simplex virus type 1 containing the genes for DNA polymerase and the 
major DNA binding protein. Nucl. Acid. Res. 13, 8143-8163.
Rahim, S.G., Trevidi, N., Selway, J., Darby, G., Collins, P., P ow ell, 
P.L. and Purifoy, D.J.M. (1992). 5-alkynyl pyrimidine nucleosides as potent 
selective inhibitors of varicella-zoster virus. Antiviral Chemistry and Chemotherapy 
3(5), 293-297.
References
Reddy, G.P.V. and Pardee, A.B. (1980). Multienzyme complex for metabolic 
channeling in mammalian DNA replication. Proc. Natl. Acad. Sci. USA. 77, 3312-3316.
Reddy, V.A. and Rao, N.A. (1976). Dihydrofolate reductase from soyabean 
seedlings. Characterisation of the enzymes purified by affinity chromatography. Arch. 
Biochem. Biophys. 176, 90-97.
Reyes, P. and Heidelberger, C. (1965). Fluorinated pyrimidines. Mol. 
Pharmacol. 1, 14-30.
Richardson, J.S ., Getzoff, E. and Richardson, D. (1981). The P-bulge: a 
common small unit of nonrepetitive protein structure. Proc. Natl. Acad. Sci. USA 75, 
2574-2578.
Richter, J., Puchtler, I. and Fleckenstein, B. (1988). Thymidylate synthase 
gene of herpesvirus ateles. J. Virol. 62, 3530-3535.
Rixon, F.J. (1993). Structure and assembly of herpesviruses. Seminars in Virology 
4, 135-144.
Roberts, D.-W. (1966). An isotopic assay for thymidylate synthetase. Biochemistry 
5(11), 3546-3548.
Rode, W., Scanlon, K.J., Moroson, B.A. and Bernito, J.R. (1 9 8 0 ).
Regulation of thymidylate synthetase in mouse leukemic cells (LI210). J. Biol. Chem. 
255, 1305-1311.
Roizman, B. (1979). The structure and isomerization of herpes simplex virus 
genomes. Cell 16, 481-494.
Roizman, B., Desrosiers, R.C., Fleckenstein, B., Lopez, C., M inson, 
A.C. and Studdart, M.J. (1992). The family Herpesviridae: an update. Arch.
Virol. 123, 425-449.
Roizman, B. (1996). Herpesviridae. In Fields Virology (3rd ed) 2, 2221-2230. BN 
Fields, DM Knipe et al (eds). Raven Press, New York
Ross, P., O'Gara, F. and Condon, S. (1990a). Cloning and charcterisation of 
the thymidylate synthase gene from Lactococcus lactis. Applied Env. Microbiol. 56, 
2156-2163.
Ross, P., O'Gara, F. and Condon, S. (1990b). Thymidylate synthase gene 
from Lactococcus lactis as a genetic marker: an alternative to antibiotic resistance. Applied 
Env. Microbiol. 56, 2164-2169.
Rouch, D.A., Messerotti, L.J., Loo, L.S.L., Jackson, C.A. and Skurray, 
R.A. (1989). Trimethoprim resistance transposon from Staphylococcus aureus encodes 
genes for dihydrofolate reductase and thymidylate synthase flanked by three copies of 
IS257. Mol. Micro. 3(2), 161-175.
Rubin, E.M ., Wilson, G.A. and Young, F.E. (1978). Transformation of 
Bacillus subtilis with cloned thymidylate synthase genes. In: S.W. Glover and L.O. 
Butler (eds), Proceedings of the 4th European meeting on bacterial transformation and 
transduction. Cotswold Press, York.
Sacks, W.R., Greene, C.C., Aschman, D.P. and Schaffer, P.A. (1 9 8 5 ).
Herpes simplex virus-type 1 ICP27 is an essential regulatory protein. J. Virol. 55, 796- 
806.
Sacks, W.R. and Schaffer, P.A. (1987). Deletion mutants in the gene encoding 
the herpes simplex virus-type 1 immediate early protein ICPO exhibit impaired growth in 
culture. J. Virol. 61, 829-839.
Santi, D.V. and Danenberg, P.V. (1984). Folates in pyrimidine nucleotide 
biosynthesis. In Folates and Pterins Vol 1. Chemistry and Biochemistry of Folates. 345-
398. RL Blakley and SJ Benkovic (eds). John Wiley and Sons, New York
Santi, D.V., McHenry, C.S., Raines, R.T. and Ivantich, K.M. (1 9 8 7 ).
Kinetics and thermodynamics of the interaction of 5-fluoro-2'-deoxyuridylate with 
thymidylate synthase. Biochemistry 26, 8606-8613.
Santi, D.V., McHendry, C.S. and Sommer, H. (1974). Mechanism of 
interaction of thymidylate synthetase with FdUMP. Biochemistry 13, 471-481.
References
Santi, D.V., Pinter, K., Kealey, J. and Davisson, V.J. (1990). Site-directed 
mutagenesis of arginine 179 of thymidylate synthase. J. Biol.Chem. 265(12), 6770- 
6775.
Sartorius, C. and Franklin, R.M. (1991). The use of antisense oligonucleotides
as chemotherapeutic agents for parasites. Parasitology Today 7, 90-93.
Savva, R., McAuley-Hecht, K., Brown, T. and Pearl, L. (1995). The
structural basis of specific base-excision repair by uracil-DNA glycosylase. Nature 373, 
487-493.
Sawyer, M.H., Ostrove, J.M., Fesler, J.M. and Straus, S.E. (1 9 8 6 ).
Mapping of the varicella-zoster virus deoxypyrimidine kinase gene and preliminary 
identification of its transcript. Virology 149, 1-9.
Sawyer, M.H., Inchauspe, G., Biron, K.K., Waters, D.J., Straus, S .E .
and Ostrove, J.M. (1988). Molecular analysis of the pyrimidine
deoxyribonucleoside kinase gene of wild type and acyclovir resistant strains of varicella- 
zoster virus. J. Gen. Virol. 69, 2585-2593.
Schalling, M., Ekman, M., Kaaya, E., Linde, A. and Biberfeld, P .
(1995). A role for a new herpes virus (KHSV) in different forms of Kaposi’s sarcoma. 
Nature Medicine 1, 707-708.
Schiffer, C.A., Davisson, V.J., Santi, D.V., Stroud, R. (1 9 9 1 ).
Crystallisation of human thymidylate synthase. J. Mol. Biol. 219, 161-163.
Schiffer, C.A., Clifton, I.J., Davisson, V.J., Santi, D.V. and Stroud,
R.M. (1995). Crystal structure of human thymidylate synthase: a structural mechanism 
for guiding substrates into the active site. Biochemistry 34, 16279-16278.
Schimmel, P. (1993). Functional analysis suggest unexpected role for conserved 
active-site residue in enzyme of known stmcture. Proc. Natl. Acad. Sci. USA 90, 9235- 
9236.
Schuck, P. (1997). Use of surface plasmon resonance to probe the equilibrium and 
dynamic aspects of interactions between biological macromolecules. Ann. Rev. Biophys. 
Biomol. Struct. 26, 541-566.
Sessa, C., Zucchetti, M., Ginier, M., Willems, Y., D ’Incalci, M. and 
Cavalli, F. (1988). Phase I study of the antifolate N l0-propargyl-5,8-dideazafolic acid 
(CB3717). Eur. J. Cancer. Clin. Oncol. 24, 769-775.
Shoichet, B.K., Stroud, R.M., Santi, D.V., Kuntz, I.D. and Perry, K .M .
(1993). Structure-based discovery of inhibitors of thymidylate synthase. Science 259, 
1445-1450.
Spector, T., Harrington, J.A. and Morrison, R.W.(1989). 2-acetylpyridine 5- 
[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (A110U), a potent inactivator of 
ribonucleotide reductase of herpes simples and varicella-zoster vimses and a potentiator of 
acyclovir. Proc. Natl. Acad. Sci. USA. 86, 1051-1055.
Spector, T., Lobe, D.C., Ellis, M.N., Blumenkopf, T.A. and Szczech , 
G.M (1992). Inactivators of herpes-simplex virus ribonucleotide reductase- 
hematological profiles and in vivo potentiation of the antiviral activity of acyclovir. 
Antimicrobial Agents And Chemotherapy 36(5), 934-937.
Stacey, K.A. and Simpson, E. (1965). Improved method for the isolation of 
thymine requiring mutants of Escherichia coli. J. Bacteriology 90, 554-555.
Stephens, T.C., Smith, M.N., McClockney, M.L. and Boyle, F .T .
(1994). ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor: in vivo 
antitumour efficacy and toxicity to normal murine tissues. Proc. Am. Assoc. Cancer Res. 
35, 305.
Stevens, J.G. and Cook, M.L. (1971). Latent herpes simplex virus in spinal 
ganglia of mice. Science 173, 843-845.
Stevens, J.G., Wagner, E.K., Devi-Rao, G.B., Cook, M.L. and
Feldman, L.T. (1987). RNA complementary to a herpesvirus alpha gene mRNA is 
prominent in latently infected neurons. Science 235, 1056-1059.
Stevenson, D., Colman, K.L. and Davison, A.J. (1992). Characterization of 
the varicella-zoster virus gene 61 protein. J. Gen. Virol. 73, 521-530.
References
Storms, R.K., Ord, R.W., Greenwood, M.T., Mirdamadi, B., Chu,
F.K., and Belfort, M. (1984). Cell cycle-dependent expression of thymidylate 
synthase in Saccharomyces cerevisiae. Mol. Cell. Biol. 4, 2858-2864.
Stow, N.D. and Davison, A.J. (1986). Identification of a varicella-zoster virus 
origin of DNA replication and its activation by herpes simplex vims type 1 gene products. 
J. Gen. Virol. 67, 1613-1623.
Stow, N.D., Weir, H.M. and Stow, E.C. (1990). Analysis of the binding sites 
for the varicella-zoster virus gene 51 product within the viral origin of replication.
Virology 177, 570-577.
Stow, N.D. and Stow, E.C. (1986). Isolation and characterisation of a herpes 
simplex vims type 1 mutant containing a deletion within the gene encoding the immediate 
early polypeptide Vmwl 10. J. Gen. Virol. 67, 2571-2585.
Straus, S.E., Aulakh, H.S., Ruyechan, W.T., Hay, J., Casey, T .A . 
Woude, V., Owens, J. and Smith, H.A. (1981). Structures of varicella-zoster 
virus DNA. J. Virol. 40, 516-525.
Straus, S.E., Hay, J., Smith, H. and Owens, J. (1983). Genome differences 
among VZV-isolates. J. Gen. Virol. 64, 1031-1041.
Straus, S.E., Owens, J. and Ruyechan, W.T. (1982). Molecular cloning and 
physical mapping of varicella-zoster virus DNA. Proc. Natl. Acad. Sci. USA 79, 993- 
997.
Stroud, R.M. and Finer-Moore, J.S. (1993). Stereochemistry of a 
multistep/bipartite methyl transfer reaction: thymidylate synthase. The FASEB Journal 7, 
671-677.
Studier, F.W. (1991). Use of bacteriophage-T7 lysozyme to improve an inducible T7 
expression system. J. Mol. Biol. 219(1), 37-44.
Studier, F.W. and Moffatt, B.A. (1986). Use of bacteriophage T7 RNA 
polymerase to direct selective high-level expression of cloned genes. J. Mol. Biol. 189, 
113-130.
Takeishi, K., Kaneda, S., Ayusawa, D., Shimizu, K., Gotoh, O. and 
Seno, T. (1985). Nucleotide-sequence of a functional cDNA for human thymidylate 
synthase. Nucl. Acid Res. 13(6), 2035-2043.
Taylor, G.R., Lagosky, P.A., Storms, R.K. and Haynes, R.H. (1 9 8 7 ).
Molecular characterisation of the cell-cycle regulated thymidylate synthase gene of 
Saccharomyces cerevisiae. J. Biol. Chem. 262, 5298-5307.
Telford, E.A.R., Watson, M.S., Aird, H.C., Perry, J. and Davison, A .J .
(1995). The DNA sequence of equine herpesvirus-2. J. Mol. Biol. 249, 520-528.
Telford, E.A.R., Watson, M.S., McBride, K. and Davison, A.J. (1 9 9 2 ).
The DNA sequence of equine-herpesvirus 1. Virology 189(1), 304-316.
Thanassi, J.W., Meisler, N.T. and Kittler, J.M. (1985). Vitamin B-6 
metabolism and cancer. Current Topics in Nutrition and Disease. Vol. 13, pp319-336. 
Edited by R.D. Reynolds and J.E. Leklem. Liss, New York.
Thompson, R., Honess, R.W., Taylor, L., Morran, J. and Davison, A .J .
(1987). Varicella-zoster virus specifies a thymidylate synthetase. J. Gen. Virol. 68, 
1449_1455.
Tolleson, W.H., Cisneros, R.J., Alibhai, M. and Dunlap, R.B. (1 9 9 0 ).
Comparison of enzyme immunoassay and active site titration methods for the 
determination of thymidylate synthase. FASEB Journal 4, A2301.
Toth, I., Lazar, G. and Goodman, H.M. (1987). Purification and 
immunochemical characterisation of a dihydrofolate reductase-thymidylate synthase 
enzyme complex from wild-carrot cells. The EMBO Journal 6, 1853-1858.
Touroutoglou, N. and Pazdur, R. (1996). Thymidylate synthase inhibitors. Clin. 
Can. Res. 2, 227-246.
Van der Wilt, C.L., Pinedo, H.M., Kuiper, C.M., Smid, K. and Peters,
G.J. (1995). Biochemical basis for the combined antiproliferative effects of AG337 or 
ZD 1694 and 5-fluorouracil. Proc. Am. Assoc. Cancer. Res. 36, 379.
References
Vest, S., Bork, E. and Hansen, H.H. (1988). A phase I evaluation of N 10- 
propargyl 5,8-dideazafolic acid. Ear. J. Cancer Clin. Oncol. 24, 201-204.
Voeller, D.M., Changchien, L-M., Maley, G.F., Maley, F., Takechi, T ., 
Turner, R., Montfort, W.R., Allegra, C.J. and Chu, E. (1 9 9 5 ).
Characterization of a specific interaction between Escherichia coli thymidylate synthase 
and Escherichia coli thymidylate synthase mRNA. Nucl. Acids Res. 23, 869-875.
Wagner, E.K. (1985). Individual HSV transcripts: characterization of specific genes. 
In The Herpesviruses. 3, 45-104. B. Roizman (ed). Plenum press, New York/London
Wang, Y. and Matthews, C.K. (1989). Analysis of T4 bacteriophage deletion 
mutats that lack td and frd  genes. J. Virol. 63, 4736-4743.
Ward, R.L. and Stevens, J.G. (1975). Effect of cytosine arabinoside on viral- 
specific protein synthesis in cells infected with herpes simplex virus. J. Virol. 15, 71-80.
Watson, R.J. and Clements, J.B. (1980). A herpes simplex virus type 1 function 
continuously required for early and late virus RNA synthesis. Nature 285, 329-330.
Wayata, Y., Matsuda, A. and Santi, D.V. (1980). Interaction of thymidylate 
synthetase with 5-nitro-2’-deoxyuridylate. J. Biol. Chem. 255, 5538-5544.
Webber, S., Shetty, B., Johnston, A., Welsh, K., Varney, M., Deal, J . ,  
Morse, C. and Soda, K .(1993). In vitro properties and antitumour activity of 
AG331, a novel lipophilic thymidylate synthase inhibitor. Proc. Am. Assoc. Cancer Res.
33, 413.
Webber, S., Johnston, A., Shetty, B., Webber, S.E., Welsh, K .,  
Hilliard, J., Kosa, M. Morse, C. and Soda, K. (1993). Preclinical studies on 
AG337, a novel lipophilic thymidylate synthase inhibitor. Proc. Am. Assoc. Cancer Res.
34, 273.
Wheeler, L., Wang, Y. and Matthews, C.K. (1992). Specific associations of 
T4 bacteriophage proteins with immobilised deox ycy tidy late hydroxymethylase. J. Biol. 
Chem. 267(11), 7664-7670.
Wu, C.A., Nelson, N.J., McGeoch, D.J. and Challberg, M.D. (1 9 8 8 ).
Identification of herpes simplex virus type 1 genes required for origin-dependent DNA 
synthesis. Virology 62, 435-443.
